

CITATION REPORT

List of articles citing

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

DOI: 10.1016/s0092-8674(00)81569-x
Cell, 1998, 93, 165-76.

Source: <https://exaly.com/paper-pdf/29269625/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2319	Zinc induced changes in the progesterone binding properties of the human endometrium. 1980 , 94, 99-106		15
2318	Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. 1998 , 396, 699-703		658
2317	Bone remodelling: a signalling system for osteoclast regulation. 1998 , 8, R679-82		48
2316	Multiple myeloma cells and cells of the human osteoclast lineage share morphological and cell surface markers. 1998 , 71, 559-568		9
2315	Pathological bone resorption in rheumatic diseases. 1998 , 8, 355-367		1
2314	Genetic control of cell differentiation in the skeleton. 1998 , 10, 614-9		123
2313	Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. 1998 , 23, 75-81		221
2312	Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. 1998 , 23, 495-8		86
2311	Commitment and differentiation of stem cells to the osteoclast lineage. 1998 , 76, 911-922		55
2310	Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. 1998 , 247, 338-41		110
2309	Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. 1998 , 248, 454-7		94
2308	Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. 1998 , 248, 696-700		87
2307	Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. 1998 , 250, 229-34		111
2306	Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. 1998 , 250, 776-81		261
2305	Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. 1998 , 251, 796-801		92
2304	Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF). 1998 , 252, 697-702		120
2303	Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. 1998 , 252, 747-52		181

2302	RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. 1998 , 253, 395-400	588
2301	Advances in the osteoblast lineage. 1998 , 76, 899-910	336
2300	The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. 1998 , 273, 34120-7	262
2299	Dissociation between bone resorption and bone formation in osteopenic transgenic mice. 1998 , 95, 13835-40	187
2298	Echistatin inhibits the migration of murine perfusion osteoclasts and the formation of multinucleated osteoclast-like cells. 1998 , 139, 5182-93	55
2297	Bone homeostasis. 1998 , 95, 13361-2	86
2296	Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. 1998 , 273, 20551-5	341
2295	TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. 1998 , 188, 997-1001	493
2294	The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. 1998 , 273, 28355-9	377
2293	Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. 1998 , 273, 27091-6	237
2292	Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. 1998 , 159, 191-5	143
2291	Osteoclastogenesis, Its Control, and Its Defects. 1998 , 289-313	
2290	The Osteoclast Molecular Phenotype. 1998 , 5, 385-421	1
2289	Pathological bone resorption in rheumatic diseases. 1998 , 8, 355-367	
2288	CD95(APO-1/Fas)-mediated apoptosis: live and let die. 1999 , 71, 163-210	282
2287	Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Secretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease. 1999 , 94, 3883-3888	94
2286	Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. 1999 , 140, 3552-61	367
2285	Cell number versus cell vigor--what really matters to a regenerating skeleton?. 1999 , 140, 4377-81	50

2284	Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. 1999 , 140, 1927-35	148
2283	The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. 1999 , 13, 819-28	195
2282	Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. 1999 , 84, 145-50	137
2281	Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. 1999 , 140, 5060-5	88
2280	Breast cancer cells interact with osteoblasts to support osteoclast formation. 1999 , 140, 4451-8	449
2279	Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. 1999 , 190, 1741-54	547
2278	Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors. 1999 , 58 Suppl 1, I2-I13	63
2277	Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. 1999 , 96, 3540-5	1373
2276	The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. 1999 , 145, 527-38	588
2275	Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. 1999 , 190, 293-8	349
2274	Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. 1999 , 274, 13613-8	330
2273	TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation. 1999 , 189, 1017-20	48
2272	Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. 1999 , 274, 9843-6	571
2271	Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. 1999 , 140, 4382-9	582
2270	Functions of new members of the human tumor necrosis factor receptor (TNFR) superfamily.	
2269	Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. 1999 , 274, 7724-31	323
2268	Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. 1999 , 96, 8156-60	301
2267	STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. 1999 , 274, 19301-8	241

2266	Human mesenchymal stem cells promote human osteoclast differentiation from CD34+ bone marrow hematopoietic progenitors. 1999 , 140, 3736-43	80
2265	Human malignant osteopetrosis: pathophysiology, management and the role of bone marrow transplantation. 1999 , 3 Suppl 1, 102-7	53
2264	Human osteoclasts derive from CD14-positive monocytes. 1999 , 106, 167-70	168
2263	Physiological doses of calcium regulatory hormones do not normalize bone cells in uraemic rats. 1999 , 29, 529-35	7
2262	Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. 1999 , 77, 188-93	107
2261	Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. 1999 , 4, 353-62	515
2260	Immunohistochemical identification of a vacuolar proton pump (V-ATPase) in bone-resorbing cells of an advanced teleost species, <i>Oreochromis niloticus</i> . 1999 , 55, 1258-1272	15
2259	Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. 1999 , 402, 43-47	101
2258	OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. 1999 , 397, 315-23	2789
2257	Gene targeting in the analysis of mammalian apoptosis and TNF receptor superfamily signaling. 1999 , 169, 283-302	66
2256	Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. 1999 , 402, 304-9	1642
2255	Clinical research is dead; long live clinical research. 1999 , 5, 477-8	13
2254	Suppression of FRP-1/CD98-mediated multinucleated giant cell and osteoclast formation by an anti-FRP-1/CD98 mAb, HBJ 127, that inhibits c-src expression. 1999 , 193, 162-9	17
2253	[Pathophysiology and therapy of osteoporosis]. 1999 , 39, 228-34	2
2252	The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. 1999 , 65, 311-6	66
2251	New insights related to aging and renal osteodystrophy. 1999 , 9, 49-56	
2250	Vacuolar H ⁺ -ATPase activity and expression in mouse bone marrow cultures. 1999 , 14, 2127-36	30
2249	Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. 1999 , 14, 518-27	263

2248	Macrophage colony stimulating factor increases bone resorption in dispersed osteoclast cultures by increasing osteoclast size. 1999 , 14, 937-45	63
2247	New developments in the pathogenesis and treatment of steroid-induced osteoporosis. 1999 , 14, 1061-6	267
2246	A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. 1999 , 14, 1478-85	152
2245	Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells. 1999 , 14, 1486-92	81
2244	Effects of dexamethasone on proliferation, activity, and cytokine secretion of normal human bone marrow stromal cells: possible mechanisms of glucocorticoid-induced bone loss. 1999 , 162, 371-9	70
2243	Bone and cytokines: beyond IL-1, IL-6 and TNF-alpha. 1999 , 64, 1-7	73
2242	Meltrin-alpha, a fusion protein involved in multinucleated giant cell and osteoclast formation. 1999 , 64, 508-15	96
2241	Aging and cytokine production. 1999 , 65, 345-51	37
2240	Characterization of the NF-kappaB activation induced by TR8, an osteoclastogenic tumor necrosis factor receptor family member. 1999 , 22, 454-8	2
2239	Expression of stem cell factor by osteoblasts in normal and hyperparathyroid bone: relation to ectopic mast cell differentiation. 1999 , 435, 50-7	19
2238	Osteoblastic cells induce fusion and activation of osteoclasts through a mechanism independent of macrophage-colony-stimulating factor production. 1999 , 298, 327-34	42
2237	Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. 1999 , 1445, 134-41	112
2236	Effects of nicotine on cultured cells suggest that it can influence the formation and resorption of bone. 1999 , 383, 387-93	78
2235	CD9 molecule expressed on stromal cells is involved in osteoclastogenesis. 1999 , 27, 853-9	27
2234	Cell biology of the osteoclast. 1999 , 27, 1229-41	470
2233	A putative role for c-Fos in the pathophysiology of Paget's disease. 1999 , 14 Suppl 2, 21-8	12
2232	Bone marrow cells produce soluble factors that inhibit osteoclast activity. 1999 , 17, 51-8	5
2231	Osteoclastogenesis is repressed by mechanical strain in an in vitro model. 1999 , 17, 639-45	74

2230	Macrophage colony-stimulating factor and interleukin-6 release by periprosthetic cells stimulates osteoclast formation and bone resorption. 1999 , 17, 686-94	42
2229	Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. 1999 , 72, 67-80	78
2228	Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. 1999 , 72, 251-261	107
2227	1,25 dihydroxyvitamin D3 and dexamethasone induce the cyclooxygenase 1 gene in osteoclast-supporting stromal cells. 1999 , 74, 587-595	27
2226	Fra-1 potentiates osteoclastic differentiation in osteoclast-macrophage precursor cell lines. 1999 , 179, 170-8	26
2225	Survey of the 1998 optical biosensor literature. 1999 , 12, 390-408	85
2224	Expression of the vitamin D receptor, of estrogen and thyroid hormone receptor alpha- and beta-isoforms, and of the androgen receptor in cultures of native mouse bone marrow and of stromal/osteoblastic cells. 1999 , 24, 465-73	69
2223	Gene expression during osteoclast-like cell formation induced by antifusion regulatory protein-1/CD98/4F2 monoclonal antibodies (MAbs): c-src is selectively induced by anti-FRP-1 MAb. 1999 , 25, 17-24	156
2222	Required and nonessential functions of nuclear factor-kappa B in bone cells. 1999 , 25, 137-9	97
2221	Genetic regulation of skeletal patterning, differentiation, and growth. 1999 , 25, 77-9	2
2220	A novel molecular mechanism modulating osteoclast differentiation and function. 1999 , 25, 109-13	217
2219	Use of genomic tools in the identification of bone-related therapeutics. 1999 , 25, 81-3	44
2218	Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. 1999 , 25, 255-9	518
2217	The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in me(v)/me(v) mutant mice. 1999 , 25, 261-7	93
2216	Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. 1999 , 25, 517-23	334
2215	Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskelatal tissues. 1999 , 25, 525-34	273
2214	Functional characterization of N-methyl-D-aspartic acid-gated channels in bone cells. 1999 , 25, 631-7	96
2213	2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. 1999 , 11, 253-61	137

2212	TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. 1999 , 4, 1041-9	520
2211	Cloning and characterization of the gene encoding mouse osteoclast differentiation factor. 1999 , 230, 121-7	24
2210	Ectodysplasin, a protein required for epithelial morphogenesis, is a novel TNF homologue and promotes cell-matrix adhesion. 1999 , 88, 133-46	104
2209	Regulation of osteoclast activity. 1999 , 65, 1087-102	80
2208	Receptor activator of NF-kappaB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. 1999 , 443, 297-302	106
2207	Expression of functional RANK on mature rat and human osteoclasts. 1999 , 463, 295-300	62
2206	Comparative tolerability of drug therapies for hypercalcaemia of malignancy. 1999 , 21, 389-406	134
2205	Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. 1999 , 20, 345-57	1792
2204	Role of the osteoclast at the bone-implant interface. 1999 , 13, 49-56	54
2203	Deficiency of SHP-1 protein-tyrosine phosphatase activity results in heightened osteoclast function and decreased bone density. 1999 , 155, 223-33	70
2202	Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. 1999 , 247, 84-93	284
2201	Identification of avian sarcoplasmic reticulum Ca(2+)-ATPase (SERCA3) as a novel 1,25(OH)(2)D(3) target gene in the monocytic lineage. 1999 , 250, 364-75	9
2200	Characterization of TNFRSF19, a novel member of the tumor necrosis factor receptor superfamily. 1999 , 62, 103-7	45
2199	Macrophage-inflammatory protein-1alpha regulates preosteoclast differentiation in vitro. 1999 , 254, 773-8	65
2198	A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. 1999 , 256, 449-55	370
2197	Indian hedgehog in the late-phase differentiation in mouse chondrogenic EC cells, ATDC5: upregulation of type X collagen and osteoprotegerin ligand mRNAs. 1999 , 257, 814-20	39
2196	Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2. 1999 , 259, 97-102	92
2195	Hedgehog signaling molecules in bone marrow cells at the initial stage of fracture repair. 1999 , 262, 443-51	47

2194	1,25-Dihydroxyvitamin D(3) and prostaglandin E(2) act directly on circulating human osteoclast precursors. 1999 , 264, 590-5	45
2193	Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells. 1999 , 265, 158-63	56
2192	Basic fibroblast growth factor inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D(3) through suppressing the production of osteoclast differentiation factor. 1999 , 265, 45-50	13
2191	Cusp patterning defect in Tabby mouse teeth and its partial rescue by FGF. 1999 , 216, 521-34	150
2190	To die or not to die--the quest of the TRAIL receptors. 1999 , 65, 535-42	113
2189	TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. 1999 , 65, 715-24	163
2188	Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. 1999 , 141, 195-210	87
2187	The effect of vitamin D on osteoblasts and osteoclasts. 1999 , 10, 339-343	9
2186	Osteoblast-osteoclast communication. 1999 , 10, 367-373	2
2185	IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. 1999 , 103, 1345-52	1273
2184	Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. 1999 , 104, 503-13	196
2183	A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. 1999 , 13, 1025-36	643
2182	TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. 1999 , 13, 1015-24	995
2181	RANK is essential for osteoclast and lymph node development. 1999 , 13, 2412-24	1100
2180	The genetic transformation of bone biology. 1999 , 13, 3037-51	234
2179	Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor B ligand (RANKL). 2000 , 99, 133	46
2178	Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor B ligand (RANKL). 2000 , 99, 133-140	87
2177	Therapeutic patenting for glucocorticoid-induced osteoporosis. 2000 , 10, 847-857	

2176	Is aplastic osteodystrophy a disease of malnutrition?. 2000 , 9, 363-7	25
2175	Expression of adhesion molecules LFA-I and ICAM-I on osteoclast precursors during osteoclast differentiation and involvement of estrogen deficiency. 2000 , 3, 278-87	14
2174	Breakthrough in bone: the molecular mechanism of osteoclast/osteoblast coupling revealed. 2000 , 11, 329-335	13
2173	Pathogenesis of bone erosions in rheumatoid arthritis. 2000 , 12, 195-9	121
2172	Osteolytic indicators found in total knee arthroplasty synovial fluid aspirates. 2000 , 186-94	25
2171	IL-4, but not vitamin D(3), induces monoblastic cell line UG3 to differentiate into multinucleated giant cells on osteoclast lineage. 2000 , 182, 214-21	7
2170	Regulation of the differentiation and function of osteoclasts. 2000 , 192, 4-13	275
2169	Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. 2000 , 192, 97-104	90
2168	Molecular mechanisms of osteolytic bone metastases. 2000 , 88, 2892-8	258
2167	Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6-type cytokines. 2000 , 79, 532-41	35
2166	Activation of osteoclasts by interleukin-1: divergent responsiveness in osteoclasts formed in vivo and in vitro. 2000 , 184, 334-40	33
2165	Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cells. 2000 , 185, 207-14	74
2164	Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. 2000 , 43, 250-8	705
2163	Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. 2000 , 43, 259-69	531
2162	Mesenchymal cells expressing bone morphogenetic protein receptors are present in the rheumatoid arthritis joint. 2000 , 43, 2046-55	84
2161	Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. 2000 , 43, 2143-51	145
2160	Expression of osteoclast differentiation factor in rheumatoid arthritis. 2000 , 43, 2523-30	196
2159	The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. 2000 , 43, 2619-33	297

2158	A neuro (endo)crine regulation of bone remodeling. 2000 , 22, 970-5	49
2157	Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. 2000 , 18, 647-54	37
2156	Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis. 2000 , 18, 849-55	95
2155	Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. 2000 , 18, 967-76	35
2154	Bone cancer pain: from mechanism to model to therapy. 2000 , 1, 303-9	76
2153	T cell life and death signalling via TNF-receptor family members. 2000 , 12, 316-22	101
2152	Molecular and cellular biology of alveolar bone. 2000 , 24, 99-126	147
2151	Osteoprotegerin ligand: a regulator of immune responses and bone physiology. 2000 , 21, 495-502	137
2150	Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. 2000 , 24, 184-7	282
2149	Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. 2000 , 6, 521-8	419
2148	Characterization of osteoclast precursors in human blood. 2000 , 111, 501-512	7
2147	Molecular control of bone remodeling and osteoporosis. 2000 , 35, 947-56	78
2146	Sequential requirements for SCL/tal-1, GATA-2, macrophage colony-stimulating factor, and osteoclast differentiation factor/osteoprotegerin ligand in osteoclast development. 2000 , 28, 833-40	31
2145	Angiogenesis and bone growth. 2000 , 10, 223-8	292
2144	Effects of ageing on proliferative ability, and the expressions of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells. 2000 , 117, 69-77	29
2143	Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. 2000 , 237, 159-73	41
2142	1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion. 2000 , 15, 175-81	25
2141	The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. 2000 , 15, 2-12	861

2140	Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. 2000 , 15, 1924-34	97
2139	Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand. 2000 , 15, 2178-86	134
2138	Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. 2000 , 15, 2293-6	64
2137	Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. 2000 , 15, 1321-9	140
2136	Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. 2000 , 15, 1459-66	114
2135	Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. 2000 , 15, 1477-88	445
2134	Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. 2000 , 15, 1766-75	78
2133	Receptor activator of NF-kappaB ligand induces the fusion of mononuclear preosteoclasts into multinucleated osteoclasts. 2000 , 33, 203-11	2
2132	Hypercalcemia of malignancy. 2000 , 1, 253-63	70
2131	Bone resorption by osteoclasts. 2000 , 289, 1504-8	2899
2130	Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. 2000 , 11, 905-13	205
2129	Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. 2000 , 18, 177-84	77
2128	An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor B ligand. 2000 , 96, 4335-4343	89
2127	Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. 2000 , 96, 1873-1878	210
2126	Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha4-integrin enhances production of osteoclast-stimulating activity. 2000 , 96, 1953-1960	195
2125	Regulatory Mechanism of Osteoblast Differentiation and Bone Formation.. 2000 , 5, 1-14	
2124	Intramedullary and extramedullary B lymphopoiesis in osteopetrotic mice. 2000 , 95, 3363-3370	42
2123	Human bone-derived cells support formation of human osteoclasts from arthroplasty-derived cells in vitro. 2000 , 82-B, 892-900	

2122	Osteoclasts: characteristics and regulation of formation and activity. 2000 , 36-45	1
2121	Activation of c-Jun N-Terminal Kinase and Activator Protein 1 by Receptor Activator of Nuclear Factor B . 2000 , 58, 1536-1545	51
2120	Mechanical strain inhibits expression of osteoclast differentiation factor by murine stromal cells. 2000 , 278, C1126-32	106
2119	Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. 2000 , 191, 275-86	1048
2118	Biochemical and molecular actions of fatty acids in bone modeling. 2001 , 88, 126-40	10
2117	The PTH/PTHrP system and calcium homeostasis. 2000 , 73-87	
2116	Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. 2000 , 151, 879-89	474
2115	RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. 2000 , 97, 1566-71	895
2114	Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. 2000 , 97, 7829-34	394
2113	Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. 2000 , 192, 1467-78	230
2112	TGF-beta 1 and IFN-gamma direct macrophage activation by TNF-alpha to osteoclastic or cytotoxic phenotype. 2000 , 165, 4957-63	65
2111	Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption. 2000 , 97, 7993-8	129
2110	Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. 2000 , 275, 20959-62	259
2109	Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. 2000 , 275, 14388-93	86
2108	Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. 2000 , 97, 3370-3375	481
2107	Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. 2000 , 21, 115-37	1487
2106	The final pathogenetic steps in focal bone erosions in rheumatoid arthritis. 2000 , 59 Suppl 1, i72-4	12
2105	Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. 2000 , 141, 4711-9	77

2104	Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. 2000 , 141, 2054-61	144
2103	Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. 2000 , 192, 463-74	446
2102	The role of cytokines in skeletal remodelling: possible consequences for renal osteodystrophy. 2000 , 15, 945-50	22
2101	Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. 2000 , 59, 26-31	44
2100	The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. 2000 , 141, 1554-9	335
2099	The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. 2000 , 141, 4768-76	230
2098	Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. 2000 , 85, 2355-63	129
2097	Role of multinuclear cells in granulation tissue in osteomyelitis: immunohistochemistry in 66 patients. 2000 , 71, 414-8	7
2096	Role of ascorbic acid in the osteoclast formation: induction of osteoclast differentiation factor with formation of the extracellular collagen matrix. 2000 , 141, 3006-11	33
2095	Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis. 2000 , 165, 4231-8	81
2094	Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. 2000 , 68, 6819-25	73
2093	Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. 2000 , 142, 661-4	50
2092	Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. 2000 , 165, 4254-63	104
2091	Nephrology and Geriatrics Integrated. 2000 ,	
2090	Osteoprotegerin and osteoclast differentiation factor in tooth eruption. 2000 , 79, 1937-42	54
2089	The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. 2000 , 275, 25163-72	148
2088	Overexpression of bcl-2 enhances LIGHT- and interferon-gamma -mediated apoptosis in Hep3BT2 cells. 2000 , 275, 38794-801	38
2087	Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. 2000 , 267, 632-7	85

2086	Activin A is an essential cofactor for osteoclast induction. 2000 , 268, 2-7	96
2085	Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. 2000 , 268, 669-72	72
2084	Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. 2000 , 269, 532-6	80
2083	Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts. 2000 , 270, 1097-100	48
2082	Osteoblast maturation suppressed osteoclastogenesis in coculture with bone marrow cells. 2000 , 274, 249-54	34
2081	Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. 2000 , 274, 281-90	47
2080	Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. 2000 , 275, 768-75	400
2079	Low calcium environment effects osteoprotegerin ligand/osteoclast differentiation factor. 2000 , 276, 524-9	20
2078	Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis. 2000 , 276, 868-72	79
2077	Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. 2000 , 279, 391-7	24
2076	Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. 2000 , 12, 613-21	86
2075	Subtraction cloning and initial characterization of novel epo-immediate response genes. 2000 , 12, 845-57	24
2074	Dental cells express factors that regulate bone resorption. 2000 , 3, 145-52	72
2073	Expression, purification, and characterization of the human receptor activator of NF-kappaB ligand (RANKL) extracellular domain. 2000 , 20, 48-57	18
2072	Apoptosis and osteoporosis. 2000 , 108, 153-64	200
2071	Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. 2000 , 157, 435-48	333
2070	Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. 2000 , 156, 761-7	223
2069	Diseases of aging. 2000 , 18, 1567-83	99

2068	Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem. 2000 , 26, 11-27	54
2067	The effect of particle phagocytosis and metallic wear particles on osteoclast formation and bone resorption in vitro. 2000 , 15, 654-62	48
2066	Relationship between the ability to support differentiation of osteoclast-like cells and adipogenesis in murine stromal cells derived from bone marrow. 2000 , 62, 319-27	28
2065	Osteoprotegerin mitigates tail suspension-induced osteopenia. 2000 , 26, 443-9	56
2064	Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. 2000 , 26, 653-61	66
2063	Hypercalcemia during the osteogenic phase after rat marrow ablation coincides with increased bone resorption assessed by the NTx marker. 2000 , 27, 103-10	14
2062	Osteoclast lineage commitment of bone marrow precursors through expression of membrane-bound TRANCE. 2000 , 27, 29-40	40
2061	Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL. 2000 , 27, 409-16	97
2060	Progressive increase in bone mass and development of odontomas in aging osteopetrotic c-src-deficient mice. 2000 , 27, 603-10	40
2059	Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. 2000 , 27, 761-4	17
2058	The possible role of osteoclastogenic oral bacterial products in etiology of Paget's disease. 2000 , 26, 101-2	3
2057	Letters to the editor. 2000 , 26, 199-200	
2056	Mouse genetics have uncovered new paradigms in bone biology. 2000 , 11, 189-93	18
2055	The central regulation of bone remodeling. 2000 , 11, 437-9	27
2054	Mechanisms of osteoporosis after hematopoietic cell transplantation. 2000 , 6, 165-74	89
2053	Osteoclast formation and resorption. 2000 , 19, 107-20	85
2052	Bone formation and factors affecting this process. 2000 , 19, 85-9	57
2051	Parathyroid hormone-related peptide and bone: pathological and physiological aspects. 2000 , 54 Suppl 1, 32s-41s	10

2050	The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. <i>Cell</i> , 2000 , 103, 41-50	56.2	593
2049	Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. <i>Cell</i> , 2000 , 100, 197-207	56.2	1682
2048	New insights into role of microenvironment in multiple myeloma. 2000 , 355, 248-50		119
2047	Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor. 2000 , 486, 23-8		68
2046	Proteinase expression during differentiation of human osteoclasts in vitro. 2000 , 78, 627-37		33
2045	Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. 2000 , 1, 387-91		215
2044	Therapeutic approaches to bone diseases. 2000 , 289, 1508-14		1393
2043	Bone loss. Factors that regulate osteoclast differentiation: an update. 2000 , 2, 451-456		136
2042	Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. 2000 , 21, 393-411		520
2041	Cathepsin K and the design of inhibitors of cathepsin K. 2000 , 6, 1-24		124
2040	The CD9 molecule on stromal cells. 2000 , 38, 265-70		5
2039	Emerging therapies for osteoporosis. 2000 , 5, 1-43		31
2038	Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. 2000 , 141, 3478-84		302
2037	Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). 2000 , 275, 31155-61		439
2036	Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. 2001 , 97, 785-91		404
2035	Differentiation of monocytes into multinucleated giant bone-resorbing cells: two-step differentiation induced by nurse-like cells and cytokines. 2001 , 3, 306-10		37
2034	Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis. 2001 , 3, 221-7		57
2033	The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. 2001 , 3, 6-12		73

2032	Think Bone The Novel Paradigm of Central Bone Mass Control. 2001 , 27, 218-225	
2031	Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. 2001 , 280, 334-9	180
2030	Temporal and spatial localization of osteoclasts in colonies from embryonic stem cells. 2001 , 280, 526-34	15
2029	Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. 2001 , 280, 831-5	83
2028	Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. 2001 , 281, 361-6	70
2027	Osteoclast differentiation factor modulates cell cycle machinery and causes a delay in s phase progression in RAW264 cells. 2001 , 282, 278-83	33
2026	Phosphate decreases osteoclastogenesis in coculture of osteoblast and bone marrow. 2001 , 282, 798-802	20
2025	Macrophage colony-stimulating factor suppresses osteoblast formation. 2001 , 285, 328-34	16
2024	Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy. 2001 , 288, 217-24	25
2023	RANKL induces formation of avian osteoclasts from macrophages but not from macrophage polykaryons. 2001 , 288, 340-6	13
2022	Adrenal and gonadal steroids inhibit IL-6 secretion by human marrow cells. 2001 , 16, 178-86	47
2021	Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. 2001 , 100, 18-24	108
2020	TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. 2001 , 159, 1689-99	667
2019	Effect of interleukin-6 deficiency on the formation of periapical lesions after pulp exposure in mice. 2001 , 92, 83-8	42
2018	An immunohistochemical study of osteoprotegerin in the human dental pulp. 2001 , 27, 666-9	5
2017	Gene expression of glucocorticoid receptor alpha and beta in giant cell tumour of bone: evidence of glucocorticoid-stimulated osteoclastogenesis by stromal-like tumour cells. 2001 , 181, 199-206	18
2016	Bioactive fatty acids: role in bone biology and bone cell function. 2001 , 40, 125-48	142
2015	L'ostéoclaste et les mécanismes moléculaires de la résorption osseuse. 2001 , 17, 1260-1269	3

2014	Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. 2001 , 22, 328-36	290
2013	Evaluation of the role of RANK and OPG genes in Paget's disease of bone. 2001 , 28, 104-7	101
2012	Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. 2001 , 28, 208-14	43
2011	Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling?. 2001 , 28, 378-86	54
2010	Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. 2001 , 28, 370-7	83
2009	Individual osteoblasts in the developing calvaria express different gene repertoires. 2001 , 28, 351-61	78
2008	Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. 2001 , 28, 474-83	103
2007	Interleukin-4 and interleukin-13: bidirectional effects on human osteoclast formation. 2001 , 29, 203-8	13
2006	Identification and characterization of mouse bone marrow stromal cell lines immortalized by temperature-sensitive SV40 T antigen: supportive activity for osteoclast differentiation. 2001 , 29, 236-41	17
2005	Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. 2001 , 12, 9-18	166
2004	Myeloma bone disease. 2001 , 38, 276-85	115
2003	Osteoprotegerin and rank ligand expression in prostate cancer. 2001 , 57, 611-6	196
2002	Osteoprotegerin: a link between osteoporosis and arterial calcification?. 2001 , 358, 257-9	100
2001	Treatment of rheumatoid arthritis in the third millennium. 2001 , 30, 249-54	7
2000	The molecular genetics of bone formation: implications for therapeutic interventions in bone disorders. 2001 , 1, 175-87	18
1999	Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. 2001 , 276, 13065-71	87
1998	The 10th international rheumatology symposium in Tokyo "2001 frontier of rheumatology". 2001 , 11, 261-73	2
1997	Tumor necrosis factor modulates fibroblast apoptosis, PMN recruitment, and osteoclast formation in response to <i>P. gingivalis</i> infection. 2001 , 80, 1875-9	106

1996	Cytokines and Bone Remodeling. 2001 , 373-403	4
1995	Parathyroid Hormone and Parathyroid hormone-Related Protein. 2001 , 221-246	1
1994	Coupling of Bone Resorption and Formation during Bone Remodeling. 2001 , 361-371	9
1993	Osteoblast Biology. 2001 , 21-71	14
1992	Embryonic stem cells as a model for studying osteoclast lineage development. 2002 , 185, 97-106	5
1991	. 2001 ,	
1990	Biology of osteoclast activation in cancer. 2001 , 19, 3562-71	240
1989	Increasing membrane-bound MCSF does not enhance OPGL-driven osteoclastogenesis from marrow cells. 2001 , 280, E103-11	10
1988	Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. 2001 , 16, 769-73	8
1987	ELISA Methodology for Detection of Modified Osteoprotegerin in Clinical Studies. 2001 , 47, 747-749	27
1986	Molecular mechanisms of receptor dysfunction: implications for endocrine disorders. 2001 , 8, 41-46	
1985	Cytokines and fracture healing. 2001 , 12, 403-408	12
1984	Characterization of phagosomal subpopulations along endocytic routes in osteoclasts and macrophages. 2001 , 130, 823-31	18
1983	Regulation of bone cell development and function: implication for renal osteodystrophy. 2001 , 49, 240-9	3
1982	Apoptosis in autoimmune diseases. 2001 , 40, 275-84	124
1981	Two novel cucurbitacins, neocucurbitacins A and B, from the Brazilian folk medicine "Buchinha" (<i>Luffa operculata</i>) and their effect on PEBP2alphaA and OCIF gene expression in a human osteoblast-like Saos-2 cell line. 2001 , 49, 1377-9	13
1980	Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. 2001 , 97, 3349-53	298
1979	Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. 2001 , 98, 3527-33	344

1978	Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. 2001 , 98, 3534-40	324
1977	Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. 2001 , 98, 2269-71	143
1976	Bifurcation of osteoclasts and dendritic cells from common progenitors. 2001 , 98, 2544-54	236
1975	FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. 2001 , 98, 2707-13	43
1974	Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. 2001 , 98, 2784-90	110
1973	Gene Expression during Fracture Healing in Normal Mouse: In Situ Hybridization on Hard Tissues for Investigation of Regenerative Mechanisms.. 2001 , 34, 321-328	5
1972	Cytokines. 2001 ,	0
1971	Musculoskeletal disorders and orthopedic conditions. 2001 , 285, 619-23	9
1970	Bone Homeostasis: Extracellular Calcium Levels and Their Control. 2001 ,	
1969	Catabolic and anabolic signals in bone: therapeutic implications. 2001 , 4, 191-6	1
1968	Glucocorticoid-induced osteoporosis. 2001 , 10, 589-95	10
1967	Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. 2001 , 68, 151-5	68
1966	Osteopenia and osteoporosis in gastrointestinal diseases: diagnosis and treatment. 2001 , 3, 399-407	12
1965	Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. 2001 , 19, 365-72	24
1964	1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice. 2001 , 19, 277-86	11
1963	Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. 2001 , 19, 220-7	26
1962	Central control of bone formation. 2001 , 19, 195-8	73
1961	Mineral density and histomorphometric assessment of bone changes in the proximal tibia early after induction of type II collagen-induced arthritis in growing and mature rats. 2001 , 19, 76-83	25

1960	Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. 2001 , 20, 3-9	29
1959	Kat1-antigen--a reliable immunological marker for identifying osteoclast precursors of rats: detection of subpopulations among precursors and initiation of osteoclastogenesis. 2001 , 115, 215-22	6
1958	The nature of giant cell tumor of bone. 2001 , 127, 467-74	147
1957	Establishment and characterization of tartrate-resistant acid phosphatase and alkaline phosphatase double positive cell lines. 2001 , 304, 351-9	6
1956	Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. 2001 , 19, 518-23	14
1955	Generation of human osteoclasts in stromal cell-free and stromal cell-rich cultures: differences in osteoclast CD11c/CD18 integrin expression. 2001 , 112, 430-7	25
1954	Nitric oxide and bone. 2001 , 103, 255-61	389
1953	Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. 2001 , 36, 56-63	83
1952	Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. 2001 , 92, 460-70	144
1951	Change in cellular localization of a rheumatoid arthritis-related antigen (RA-A47) with downregulation upon stimulation by inflammatory cytokines in chondrocytes. 2001 , 186, 268-281	15
1950	Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. 2001 , 58, 393-400	26
1949	Inhibition of leukotriene function can modulate particulate-induced changes in bone cell differentiation and activity. 2001 , 58, 406-14	18
1948	Increased mRNA expression and protein secretion of interleukin-6 in primary human osteoblasts differentiated in vitro from rheumatoid and osteoarthritic bone. 2001 , 81, 666-78	26
1947	Regulation of osteoclastogenesis and RANK expression by TGF-beta1. 2001 , 83, 320-5	93
1946	Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. 2001 , 83, 70-83	111
1945	Carbonic anhydrase II is an AP-1 target gene in osteoclasts. 2001 , 188, 89-97	41
1944	Immunolocalization of vacuolar-type H ⁺ -ATPase, cathepsin K, matrix metalloproteinase-9, and receptor activator of NFkappaB ligand in odontoclasts during physiological root resorption of human deciduous teeth. 2001 , 264, 305-11	61
1943	The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. 2001 , 44, 253-9	83

1942	Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. 2001 , 44, 1003-12	552
1941	The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. 2001 , 44, 2768-76	96
1940	Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. 2001 , 31, 2179-88	141
1939	Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. 2001 , 19, 163-96	1068
1938	Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. 2001 , 207, 118-26	11
1937	Involvement of ADAM9 in multinucleated giant cell formation of blood monocytes. 2001 , 213, 104-13	55
1936	Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. 2001 , 20, 333-49	150
1935	Acid attack and cathepsin K in bone resorption around total hip replacement prosthesis. 2001 , 16, 1780-6	80
1934	Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. 2001 , 16, 1787-94	214
1933	Conditional ablation of the osteoblast lineage in Col2.3deltak transgenic mice. 2001 , 16, 2222-31	93
1932	T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. 2001 , 16, 328-37	135
1931	The effect of a single dose of osteoprotegerin in postmenopausal women. 2001 , 16, 348-60	358
1930	Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. 2001 , 16, 1004-14	412
1929	The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. 2001 , 16, 1015-27	109
1928	Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. 2001 , 16, 1416-25	85
1927	Glucocorticoid-induced osteoporosis. 2001 , 2, 65-73	142
1926	Paget's disease of bone: a disease of the osteoclast. 2001 , 2, 195-201	35
1925	Regulation of osteoclast formation and function. 2001 , 2, 95-104	46

1924	The effects of osteoprotegerin on the mechanical properties of rat bone. 2001 , 12, 583-8	22
1923	Hydroxyapatite particles are capable of inducing osteoclast formation. 2001 , 12, 659-64	32
1922	Phenotypic characteristics of T lymphocytes in the interfacial tissue of aseptically loosened prosthetic joints. 2001 , 12, 1063-7	17
1921	Dexamethasone inhibits bone resorption by indirectly inducing apoptosis of the bone-resorbing osteoclasts via the action of osteoblastic cells. 2001 , 35, 25-34	7
1920	Human interleukin-1 beta and interleukin-1 receptor antagonist secretion and velocity of tooth movement. 2001 , 46, 185-9	89
1919	Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. 2001 , 61, 579-86	97
1918	Osteoprotegerin levels before and after renal transplantation. 2001 , 38, S175-7	46
1917	Bone changes in early rheumatoid arthritis. 2001 , 15, 105-23	28
1916	Emerging therapies in osteoporosis. 2001 , 15, 483-96	5
1915	Osteoprotegerin: a new therapeutic agent for the treatment of bone disease. 2001 , 6, 1241-1242	13
1914	The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. 2001 , 13, 389-400	297
1913	Presence of osteoclast precursors in colonies cloned in the presence of hematopoietic colony-stimulating factors. 2001 , 29, 68-76	24
1912	Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. 2001 , 276, 563-8	397
1911	Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. 2001 , 276, 14665-74	116
1910	A novel osteoblast-derived C-type lectin that inhibits osteoclast formation. 2001 , 276, 14916-23	63
1909	Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. 2001 , 276, 36241-50	113
1908	Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegerin gene expression. 2001 , 276, 10119-25	82
1907	Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling. 2001 , 169, 285-94	175

1906	Postmenopausal Osteoporosis. 2001 , 85-101	0
1905	Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium. 2001 , 40, 673-82	46
1904	Involvement of T-lymphocytes in periodontal disease and in direct and indirect induction of bone resorption. 2001 , 12, 125-35	225
1903	CD30:CD30 ligand interactions in the immune response. 2000 , 33, 45-60	7
1902	Bone Cements and Cementing Technique. 2001 ,	1
1901	Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. 2001 , 142, 4047-54	336
1900	Embryonic Stem Cells. 2001 ,	1
1899	Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. 2001 , 142, 3656-62	205
1898	Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. 2001 , 3, 197-205	84
1897	Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. 2001 , 98, 5798-803	185
1896	Connection between B lymphocyte and osteoclast differentiation pathways. 2001 , 167, 2625-31	190
1895	Wnt signaling regulates hemopoiesis through stromal cells. 2001 , 167, 765-72	75
1894	Severe osteopenia in a young boy with Kostmann's congenital neutropenia treated with granulocyte colony-stimulating factor: suggested therapeutic approach. 2001 , 108, E54	18
1893	Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. 2001 , 170, 451-60	152
1892	Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. 2001 , 98, 13960-5	423
1891	Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. 2001 , 166, 3574-9	193
1890	Mechanism of stimulation of osteoclastic bone resorption through Gas6/Tyro 3, a receptor tyrosine kinase signaling, in mouse osteoclasts. 2001 , 276, 7376-82	52
1889	Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. 2001 , 86, 631-7	391

1888	Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. 2001 , 21, 1610-6	291
1887	Lactosylceramide is essential for the osteoclastogenesis mediated by macrophage-colony-stimulating factor and receptor activator of nuclear factor-kappa B ligand. 2001 , 276, 46031-8	42
1886	Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. 2001 , 276, 8836-40	264
1885	Regulation of receptor activator of NF-kappaB ligand-induced tartrate-resistant acid phosphatase gene expression by PU.1-interacting protein/interferon regulatory factor-4. Synergism with microphthalmia transcription factor. 2001 , 276, 33086-92	19
1884	Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. 2001 , 276, 20659-72	285
1883	Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. 2001 , 166, 1482-91	157
1882	Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. 2001 , 171, 425-33	74
1881	Localization of receptor activator of NFkappaB ligand, RANKL, in periodontal tissues during experimental movement of rat molars. 2001 , 50, 365-9	50
1880	rDrak1, a novel kinase related to apoptosis, is strongly expressed in active osteoclasts and induces apoptosis. 2001 , 276, 19238-43	14
1879	Leptin reduces ovariectomy-induced bone loss in rats. 2001 , 142, 3546-53	236
1878	Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. 2001 , 98, 11581-6	430
1877	Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. 2001 , 40, 623-30	173
1876	Osteoclast differentiation antigen, distinct from receptor activator of nuclear factor kappa B, is involved in osteoclastogenesis under calcitonin-regulated conditions. 2001 , 170, 175-83	9
1875	Spezielle medikamentöse Therapie der Osteoporose bei chronisch-entzündlichen Erkrankungen des Bewegungsapparates. 2001 , 26, 129-137	2
1874	Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. 2001 , 86, 3162-5	173
1873	The genetics of Paget's disease of the bone. 2001 , 86, 24-8	27
1872	Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. 2001 , 142, 3632-7	56
1871	Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. 2001 , 142, 1419-26	153

1870	Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors. 2001 , 142, 1290-5	105
1869	17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. 2001 , 142, 2205-12	161
1868	OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. 2001 , 142, 4295-304	115
1867	Minireview: the OPG/RANKL/RANK system. 2001 , 142, 5050-5	1071
1866	Osteoclast differentiation factor induces synovial macrophage-osteoclast differentiation in rheumatoid arthritis. 2001 , 11, 314-20	1
1865	Animal Cell Technology: Challenges for the 21st Century. 2002 ,	
1864	Antagonistic selective binding agents of osteoprotegerin binding protein. 2002 , 12, 469-470	
1863	Rationale for the role of osteoclast-like cells in arterial calcification. 2002 , 16, 577-82	86
1862	The osteopetrotic mutation toothless (tl) is a loss-of-function frameshift mutation in the rat Csf1 gene: Evidence of a crucial role for CSF-1 in osteoclastogenesis and endochondral ossification. 2002 , 99, 14303-8	101
1861	Role of RANKL and RANK in bone loss and arthritis. 2002 , 61 Suppl 2, ii32-9	136
1860	Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. 2002 , 277, 6631-6	55
1859	Are coroners' necropsies necessary? A prospective study examining whether a "view and grant" system of death certification could be introduced into England and Wales. 2002 , 55, 878-9	1
1858	LIGHT, a member of the tumor necrosis factor ligand superfamily, prevents tumor necrosis factor-alpha-mediated human primary hepatocyte apoptosis, but not Fas-mediated apoptosis. 2002 , 277, 50054-61	29
1857	CpG oligonucleotides: novel regulators of osteoclast differentiation. 2002 , 16, 274-82	46
1856	Osteoprotegerin ligand induces beta-casein gene expression through the transcription factor CCAAT/enhancer-binding protein beta. 2002 , 277, 5339-44	18
1855	Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. 2002 , 87, 4080-4	93
1854	Osteoprotegerin deficiency and juvenile Paget's disease. 2002 , 347, 175-84	374
1853	Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases. 2002 , 6, 679-89	22

1852	High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. 2002 , 22, 6222-33	220
1851	Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. 2002 , 277, 6622-30	165
1850	TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. 2002 , 277, 6799-805	94
1849	Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. 2002 , 277, 21971-82	146
1848	U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. 2002 , 277, 47366-72	249
1847	Giant cell tumor of bone. The role of fibroblast growth factor 3 positive mesenchymal stem cells in its pathogenesis. 2002 , 70, 333-42	29
1846	Gender- and age-related differences in osteoclast formation from circulating precursors. 2002 , 172, 673-81	33
1845	A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. 2002 , 277, 44347-56	186
1844	Effect of IL-12 on TNF-alpha-mediated osteoclast formation in bone marrow cells: apoptosis mediated by Fas/Fas ligand interaction. 2002 , 169, 4732-8	63
1843	Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. 2002 , 277, 11077-83	187
1842	Osteoclast inhibitory lectin, a family of new osteoclast inhibitors. 2002 , 277, 48808-15	44
1841	Osteoporosis in the rheumatic disease patient. 2002 , 11, 675-9	14
1840	Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis. 2002 , 61 Suppl 2, ii82-3	27
1839	Bone destruction in arthritis. 2002 , 61 Suppl 2, ii84-6	239
1838	Fibroblasts from the inner granulation tissue of the pseudocapsule in hips at revision arthroplasty induce osteoclast differentiation, as do stromal cells. 2002 , 61, 103-9	38
1837	Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation. 2002 , 277, 27880-6	71
1836	Estrogen inhibition of PTH-stimulated osteoclast formation and attachment in vitro: involvement of both PKA and PKC. 2002 , 143, 627-35	31
1835	Transcriptional activity of nuclei in multinucleated osteoclasts and its modulation by calcitonin. 2002 , 143, 1913-21	49

1834	RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. 2002 , 117, 210-6	132
1833	Stem cells in bone formation growth and remodeling. 2002 , 201-221	1
1832	Bone turnover following autologous transplantation in multiple myeloma. 2002 , 43, 511-6	5
1831	Estrogen receptor-related receptor alpha impinges on the estrogen axis in bone: potential function in osteoporosis. 2002 , 143, 3658-70	46
1830	Rheumatoid arthritis: new insights into the role of synovial inflammation in joint destruction. 2002 , 12, 287-93	2
1829	Chronic recurrent multifocal osteomyelitis (CRMO): evidence for a susceptibility gene located on chromosome 18q21.3-18q22. 2002 , 10, 217-21	152
1828	Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function. 2002 , 143, 4868-74	37
1827	Multiple myeloma. 2002 , 2002, 214-40	54
1826	Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. 2002 , 87, 4033-41	148
1825	Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype. 2002 , 143, 4711-7	17
1824	Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma. 2002 , 7 Suppl 1, 20-9	15
1823	Hyaluronan-CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9. 2002 , 158, 1133-44	72
1822	8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. 2002 , 277, 14221-6	100
1821	Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. 2002 , 22, 992-1000	227
1820	Synovial macrophage-osteoclast differentiation in inflammatory arthritis. 2002 , 61, 916-21	67
1819	Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases. 2002 , 55, 877-8	55
1818	Mechanisms balancing skeletal matrix synthesis and degradation. 2002 , 364, 329-41	125
1817	Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone. 2002 , 277, 26217-24	67

1816	Modulation of growth factor/cytokine synthesis and signaling by 1alpha,25-dihydroxyvitamin D(3): implications in cell growth and differentiation. 2002 , 23, 763-86	138
1815	A novel member of the leukocyte receptor complex regulates osteoclast differentiation. 2002 , 195, 201-9	220
1814	Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. 2002 , 277, 48868-75	167
1813	Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors. 2002 , 55, 879; author reply 879	
1812	Rare presentation of intestinal amyloidosis with acute intestinal pseudo-obstruction and perforation. 2002 , 55, 876	10
1811	Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. 2002 , 147, 269-73	54
1810	Sensitivity to Quorn mycoprotein (<i>Fusarium venenatum</i>) in a mould allergic patient. 2002 , 55, 876-7	13
1809	Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. 2002 , 61, 1047-54	132
1808	Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. 2002 , 277, 41147-56	320
1807	Localization of osteoprotegerin (OPG) on bone surfaces and cement lines in rat tibia. 2002 , 50, 945-53	16
1806	Prostate Cancer: New Horizons in Research and Treatment. 2002 ,	
1805	Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. 2002 , 39, 551-6	26
1804	Chapter 10 Genetic and dietary factors in age-related bone loss. 2002 , 179-199	1
1803	Pathogenesis of bone erosions in rheumatoid arthritis. 2002 , 14, 406-10	52
1802	Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. 2002 , 25, 53-9	91
1801	Role of cytokines and chemokines in cartilage and bone destruction in arthritis. 2002 , 13, 351-362	4
1800	Bisphosphonates in cancer therapy. 2002 , 14, 609-15	35
1799	Novel therapeutic options for osteoporosis. 2002 , 14, 447-52	10

1798	Familial expansile osteolysis (excessive RANK effect) in a 5-generation American kindred. 2002 , 81, 101-21	33
1797	Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. 2002 , 100, 2530-6	38
1796	Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. 2002 , 99, 634-40	142
1795	Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. 2002 , 100, 3646-55	72
1794	Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. 2002 , 100, 4615-21	214
1793	Bone resorption in chronic otitis media: the role of the osteoclast. 2002 , 64, 95-107	39
1792	Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. 2002 , 2, 407-21	106
1791	Arsenic trioxide in multiple myeloma: rationale and future directions. 2002 , 8, 12-25	30
1790	Morphology and Chemical Composition of Connective Tissue: Bone. 67-120	3
1789	Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. 2002 , 34, 145-51	44
1788	Changes in proinflammatory cytokine activity after menopause. 2002 , 23, 90-119	647
1787	Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. 2002 , 161, 1419-27	332
1786	Protein Kinase C is a mediator of the synthesis and secretion of osteoprotegerin in osteoblast-like cells. 2002 , 290, 42-6	9
1785	Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. 2002 , 290, 650-5	84
1784	Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. 2002 , 291, 680-6	243
1783	A novel interaction between thyroid hormones and 1,25(OH)(2)D(3) in osteoclast formation. 2002 , 291, 987-94	65
1782	Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. 2002 , 103, 231-42	70
1781	Osteoprotegerin levels increased by interleukin-1beta in human periodontal ligament cells are suppressed through prostaglandin E(2) synthesized de novo. 2002 , 18, 133-9	21

1780	Neutralization of interleukin-11 activity decreases osteoclast formation and increases cancellous bone volume in ovariectomized mice. 2002 , 20, 78-85	18
1779	RANK-L and RANK: T cells, bone loss, and mammalian evolution. 2002 , 20, 795-823	649
1778	The aging of the immune system. 2002 , 80, 243-84	190
1777	Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. 2002 , 39, 525-32	136
1776	Signaling crosstalk between RANKL and interferons in osteoclast differentiation. 2002 , 4 Suppl 3, S227-32	119
1775	Osteoprotegerin differentially regulates protease expression in osteoclast cultures. 2002 , 293, 38-44	51
1774	Epigenetic control of mouse receptor activator of NF-kappa B ligand gene expression. 2002 , 293, 126-31	16
1773	Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. 2002 , 295, 417-22	76
1772	A feline assay using osteoclasts generated in vitro from peripheral blood for screening anti-resorptive agents. 2002 , 73, 283-90	7
1771	Histamine stimulates production of osteoclast differentiation factor/receptor activator of nuclear factor-kappaB ligand by osteoblasts. 2002 , 298, 240-6	33
1770	Localisation and activity of cathepsins K and B in equine osteoclasts. 2002 , 72, 95-103	13
1769	Generation and activity of equine osteoclasts in vitro: effects of the bisphosphonate pamidronate (APD). 2002 , 72, 105-13	15
1768	Current concepts in the biology of orthodontic tooth movement. 2002 , 8, 6-12	16
1767	Human periodontal ligament cells derived from deciduous teeth induce osteoclastogenesis in vitro. 2002 , 34, 44-51	37
1766	Periapical lesion development in rats inhibited by dexamethasone. 2002 , 28, 643-5	21
1765	Novel bone antiresorptive approaches. 2002 , 2, 330-7	2
1764	Reaching a genetic and molecular understanding of skeletal development. 2002 , 2, 389-406	1186
1763	Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. 2002 , 3, 889-901	1920

1762	Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. 2002 , 2, 25-38	38
1761	The generation of highly enriched osteoclast-lineage cell populations. 2002 , 30, 164-70	53
1760	Macrophage colony-stimulating factor and receptor activator NF-kappaB ligand fail to rescue osteoclast-poor human malignant infantile osteopetrosis in vitro. 2002 , 30, 85-90	23
1759	The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. 2002 , 30, 71-7	241
1758	Cbfa1 does not regulate RANKL gene activity in stromal/osteoblastic cells. 2002 , 30, 453-62	54
1757	Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway. 2002 , 30, 553-8	29
1756	ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. 2002 , 30, 582-8	104
1755	Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. 2002 , 30, 726-32	56
1754	Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. 2002 , 30, 853-8	48
1753	Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. 2002 , 31, 252-9	72
1752	[Regulation of bone remodeling. Physiologic basis]. 2002 , 9 Suppl 2, 92s-94s	
1751	Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. 2002 , 282, 1-17	277
1750	Fenton reaction is primarily involved in a mechanism of (-)-epigallocatechin-3-gallate to induce osteoclastic cell death. 2002 , 292, 94-101	131
1749	[Histogenesis of giant cell tumors]. 2002 , 23, 332-9	13
1748	Differential effects of interleukin-6 receptor activation on intracellular signaling and bone resorption by isolated rat osteoclasts. 2002 , 173, 395-405	22
1747	Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. 2002 ,	
1746	Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. 2002 , 283, C679-87	68
1745	Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. 2002 , 197-213	

1744	Mechanisms involved in the side effects of glucocorticoids. 2002 , 96, 23-43	1255
1743	Effects of oestrogen deficiency on osteoclastogenesis in the rat periodontium. 2002 , 47, 67-73	29
1742	Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption. 2002 , 47, 247-54	34
1741	Cytokine expression in feline osteoclastic resorptive lesions. 2002 , 127, 169-77	27
1740	The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. 2002 , 12, 83-8	53
1739	Cytokine inhibition: a new therapeutic avenue for skeletal diseases. 2002 , 7, 289	
1738	Ultrastructural study of cell-cell interaction between osteoclasts and osteoblasts/stroma cells in vitro. 2002 , 184, 221-7	7
1737	Regulation of activation-induced receptor activator of NF-kappaB ligand (RANKL) expression in T cells. 2002 , 32, 1090-8	66
1736	Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. 2002 , 58, 77-84	155
1735	Immunohistochemical study of receptor activator of nuclear factor kappa-B ligand (RANK-L) in human osteolytic bone tumors. 2002 , 79, 174-9	23
1734	Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. 2002 , 46, 1926-36	71
1733	Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. 2002 , 46, 3055-64	61
1732	Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. 2002 , 46, 3121-35	45
1731	How important are T cells in chronic rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to end. 2002 , 46, 298-308	172
1730	Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice. 2002 , 266, 218-25	84
1729	Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. 2002 , 268, 137-46	51
1728	Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. 2002 , 84, 725-35	70
1727	Characterization of the osteoblast-like cell phenotype under microgravity conditions in the NASA-approved rotating wall vessel bioreactor (RWV). 2002 , 85, 167-179	78

1726	Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. 2002 , 86, 642-50	25
1725	Physiopathology of cancer metastases in bone and of the changes they induce in bone remodeling. 2002 , 13, 181-246	3
1724	New insights into role of microenvironment in multiple myeloma. 2002 , 76 Suppl 1, 334-6	20
1723	Giant cell tumor of bone. 2002 , 4, 520-6	14
1722	Mechanisms of bone resorption and new bone formation in spondyloarthropathies. 2002 , 4, 513-7	8
1721	Pathogenesis of bone lesions in rheumatoid arthritis. 2002 , 4, 226-31	41
1720	Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. 2002 , 20, 14-20	21
1719	Differential localization of myosin II isoforms in resting and activated osteoclasts. 2002 , 71, 530-8	39
1718	Immunohistochemical localization of receptor activator of nuclear factor kappaB (RANK) and its ligand (RANKL) in human deciduous teeth. 2002 , 71, 45-52	84
1717	Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. 2002 , 59, 1569-76	45
1716	The anabolic effects of parathyroid hormone. 2002 , 13, 267-77	102
1715	Correlates of osteoprotegerin levels in women and men. 2002 , 13, 394-9	160
1714	Syndecan-1 in B lymphoid malignancies. 2002 , 81, 125-35	56
1713	RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. 2002 , 117, 283-92	45
1712	Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. 2002 , 20, 337-44	122
1711	SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. 2002 , 31, 345-52	20
1710	Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells. 2002 , 37, 405-11	97
1709	Regulatory mechanisms of osteoblast and osteoclast differentiation. 2002 , 8, 147-59	414

1708	TNF ligands and receptors in autoimmunity: an update. 2002 , 14, 783-90	94
1707	Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. 2002 , 116, 278-90	248
1706	RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. 2002 , 117, 86-92	95
1705	Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. 2002 , 20, 169-73	92
1704	Phenotypic characterization of mononuclear and multinucleated cells of giant cell reparative granuloma of small bones. 2002 , 198, 30-6	17
1703	Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. 2002 , 198, 220-7	204
1702	RANK ligand is a prerequisite for cancer-associated osteolytic lesions. 2002 , 198, 228-36	124
1701	Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. 2002 , 52, 20-33	170
1700	Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells. 2002 , 23, 2359-65	28
1699	SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. 2002 , 8, 943-9	214
1698	Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. 2002 , 62, 1277-84	62
1697	Mechanisms involved in bone resorption. 2002 , 3, 79-83	29
1696	Hormonal control of alveolar development and its implications for breast carcinogenesis. 2002 , 7, 39-48	94
1695	Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR. 2002 , 74, 255-69	82
1694	Large-scale screening for candidate genes of ossification of the posterior longitudinal ligament of the spine. 2002 , 17, 128-37	67
1693	Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. 2002 , 17, 1961-7	57
1692	Identification of estrogen-regulated genes of potential importance for the regulation of trabecular bone mineral density. 2002 , 17, 2183-95	28
1691	In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. 2002 , 17, 192-9	127

1690	Leptin inhibits osteoclast generation. 2002 , 17, 200-9	295
1689	Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor. 2002 , 17, 257-65	98
1688	Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand. 2002 , 17, 612-21	76
1687	Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. 2002 , 17, 622-9	56
1686	NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. 2002 , 17, 1200-10	131
1685	Dual modulation of osteoclast differentiation by lipopolysaccharide. 2002 , 17, 1211-8	170
1684	Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. 2002 , 17, 1245-55	139
1683	Activation of extracellular signal-regulated kinase is involved in mechanical strain inhibition of RANKL expression in bone stromal cells. 2002 , 17, 1452-60	96
1682	Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. 2002 , 17, 1667-79	118
1681	Hypercalcemia of malignancy. 2002 , 1, 51-64	3
1680	Nutrition and bone health in the elderly. 2003 , 1, 249-260	2
1679	The TNF receptor superfamily: role in immune inflammation and bone formation. 2003 , 27, 287-94	27
1678	Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. 2003 , 20, 639-46	29
1677	Regulation of bone lysis in inflammatory diseases. 2003 , 11, 323-31	8
1676	Programme and Abstracts. 2003 , 11, 471-562	
1675	Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. 2004 , 19, 155-64	81
1674	Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. 2004 , 19, 19-24	195
1673	Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts. 2004 , 19, 89-99	35

1672	PTH differentially regulates expression of RANKL and OPG. 2004 , 19, 235-44	251
1671	RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. 2004 , 19, 207-13	165
1670	Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. 2004 , 19, 652-60	97
1669	Biglycan deficiency interferes with ovariectomy-induced bone loss. 2003 , 18, 2152-8	43
1668	12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. 2003 , 18, 2159-68	117
1667	Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. 2003 , 18, 270-7	118
1666	Overexpression of RANKL implicates IFN-beta-mediated elimination of B-cell precursors in the osteopetrotic bone of microphthalmic mice. 2003 , 18, 278-88	13
1665	Cytokine Regulation and the signaling mechanism of osteoclast inhibitory peptide-1 (OIP-1/hSca) to inhibit osteoclast formation. 2003 , 18, 458-65	19
1664	Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. 2003 , 18, 529-38	44
1663	Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. 2003 , 18, 599-609	120
1662	Osteoclastogenesis-related antigen, a novel molecule on mouse stromal cells, regulates osteoclastogenesis. 2003 , 18, 686-95	3
1661	Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. 2003 , 18, 852-8	82
1660	RANKL expression is related to the differentiation state of human osteoblasts. 2003 , 18, 1088-98	195
1659	T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis. 2003 , 18, 984-93	48
1658	Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. 2003 , 18, 1198-205	80
1657	Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. 2003 , 18, 1206-16	204
1656	Metabolic acidosis stimulates RANKL RNA expression in bone through a cyclo-oxygenase-dependent mechanism. 2003 , 18, 1317-25	72
1655	Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. 2003 , 18, 1584-92	319

1654	Discrete types of osteoclast precursors can be generated from embryonic stem cells. 2003 , 21, 670-80	13
1653	The role of acquired immunity and periodontal disease progression. 2003 , 14, 237-52	106
1652	Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. 2003 , 115, 291-7	44
1651	Bone metastases in breast cancer. 2003 , 4, 151-8	22
1650	Interstitial collagenase activity stimulates the formation of actin rings and ruffled membranes in mouse marrow osteoclasts. 2003 , 72, 206-14	20
1649	Matrix proteins versus cytokines in the regulation of osteoblast function and bone formation. 2003 , 72, 5-7	13
1648	Treatment of myoblastic C2C12 cells with BMP-2 stimulates vitamin D-induced formation of osteoclasts. 2003 , 73, 72-7	42
1647	Menatetrenone (vitamin K2) acts directly on circulating human osteoclast precursors. 2003 , 73, 78-85	13
1646	Blockade of the pore-forming P2X7 receptor inhibits formation of multinucleated human osteoclasts in vitro. 2003 , 73, 361-9	76
1645	Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. 2003 , 73, 210-6	28
1644	Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. 2004 , 74, 103-6	83
1643	A rapid multiparameter approach to study factors that regulate osteoclastogenesis: demonstration of the combinatorial dominant effects of TNF-alpha and TGF-ss in RANKL-mediated osteoclastogenesis. 2003 , 73, 584-93	18
1642	Heparanase mRNA expression during fracture repair in mice. 2003 , 120, 493-503	40
1641	Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. 2003 , 443, 146-51	38
1640	Overview of osteoporosis: pathophysiology and determinants of bone strength. 2003 , 12 Suppl 2, S90-6	46
1639	Urinary excretion of deoxypyridinoline increases after gastrointestinal surgery. 2003 , 19, 747-53	1
1638	The anti-tumor potential of zoledronic acid. 2003 , 12 Suppl 2, S30-6	31
1637	Hepatocellular carcinoma with osteoclast-like giant cells: possibility of osteoclastogenesis by hepatocyte-derived cells. 2003 , 53, 450-6	29

1636	Molecular mechanisms underlying osteoclast formation and activation. 2003 , 38, 605-14	105
1635	Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. 2003 , 31, 1081-8	31
1634	Expression of tumour necrosis factor-alpha in the rat dental follicle. 2003 , 48, 47-54	30
1633	Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. 2003 , 97, 818-24	32
1632	RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. 2003 , 97, 802-12	86
1631	A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. 2003 , 97, 887-92	319
1630	Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. 2003 , 98, 458-67	62
1629	TRANCE together with IL-7 induces pre-B cells to proliferate. 2003 , 33, 334-41	8
1628	Differentiation of human bone-derived cells grown on GRGDSP-peptide bound titanium surfaces. 2003 , 64, 105-13	72
1627	Vitamin D and bone. 2003 , 88, 259-66	160
1626	Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. 2003 , 88, 650-9	74
1625	Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. 2003 , 89, 771-7	111
1624	In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. 2003 , 90, 267-77	35
1623	NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. 2003 , 90, 424-36	53
1622	Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. 2003 , 196, 180-9	74
1621	Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption. 2003 , 61, 483-95	99
1620	Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. 2003 , 61, 504-13	233
1619	Effect of glucocorticoids on bone density. 2003 , 41, 212-6	57

1618	Suppression of osteoclastogenesis in rheumatoid arthritis by induction of apoptosis in activated CD4+ T cells. 2003 , 48, 3350-8	24
1617	Interleukin-4 directly inhibits tumor necrosis factor-alpha-mediated osteoclast formation in mouse bone marrow macrophages. 2003 , 88, 193-8	26
1616	Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. 2003 , 21, 73-80	104
1615	Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. 2003 , 21, 676-84	71
1614	Porphyromonas gingivalis antigen preferentially stimulates T cells to express IL-17 but not receptor activator of NF-kappaB ligand in vitro. 2003 , 18, 30-6	80
1613	Multiple myeloma biology: lessons from the 5TMM models. 2003 , 194, 196-206	98
1612	Cellular mechanisms of osteoclast formation and lacunar resorption in giant cell granuloma of the jaw. 2003 , 32, 224-31	78
1611	Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. 2003 , 32, 367-75	132
1610	Jaw bone remodeling at the invasion front of gingival squamous cell carcinomas. 2003 , 32, 10-7	11
1609	Expression and role of RANKL in periodontal ligament cells during physiological root-resorption in human deciduous teeth. 2003 , 111, 346-52	89
1608	Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. 2003 , 38, 380-7	222
1607	Osteoclast differentiation by human osteoblastic cell line SaOS-2 primed with bacterial lipid A. 2003 , 38, 71-9	11
1606	Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. 2003 , 14, 342-9	67
1605	TRAF6 and C-SRC induce synergistic AP-1 activation via PI3-kinase-AKT-JNK pathway. 2003 , 270, 1257-68	40
1604	Adenocarcinoma in Crohn's disease. 2003 , 42, 404-5	3
1603	Intestinal polyposis due to multiple myeloma. 2003 , 42, 405-6	1
1602	CD30 expression in L&H cells of Hodgkin's disease, nodular lymphocyte predominant type. 2003 , 42, 406-7	4
1601	The origin of osteoclast-like giant cells in atypical fibroxanthoma. 2003 , 42, 407-10	16

1600	Intra-abdominal small round cell tumour with EWS-WT1 fusion transcript in an elderly patient. 2003 , 42, 410-2	2
1599	Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. 2003 , 122, 39-52	60
1598	Upregulation of osteoclast alpha2beta1 integrin compensates for lack of alphavbeta3 vitronectin receptor in Iraqi-Jewish-type Glanzmann thrombasthenia. 2003 , 122, 950-7	40
1597	New insights into the pathophysiology and management of bone disease in multiple myeloma. 2003 , 123, 758-69	41
1596	The comparative biology of skeletal metastasis. 2003 , 1, 131-9	2
1595	New aspects of IFN-alpha/beta signalling in immunity, oncogenesis and bone metabolism. 2003 , 94, 405-11	65
1594	Osteoclast differentiation and activation. 2003 , 423, 337-42	4586
1593	M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. 2003 , 10, 1165-77	281
1592	Human T-cell leukemia virus type I and adult T-cell leukemia. 2003 , 22, 5131-40	165
1591	Osteoclast stimulating and differentiating factors in human cholesteatoma. 2003 , 113, 436-42	38
1590	Bumetanide, the specific inhibitor of Na ⁺ -K ⁺ -2Cl ⁻ cotransport, inhibits 1alpha,25-dihydroxyvitamin D3-induced osteoclastogenesis in a mouse co-culture system. 2003 , 88, 569-74	6
1589	Genetic regulation of osteoclast development and function. 2003 , 4, 638-49	1297
1588	Signalling pathways of the TNF superfamily: a double-edged sword. 2003 , 3, 745-56	2051
1587	RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. 2003 , 21, 202-12	81
1586	Expression and function of TNF-family proteins and receptors in human osteoblasts>. 2003 ,	
1585	Highlights from: The 39th Annual Meeting of the American Society of Clinical Oncology; Chicago, Illinois. 2003 , 1, 8-15	
1584	Histología y citología del hueso normal. 2003 , 36, 1-6	
1583	Vitamin D: Biological Effects of 1,25(OH) ₂ D ₃ in Bone. 2003 , 609-615	

1582	Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. 2003 , 26, 748-53	80
1581	Clinical review 165: Markers of bone remodeling in metastatic bone disease. 2003 , 88, 5059-75	91
1580	Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. 2003 , 85, 1196-201	97
1579	The synergistic effect of peptidoglycan and lipopolysaccharide on osteoclast formation. 2003 , 96, 738-43	22
1578	Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. 2003 , 163, 2021-31	220
1577	Delitto Perfetto Targeted Mutagenesis in Yeast with Oligonucleotides. 2003 , 189-207	17
1576	Expression and function of TNF-family proteins and receptors in human osteoblasts. 2003 , 33, 760-70	78
1575	Regulation of osteoclast protease expression by RANKL. 2003 , 310, 774-8	46
1574	Regulatory effects of osteoprotegerin on cellular and humoral immune responses. 2003 , 109, 347-54	39
1573	Inducible nitric oxide synthase mediates bone loss in ovariectomized mice. 2003 , 144, 1098-107	64
1572	IL-13 regulates vascular cell adhesion molecule-1 expression in human osteoblasts. 2003 , 89, 213-9	8
1571	Ultrastructural and cytobiological studies on possible interactions between PTHrP-secreting tumor cells, stromal cells, and bone cells. 2003 , 21, 353-62	4
1570	Transcriptional regulation by calcium, calcineurin, and NFAT. 2003 , 17, 2205-32	1468
1569	High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. 2003 , 38, 395-400	82
1568	Mitogen-activated protein (MAP) kinases mediate PMMA-induction of osteoclasts. 2003 , 21, 1041-8	49
1567	Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis. 2003 , 300, 957-64	54
1566	p44/42 MAPK activation is necessary for receptor activator of nuclear factor-kappaB ligand induction by high extracellular calcium. 2003 , 304, 729-35	21
1565	Association of sustained ERK activity with integrin beta3 induction during receptor activator of nuclear factor kappaB ligand (RANKL)-directed osteoclast differentiation. 2003 , 289, 368-77	30

1564	Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis. 2003 , 34, 65-73	28
1563	Calcium hydroxide reduces lipopolysaccharide-stimulated osteoclast formation. 2003 , 95, 348-54	37
1562	The stable analog carbocyclic TXA2 but not platelet-released TXA2 induces osteoclast-like cell formation. 2003 , 68, 267-72	5
1561	Protective role of n-3 lipids and soy protein in osteoporosis. 2003 , 68, 361-72	62
1560	Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. 2003 , 19, 849-61	124
1559	Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men. 2003 , 80, 344-9	48
1558	Biology of the TRANCE axis. 2003 , 14, 251-63	163
1557	Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. 2003 , 4, 284-92	61
1556	Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. 2003 , 32, 1-7	369
1555	Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. 2003 , 32, 96-106	55
1554	Participation of protein kinase C beta in osteoclast differentiation and function. 2003 , 32, 217-27	33
1553	Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. 2003 , 32, 621-9	31
1552	The surface antigen CD45R identifies a population of estrogen-regulated murine marrow cells that contain osteoclast precursors. 2003 , 32, 581-90	35
1551	Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. 2003 , 33, 721-32	68
1550	The anabolic effects of parathyroid hormone therapy. 2003 , 19, 415-32	81
1549	RANKL (Receptor activator of NFB ligand). 2003 , 871-883	
1548	The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. 2003 , 349, 2483-94	1215
1547	The role of osteoprotegerin in arthritis. 2003 , 5, 239-45	22

1546	Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation. 2003 , 5, R49-59	52
1545	Current management strategies for hypercalcemia. 2003 , 2, 273-92	35
1544	The 12th international rheumatology symposium in Tokyo. 2003 , 13, 376-96	
1543	Signalling in osteoclasts and the role of Fos/AP1 proteins. 2003 , 62 Suppl 2, ii83-5	36
1542	The Role of RANKL (TRANCE/TNFSF11), a Tumor Necrosis Factor Family Member, in Skeletal Development: Effects of Gene Knockout and Transgenic Rescue. 2003 , 44, 264-271	58
1541	Novel therapies for osteoporosis. 2003 , 12, 611-21	13
1540	Expression of vascular endothelial growth factor and the effects on bone remodeling during experimental tooth movement. 2003 , 82, 177-82	64
1539	Osteoclast apoptosis: the role of Fas in vivo and in vitro. 2003 , 144, 5545-55	76
1538	An essential role of cytosolic phospholipase A2alpha in prostaglandin E2-mediated bone resorption associated with inflammation. 2003 , 197, 1303-10	149
1537	Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome. 2003 , 49, 2085-8	58
1536	Induction of osteoclastogenesis and matrix metalloproteinase expression by the lipooligosaccharide of Treponema denticola. 2003 , 71, 226-33	40
1535	Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. 2003 , 77, 8562-9	18
1534	Hedgehog signaling enhances core-binding factor a1 and receptor activator of nuclear factor-kappaB ligand (RANKL) gene expression in chondrocytes. 2003 , 177, 413-21	30
1533	Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. 2003 , 278, 21258-66	44
1532	Catalytic properties of ADAM19. 2003 , 278, 22331-40	101
1531	The receptor activator of nuclear factor-kappa B ligand-mediated osteoclastogenic pathway is elevated in amelogenin-null mice. 2003 , 278, 35743-8	79
1530	Multimerization of the receptor activator of nuclear factor-kappaB ligand (RANKL) isoforms and regulation of osteoclastogenesis. 2003 , 278, 47217-22	42
1529	RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. 2003 , 17, 2163-5	70

1528	The receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) is a new chemotactic factor for human monocytes. 2003 , 17, 1751-3	228
1527	Mycobacterium tuberculosis chaperonin 10 heptamers self-associate through their biologically active loops. 2003 , 185, 4172-85	23
1526	Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. 2003 , 149, 351-62	92
1525	Tuning of innate immunity and polarized responses by decoy receptors. 2003 , 132, 109-15	26
1524	RANK ligand-induced elevation of cytosolic Ca ²⁺ accelerates nuclear translocation of nuclear factor kappa B in osteoclasts. 2003 , 278, 8286-93	74
1523	Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. 2003 , 278, 39548-57	89
1522	Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL. 2003 , 197, 1029-35	70
1521	Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. 2003 , 82, 546-50	22
1520	Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha. 2003 , 171, 5130-9	50
1519	Direct inhibition of NF-kappa B blocks bone erosion associated with inflammatory arthritis. 2003 , 171, 5547-53	84
1518	Expression and role of mannose receptor/terminal high-mannose type oligosaccharide on osteoclast precursors during osteoclast formation. 2003 , 176, 285-92	29
1517	Bone Research Protocols. 2003 ,	12
1516	CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation. 2003 , 171, 6541-8	98
1515	RANK ligand and osteoprotegerin in myeloma bone disease. 2003 , 101, 2094-8	211
1514	Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. 2003 , 88, 1318-26	80
1513	Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. 2003 , 176, 339-48	99
1512	Lipopolysaccharide promotes the survival of osteoclasts via Toll-like receptor 4, but cytokine production of osteoclasts in response to lipopolysaccharide is different from that of macrophages. 2003 , 170, 3688-95	149
1511	Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. 2003 , 278, 46171-8	98

1510	Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor osteoclast-associated receptor gene expression. 2003 , 278, 24209-16	78
1509	Effects of matrix metalloproteinase inhibitors on bone resorption and orthodontic tooth movement. 2003 , 82, 687-91	39
1508	Osteoclast formation from circulating precursors in osteoporosis. 2003 , 32, 95-100	27
1507	Involvement of upstream stimulatory factors 1 and 2 in RANKL-induced transcription of tartrate-resistant acid phosphatase gene during osteoclast differentiation. 2003 , 278, 20603-11	32
1506	Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. 2003 , 171, 3620-6	53
1505	Dominant-negative I kappa B facilitates apoptosis of osteoclasts by tumor necrosis factor-alpha. 2003 , 278, 20077-82	40
1504	Normal mineral homeostasis. Interplay of parathyroid hormone and vitamin D. 2003 , 6, 14-33	14
1503	Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. 2003 , 278, 29420-34	188
1502	IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. 2003 , 171, 142-51	55
1501	RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. 2003 , 278, 48745-53	125
1500	Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. 2003 , 49, 2083-5	36
1499	Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2 ^{-/-} mice by RANKL transgene. 2003 , 278, 23971-7	121
1498	HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. 2003 , 278, 48251-8	126
1497	Receptor activator of nuclear factor kappa B ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. 2003 , 32, 287-94	55
1496	Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. 2003 , 21, 3526-34	96
1495	Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. 2003 , 278, 43603-14	107
1494	Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. 2003 , 278, 44667-74	66
1493	Clinicopathologic and molecular features of Hodgkin's lymphoma. 2003 , 2, 500-7	12

1492	CpG oligodeoxynucleotides modulate the osteoclastogenic activity of osteoblasts via Toll-like receptor 9. 2003 , 278, 16732-40	73
1491	Defective bone remodelling in osteoprotegerin-deficient mice. 2003 , 52, 503-13	30
1490	Molecular and genetic mechanisms of osteoporosis: implication for treatment. 2003 , 3, 737-57	15
1489	Generating human osteoclasts from peripheral blood. 2003 , 80, 101-11	15
1488	Collagenase cleavage of type I collagen is essential for both basal and parathyroid hormone (PTH)/PTH-related peptide receptor-induced osteoclast activation and has differential effects on discrete bone compartments. 2003 , 144, 4106-16	35
1487	Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. 2003 , 88, 4206-13	81
1486	Analysis of osteoclast function in mouse calvarial cultures. 2003 , 80, 169-82	1
1485	The role of calmodulin in the regulation of osteoclastogenesis. 2003 , 144, 4536-43	29
1484	Generating murine osteoclasts from bone marrow. 2003 , 80, 129-44	43
1483	Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficient mice. 2003 , 52, 515-25	17
1482	Abstract. 2003 , 21, 1-108	24
1481	Understanding osteoclast formation and function: implications for future therapies for osteoporosis. 2003 , 14, 341-350	4
1480	RANKL and RANK as novel therapeutic targets for arthritis. 2003 , 15, 280-7	66
1479	Parallels between arterial and cartilage calcification: what understanding artery calcification can teach us about chondrocalcinosis. 2003 , 15, 302-10	33
1478	Collagen turnover in bone diseases. 2003 , 6, 65-71	7
1477	Regulation of bone cell function by acid-base balance. 2003 , 62, 511-20	138
1476	The role of bisphosphonates in breast cancer. 2003 , 1, 232-41	2
1475	The development of supportive-care agents for patients with cancer. 2003 , 9, 397-417	1

1474	Advances in Biology and Therapy of Multiple Myeloma. 2003 , 2003, 248-278	52
1473	Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. 2003 , 101, 2227-34	106
1472	Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. 2003 , 101, 3451-9	156
1471	Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. 2003 , 101, 2983-9	68
1470	IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. 2003 , 102, 1078-86	110
1469	New insights in myeloma-induced osteolysis. 2003 , 44, 1463-7	49
1468	Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. 2003 , 78, 593S-609S	278
1467	Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment. 2003 , 56, 116-20	32
1466	Parathyroid Hormone and Calcium Homeostasis. 2003 , 135-172	
1465	Literature Cited. 2003 , 609-637	
1464	Differentiation and function of osteoclasts. 2003 , 52, 1-7	113
1463	Receptor activator of NF-[kappa]B ligand arrests bone growth and promotes cortical bone resorption in growing rats. 2003 , 95, 672-6	2
1462	Bisphosphonates in Oncology: Physiopathologic Bases and Clinical Activity. 2003 , 89, 223-236	9
1461	Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. 2004 , 287, G836-44	37
1460	Osteoporose e erosões osseas focais na artrite reumatóide: da patogênese ao tratamento. 2004 , 44, 347-354	2
1459	Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunology. 2004 , 53, 78-84	30
1458	Osteoclastic bone resorption through receptor tyrosine kinase and extracellular signal-regulated kinase signaling in mature osteoclasts. 2004 , 14, 1-5	12
1457	Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development. 2004 , 55, 1001-8	31

1456	Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism. 2004 , 89, 1246-54	27
1455	Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. 2004 , 89, 188-92	42
1454	[Expression of osteoclast stimulating and differentiating factors in a murine model of localized inflammatory bone resorption]. 2004 , 83, 14-9	5
1453	Lipopolysaccharide-induced osteoclastogenesis in Src homology 2-domain phosphatase-1-deficient viable motheaten mice. 2004 , 145, 2721-9	11
1452	Opg, Rank, and Rankl in tooth development: co-ordination of odontogenesis and osteogenesis. 2004 , 83, 241-4	62
1451	Essential role for ADAM19 in cardiovascular morphogenesis. 2004 , 24, 96-104	113
1450	Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. 2004 , 63, 1379-86	94
1449	The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. 2004 , 15, 2834-41	116
1448	Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. 2004 , 145, 751-9	94
1447	A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. 2004 , 279, 30202-9	51
1446	Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. 2004 , 279, 26475-80	438
1445	Postmenopausal osteoporosis, T cells, and immune dysfunction. 2004 , 101, 16711-2	57
1444	The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. 2004 , 279, 13984-92	207
1443	Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. 2004 , 279, 45969-79	325
1442	Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation. 2004 , 172, 2504-10	133
1441	Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. 2004 , 173, 4838-46	152
1440	IL-1alpha stimulates cathepsin K expression in osteoclasts via the tyrosine kinase-NF-kappaB pathway. 2004 , 83, 791-6	27
1439	Soluble RANKL and risk of nontraumatic fracture. 2004 , 291, 1108-13	106

1438	Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease. 2004 , 13, 849	1
1437	Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. 2004 , 145, 426-36	47
1436	Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. 2004 , 95, 1046-57	345
1435	The role of TNF-related activation-induced cytokine-receptor activating NF-kappa B interaction in acute allograft rejection and CD40L-independent chronic allograft rejection. 2004 , 172, 1619-29	29
1434	Functional identification of three receptor activator of NF-kappa B cytoplasmic motifs mediating osteoclast differentiation and function. 2004 , 279, 54759-69	47
1433	Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis. 2004 , 279, 13555-63	41
1432	Anabolic Therapy of Osteoporosis in Women and in Men. 2004 , 995-1009	
1431	The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. 2004 , 145, 848-59	149
1430	Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. 2004 , 172, 5940-7	210
1429	Gene expression relevant to osteoclastogenesis in the synovium and bone marrow of mature rats with collagen-induced arthritis. 2004 , 43, 1496-503	15
1428	Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. 2004 , 145, 3554-62	102
1427	Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll-like receptors: the new entry TIR8/SIGIRR. 2004 , 75, 738-42	55
1426	Psoriatic arthritis. 2004 , 17, 350-63	57
1425	Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. 2004 , 126, 192-201	72
1424	Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. 2004 , 126, 475-86	88
1423	Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. 2004 , 60, 87-91	39
1422	The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. 2004 , 61, 244-9	28
1421	Osteoclasts and giant cells: macrophage-macrophage fusion mechanism. 2000 , 81, 291-304	89

1420	Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. 2004 , 33, 46-52	37
1419	Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. 2004 , 60, 307-15	284
1418	Antigen specificity and T-cell clonality in periodontal disease. 2004 , 35, 75-100	18
1417	Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. 2004 , 10, 617-24	423
1416	Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. 2004 , 11 Suppl 1, S97-107	70
1415	The vital osteoclast: how is it regulated?. 2004 , 11 Suppl 1, S5-7	19
1414	Aseptic loosening. 2004 , 11, 402-7	161
1413	Gene expression in giant-cell tumors. 2004 , 144, 193-200	50
1412	Role for osteoprotegerin in rheumatoid inflammation. 2004 , 71, 9-13	63
1411	Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. 2004 , 32, 351-9	20
1410	New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). 2004 , 32, 685-91	97
1409	Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). 2004 , 32, 905-10	27
1408	Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK. 2004 , 1644, 1-7	36
1407	RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. 2004 , 1704, 49-57	96
1406	Inhibition of osteoclast formation by 3-methylcholanthrene, a ligand for arylhydrocarbon receptor: suppression of osteoclast differentiation factor in osteogenic cells. 2004 , 67, 119-27	31
1405	Ranking the role of RANK ligand in apoptosis. 2004 , 9, 677-90	34
1404	Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link?. 2004 , 23, 1-10	201
1403	Primary adult T-cell leukemia/lymphoma of bone. 2004 , 79, 157-60	12

1402	Immunohistological identification of receptor activator of NF-kappaB ligand (RANKL) in human, ovine and bovine bone tissues. 2004 , 15, 367-72	11
1401	Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis. 2004 , 24, 370-8	34
1400	Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. 2004 , 19, 722-7	78
1399	A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004 , 19, 1059-66	550
1398	RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1. 2004 , 19, 1339-48	44
1397	Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. 2004 , 19, 1506-11	53
1396	1 alpha,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. 2004 , 19, 1411-9	58
1395	Malignant autosomal recessive osteopetrosis caused by spontaneous mutation of murine Rank. 2004 , 19, 1689-97	30
1394	Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. 2004 , 19, 1873-81	114
1393	SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL. 2005 , 20, 15-22	5
1392	Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44. 2005 , 20, 30-40	58
1391	Mice lacking the integrin beta5 subunit have accelerated osteoclast maturation and increased activity in the estrogen-deficient state. 2005 , 20, 58-66	26
1390	RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts. 2005 , 20, 107-16	58
1389	Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. 2005 , 20, 480-6	96
1388	Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. 2005 , 20, 653-62	124
1387	TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. 2005 , 20, 840-7	81
1386	Influence of glucocorticoids on human osteoclast generation and activity. 2005 , 20, 390-8	78
1385	The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). 2004 , 19, 147-54	123

1384	Osteopontin-deficiency suppresses growth of B16 melanoma cells implanted in bone and osteoclastogenesis in co-cultures. 2004 , 19, 1706-11	26
1383	Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6). 2004 , 19, 1128-36	52
1382	Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells. 2004 , 130, 469-74	28
1381	Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. 2004 , 22, 132-8	75
1380	Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL). 2004 , 22, 185-91	21
1379	The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage. 2004 , 22, 318-28	19
1378	Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation. 2004 , 22, 415-29	27
1377	Renal osteodystrophy. 2004 , 154, 107-18	4
1376	Bone lysis and inflammation. 2004 , 53, 596-600	48
1375	Calcium sensing and cell signaling processes in the local regulation of osteoclastic bone resorption. 2004 , 79, 79-100	38
1374	Rôle de l'ostéoprotégérine dans l'inflammation et la polyarthrite rhumatoïde. 2004 , 71, 11-16	1
1373	Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFKappaB, RANK ligand and osteoprotegerin. 2004 , 25, 565-73	128
1372	Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity. 2004 , 22, 21-9	60
1371	NF-kB signaling blockade abolishes implant particle-induced osteoclastogenesis. 2004 , 22, 13-20	99
1370	Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis. 2004 , 58, 41-9	34
1369	Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. 2004 , 60, 214-9	46
1368	Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. 2004 , 50, 265-76	176
1367	In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells. 2004 , 111, 829-38	44

1366	Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity. 2004 , 70, 361-9	172
1365	Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. 2004 , 91, 718-29	208
1364	Bone morphogenetic protein signaling in prostate cancer cell lines. 2004 , 91, 151-60	86
1363	TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. 2004 , 93, 980-9	23
1362	Regulation of RANKL promoter activity is associated with histone remodeling in murine bone stromal cells. 2004 , 93, 807-18	31
1361	A low dose of daidzein acts as an ERbeta-selective agonist in trabecular osteoblasts of young female piglets. 2004 , 200, 253-62	55
1360	Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. 2004 , 201, 17-25	56
1359	Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. 2004 , 229, 293-309	304
1358	Expression of membrane-bound and soluble receptor activator of NF-kappaB ligand (RANKL) in human T cells. 2004 , 94, 239-46	63
1357	Regulation of osteoclast activity in peri-implant tissues. 2004 , 25, 4877-85	58
1356	The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts. 2004 , 25, 5803-8	64
1355	The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression. 2004 , 45, 1111-8	39
1354	Multiple myeloma: clinical review and diagnostic imaging. 2004 , 231, 11-23	204
1353	Proteasome Inhibitors in Cancer Therapy. 2004 ,	21
1352	Regulatory effects of interleukin-1beta and prostaglandin E2 on expression of receptor activator of nuclear factor-kappaB ligand in human periodontal ligament cells. 2004 , 75, 249-59	53
1351	The pathophysiology of cancer-induced bone pain: current understanding. 2004 , 18, 267-74	101
1350	Levels of cytokine receptor activator of nuclear factor kappaB ligand in gingival crevicular fluid in untreated chronic periodontitis patients. 2004 , 75, 1586-91	66
1349	Identification of RANKL in osteolytic lesions of the facial skeleton. 2004 , 83, 349-53	49

1348	Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. 2004 , 6, 354-63	74
1347	Ion channels in osteoblasts: a story of two intracellular organelles. 2004 , 2, 63-9	3
1346	Skeleton key to vascular disease. 2004 , 44, 1977-9	6
1345	Mechanisms of bone metastasis. 2004 , 350, 1655-64	1762
1344	Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. 2004 , 2, 6	76
1343	Osteopetrosis. 2004 , 351, 2839-49	418
1342	Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. 2004 , 83, 166-9	187
1341	Crystal structure of RANK ligand involved in bone metabolism. 2004 , 67, 19-33	9
1340	T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion. 2004 , 43, 122-30	30
1339	Targeting Syk as a treatment for allergic and autoimmune disorders. 2004 , 13, 743-62	120
1338	Systemic and Local Regulators of Bone Remodeling. 2004 , 44-70	
1337	Biology of recently discovered cytokines: interleukin-17--a unique inflammatory cytokine with roles in bone biology and arthritis. 2004 , 6, 240-7	95
1336	Enhanced osteoclast development in collagen-induced arthritis in interferon-gamma receptor knock-out mice as related to increased splenic CD11b+ myelopoiesis. 2004 , 6, R220-31	49
1335	Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. 2004 , 292, 490-5	678
1334	Evidence of a role for RANKL in the development of myeloma bone disease. 2004 , 4, 340-6	21
1333	IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. 2004 , 15, 49-60	696
1332	The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. 2004 , 15, 457-75	474
1331	YY1 is involved in RANKL-induced transcription of the tartrate-resistant acid phosphatase gene in osteoclast differentiation. 2004 , 343, 117-26	13

1330	Molecular characterization of two novel isoforms of the human calcitonin receptor. 2004 , 343, 143-51	8
1329	Bone metabolism in relation to alterations in systemic growth hormone. 2004 , 14, 404-17	38
1328	Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. 2004 , 34, 425-31	29
1327	Mitf-PU.1 interactions with the tartrate-resistant acid phosphatase gene promoter during osteoclast differentiation. 2004 , 34, 237-45	24
1326	Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappa B ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. 2004 , 35, 256-65	44
1325	High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. 2004 , 35, 785-91	38
1324	Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. 2004 , 35, 629-35	121
1323	Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. 2004 , 314, 1021-7	48
1322	Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. 2004 , 316, 809-15	37
1321	Vitamin A differentially regulates RANKL and OPG expression in human osteoblasts. 2004 , 322, 162-7	26
1320	Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells. 2004 , 324, 655-60	19
1319	Myeloma cells (5TMM) and their interactions with the marrow microenvironment. 2004 , 33, 111-9	26
1318	Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. 2004 , 293, 292-301	46
1317	Parathyroid hormone: a double-edged sword for bone metabolism. 2004 , 15, 60-5	209
1316	Identification of a peptide binding motif for secreted frizzled-related protein-1. 2004 , 25, 1831-8	16
1315	Bisphosphonates: new therapeutic agents for the treatment of bone tumors. 2004 , 10, 337-43	109
1314	Cell lines and primary cell cultures in the study of bone cell biology. 2004 , 228, 79-102	166
1313	Rheumatoid arthritis, new standards of care: nursing implications of infliximab. 2004 , 8, 41-49	2

1312	MicroCT quantification of in vitro bone resorption of neonatal murine calvaria exposed to IL-1 or PTH. 2004 , 147, 185-99	23
1311	Preclinical Profile of Zoledronic Acid in Prostate Cancer Models. 2004 , 3, 16-24	2
1310	[New treatments in osteoporosis]. 2004 , 25 Suppl 5, S573-9	4
1309	Interleukin-6 family of cytokines as biochemical markers of osseous changes in the temporomandibular joint disorders. 2004 , 42, 246-50	35
1308	The origins of osteoclasts. 2004 , 16, 464-8	42
1307	Pax5-deficient mice exhibit early onset osteopenia with increased osteoclast progenitors. 2004 , 173, 6583-91	52
1306	Evidence that receptor activator of nuclear factor (NF)-kappaB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappaB-independent and TRAF6-dependent mechanism. 2004 , 279, 6065-76	87
1305	Bone loss in inflammatory arthritis: mechanisms and treatment strategies. 2004 , 16, 419-27	88
1304	NEW MOLECULES IN THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR SUPERFAMILIES WITH IMPORTANCE FOR PHYSIOLOGICAL AND PATHOLOGICAL BONE RESORPTION. 2004 , 15, 64-81	102
1303	17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. 2004 , 104, 1404-10	125
1302	T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. 2004 , 104, 3722-30	128
1301	TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. 2004 , 104, 2044-50	88
1300	B-Lymphocytes are Elevated in Mouse Bone Marrow by Estrogen Deficiency, and Induce Receptor Activator of Nuclear Factor .KAPPA.B Ligand (RANKL) Expression in Osteoblasts via Cell Adhesion. 2004 , 50, 309-314	1
1299	Suppressive effect of Kanzo-bushi-to, a Kampo medicine, on collagen-induced arthritis. 2004 , 27, 1406-13	26
1298	Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts. 2004 , 27, 504-9	99
1297	Suppressive effect of Dai-bofu-to on collagen-induced arthritis. 2004 , 27, 857-62	5
1296	Vitamin D and bone-How does vitamin D regulate bone formation and resorption?-. 2004 , 80, 407-421	6
1295	Sex differences in skeletal development. 2004 , 229-245	1

1294 BIO-PATHOLOGY OF BONE TUMORS. **2005**, 413-434

1293 Parathyroid Hormone-Related Peptide and Malignancy. **2005**, 13-27

1292 REGULATION OF BONE REMODELING. **2005**, 279-298

1291 Bone health in pediatric rheumatic disease. **2005**, 17, 703-8

14

1290 Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. **2005**, 65, 11001-9

206

1289 Receptor activator of nuclear κ B ligand and osteoprotegerin: where are we now and what about future treatment uses?. **2005**, 16, 370-375

3

1288 In Situ Hybridization on Calcified Tissue: Detection of RANKL mRNA in Mouse Osteolytic Bone Lesions. **2005**, 38, 143-149

2

1287 Hormone and Exercise-Induced Modulation of Bone Metabolism. 408-425

1

1286 Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment. **2005**, 10, 215-24

22

1285 High-phosphorus diet stimulates receptor activator of nuclear factor-kappaB ligand mRNA expression by increasing parathyroid hormone secretion in rats. **2005**, 94, 666-74

20

1284 Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. **2005**, 106, 3160-5

292

1283 Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis. **2005**, 106, 1240-5

48

1282 Role of Bisphosphonates in Skeletal Metastases. **2005**, 305-321

1281 Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. **2005**, 29, 761-9

47

1280 Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening. **2005**, 23, 511-9

46

1279 Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact. **2005**, 23, 979-87

41

1278 Pulsed electromagnetic fields stimulation affects osteoclast formation by modulation of osteoprotegerin, RANK ligand and macrophage colony-stimulating factor. **2005**, 23, 1308-14

41

1277 The bisphosphonate pamidronate on the surface of titanium stimulates bone formation around tibial implants in rats. **2005**, 26, 581-7

106

1276	Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. 2005 , 26, 1695-702	52
1275	Symbioimine and neosymbioimine, amphoteric iminium metabolites from the symbiotic marine dinoflagellate <i>Symbiodinium</i> sp. 2005 , 13, 5253-8	57
1274	Bones in coeliac disease: diagnosis and treatment. 2005 , 19, 453-65	55
1273	The role of macrophages in osteolysis of total joint replacement. 2005 , 26, 1271-86	529
1272	Does human relaxin-2 affect peripheral blood mononuclear cells to increase inflammatory mediators in pathologic bone loss?. 2005 , 1041, 317-9	10
1271	Thapsigargin modulates osteoclastogenesis through the regulation of RANKL-induced signaling pathways and reactive oxygen species production. 2005 , 20, 1462-71	66
1270	Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. 2005 , 20, 1659-68	128
1269	BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. 2005 , 20, 1669-79	56
1268	Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis. 2005 , 20, 1692-9	25
1267	Self-assembled RANK induces osteoclastogenesis ligand-independently. 2005 , 20, 2053-60	39
1266	Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. 2005 , 20, 2036-43	28
1265	Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. 2005 , 20, 2224-32	132
1264	Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor. 2005 , 20, 2264-70	12
1263	Dominant negative N-cadherin inhibits osteoclast differentiation by interfering with beta-catenin regulation of RANKL, independent of cell-cell adhesion. 2005 , 20, 2200-12	24
1262	Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification. 2006 , 21, 58-66	63
1261	Gorham-Stout syndrome: a monocyte-mediated cytokine propelled disease. 2006 , 21, 207-18	53
1260	Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL. 2006 , 21, 438-45	37
1259	A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004. 2005 , 20, 2275-82	41

- 1258 Miscellaneous hormone therapies for osteoporosis. **2005**, 3, 067-074
- 1257 RANKing intracellular signaling in osteoclasts. **2005**, 57, 389-95 156
- 1256 Skeletal function and structure: implications for tissue-targeted therapeutics. **2005**, 57, 945-57 64
- 1255 Expression of mRNA for osteoprotegerin and receptor activator of nuclear factor kappa beta ligand (RANKL) during root resorption induced by the application of heavy orthodontic forces on rat molars. **2005**, 128, 497-503 56
- 1254 Maternal plasma osteoprotegerin concentration in normal pregnancy. **2005**, 193, 1011-5 28
- 1253 Enforced expression of PU.1 rescues osteoclastogenesis from embryonic stem cells lacking Tal-1. **2005**, 23, 134-43 13
- 1252 Periodontitis and rheumatoid arthritis: a review. **2005**, 76, 2066-74 200
- 1251 Immunolocalization of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) in Meckel's cartilage compared with developing endochondral bones in mice. **2005**, 207, 325-37 35
- 1250 Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. **2005**, 6, 145-50 48
- 1249 Osteoprotegerin and RANKL in alcoholic liver cirrhosis. **2005**, 25, 305-10 34
- 1248 Tocotrienol offers better protection than tocopherol from free radical-induced damage of rat bone. **2005**, 32, 761-70 101
- 1247 Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. **2005**, 11, 291-7 231
- 1246 Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. **2005**, 115, 172-7 81
- 1245 Leptin regulation of bone resorption by the sympathetic nervous system and CART. **2005**, 434, 514-20 962
- 1244 Recognition of bacterial glycosphingolipids by natural killer T cells. **2005**, 434, 520-5 784
- 1243 Inflammatory bone destruction and osteoimmunology. **2005**, 40, 287-93 197
- 1242 Areca nut extracts modulated expression of alkaline phosphatase and receptor activator of nuclear factor kappaB ligand in osteoblasts. **2005**, 32, 353-9 14
- 1241 Ostéoporose post-ménopausique : traiter aujourd'hui et demain. **2005**, 72, S10-S15

1240	The role of T lymphocytes in bone metabolism. 2005 , 208, 154-68	148
1239	Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. 2005 , 208, 30-49	241
1238	B cells and osteoblast and osteoclast development. 2005 , 208, 141-53	56
1237	alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. 2005 , 208, 88-105	254
1236	Fos/AP-1 proteins in bone and the immune system. 2005 , 208, 126-40	385
1235	The role of the immune system in the pathophysiology of osteoporosis. 2005 , 208, 207-27	263
1234	Osteoclast precursors, RANKL/RANK, and immunology. 2005 , 208, 19-29	164
1233	Interplay between interferon and other cytokine systems in bone metabolism. 2005 , 208, 181-93	139
1232	Rheumatic diseases: the effects of inflammation on bone. 2005 , 208, 228-51	301
1231	Role of interleukin-7 in bone and T-cell homeostasis. 2005 , 208, 169-80	58
1230	A glycoprotein from <i>Spirometra erinaceieuropaei</i> plerocercoids suppresses osteoclastogenesis and proinflammatory cytokine gene expression. 2005 , 35, 1399-406	9
1229	Deficiencies of physiologic calcification inhibitors and low-grade inflammation in arterial calcification: lessons for cartilage calcification. 2005 , 72, 110-8	26
1228	Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha). 2005 , 69, 87-95	33
1227	Pathogenesis of myelofibrosis with myeloid metaplasia: lessons from mouse models of the disease. 2005 , 32, 365-72	13
1226	Ameloblastoma induces osteoclastogenesis: a possible role of ameloblastoma in expanding in the bone. 2005 , 41, 637-44	37
1225	Pulsed electromagnetic fields stimulation affects osteoclast formation by modulation of osteoprotegerin, RANK ligand and macrophage colony-stimulating factor. 2005 , 23, 1308-1314	43
1224	Characterization of the cytokine pattern of porcine bone marrow-derived cells treated with 1alpha,25(OH)D. 2005 , 52, 382-7	7
1223	CBP sensitizes v-myb-transformed monoblasts to differentiation inducers. 2005 , 73, 222-32	3

1222	Influence of receptor activator of nuclear factor kappa B on human aortic valve myofibroblasts. 2005 , 78, 36-40	29
1221	Suppression of polyethylene particle-induced osteolysis by exogenous osteoprotegerin. 2005 , 75, 288-94	31
1220	Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation. 2005 , 74, 582-8	22
1219	Osteolytic potential of triphenyl bismuth as an alternative contrast medium in acrylic bone cement. 2005 , 75, 64-73	9
1218	Effect of CD44 deficiency on in vitro and in vivo osteoclast formation. 2005 , 94, 954-66	79
1217	Receptor activator of NF-kappaB ligand protein expression in UMR-106 cells is differentially regulated by parathyroid hormone and calcitriol. 2005 , 95, 1029-41	11
1216	Sp1 and Sp3 regulate the basal transcription of receptor activator of nuclear factor kappa B ligand gene in osteoblasts and bone marrow stromal cells. 2005 , 96, 716-27	30
1215	TNF-alpha expression is transcriptionally regulated by RANK ligand. 2005 , 202, 371-8	29
1214	Evidence of reciprocal regulation between the high extracellular calcium and RANKL signal transduction pathways in RAW cell derived osteoclasts. 2005 , 202, 554-62	20
1213	Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. 2005 , 203, 573-82	28
1212	Organization of transcriptional regulatory machinery in osteoclast nuclei: compartmentalization of Runx1. 2005 , 204, 871-80	21
1211	Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. 2005 , 204, 714-23	124
1210	Collagen type I signaling reduces the expression and the function of human receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes. 2005 , 35, 3673-82	12
1209	Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. 2005 , 116, 253-62	39
1208	Amelioration of rat adjuvant-induced arthritis by Met-RANTES. 2005 , 52, 1907-19	94
1207	RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. 2005 , 52, 2307-12	94
1206	Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis. 2005 , 52, 3257-68	47
1205	The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. 2005 , 52, 2960-7	27

1204	Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. 2005 , 26, 63-9	46
1203	Mechanistic insight into osteoclast differentiation in osteoimmunology. 2005 , 83, 170-9	320
1202	Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. 2005 , 76, 1-6	59
1201	Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemical markers in patients with recent spinal cord injury. 2005 , 76, 404-11	61
1200	Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. 2005 , 76, 90-7	57
1199	Characterization of circulating human osteoclast progenitors: development of in vitro resorption assay. 2005 , 76, 222-30	61
1198	Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. 2005 , 77, 239-49	15
1197	Neuronal signaling and the regulation of bone remodeling. 2005 , 62, 2339-49	100
1196	Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa. 2005 , 16, 424-9	18
1195	Bone remodeling: new aspects of a key process that controls skeletal maintenance and repair. 2005 , 16 Suppl 2, S18-24	35
1194	The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women. 2005 , 16, 1519-24	67
1193	Inflammation de bas grade et déficit en inhibiteurs physiologiques de la calcification dans les calcifications des artères: mécanismes permettant de comprendre les calcifications du cartilage. 2005 , 72, 186-194	
1192	Upregulation of receptor activator of nuclear factor-kappaB ligand expression in the thymic subcapsular, paraseptal, perivascular, and medullary epithelial cells during thymus regeneration. 2005 , 123, 491-500	14
1191	Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). 2005 , 23, 41-7	51
1190	Roles for NF-kappaB and c-Fos in osteoclasts. 2005 , 23 Suppl, 11-5	74
1189	Mouse models in skeletal physiology and osteoporosis: experiences and data on 14,839 cases from the Hamburg Mouse Archives. 2005 , 23 Suppl, 97-102	33
1188	Osteoprotegerin as a potential therapy for osteoporosis. 2005 , 3, 121-5	10
1187	Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. 2005 , 10, 169-80	251

1186	Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. 2005 , 36, 59-67	84
1185	Unsatisfactory gene transfer into bone-resorbing osteoclasts with liposomal transfection systems. 2005 , 4, 5	12
1184	Proteomic identification of the TRAF6 regulation of vacuolar ATPase for osteoclast function. 2005 , 5, 4152-60	10
1183	Comparative study of protein and mRNA expression during osteoclastogenesis. 2005 , 5, 3868-75	39
1182	RECENT ADVANCES IN BONE BIOLOGY RESEARCH. 2005 , 497-511	
1181	Psoriatic Arthritis. 2005 , 36-45	1
1180	Modulation of Osteoclast Differentiation by RANKL-RANK Signaling. 2005 , 59, 199-209	
1179	Bacterial toxins and bone remodelling. 2005 , 147-168	1
1178	Bone Remodeling and Mineralization. 2005 , 20, 543	2
1177	RANK, RANKL and osteoprotegerin in arthritic bone loss. 2005 , 38, 161-70	69
1176	Rolipram, a phosphodiesterase 4 inhibitor, stimulates inducible cAMP early repressor expression in osteoblasts. 2005 , 46, 149-54	9
1175	TNF-alpha and pathologic bone resorption. 2005 , 54, 127-31	150
1174	IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. 2005 , 289, E784-93	59
1173	Activation of the extracellular signal-regulated kinase by complement C5b-9. 2005 , 289, F593-603	28
1172	New insights in the mechanism of bone loss in arthritis. 2005 , 11, 3039-49	19
1171	Craniofacial anomalies: from development to molecular pathogenesis. 2005 , 5, 699-722	75
1170	Design of cathepsin K inhibitors for osteoporosis. 2005 , 5, 1639-75	34
1169	Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis. 2005 , 11, 6109-15	17

1168	Interleukin-3 and granulocyte-macrophage colony-stimulating factor inhibits tumor necrosis factor (TNF)-alpha-induced osteoclast differentiation by down-regulation of expression of TNF receptors 1 and 2. 2005 , 280, 11759-69	35
1167	The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. 2005 , 54, 479-87	163
1166	GH/IGF-I and bone resorption in vivo and in vitro. 2005 , 152, 327-32	58
1165	Effects of cyclic tensile forces on the expression of vascular endothelial growth factor (VEGF) and macrophage-colony-stimulating factor (M-CSF) in murine osteoblastic MC3T3-E1 cells. 2005 , 84, 422-7	36
1164	Regulation of Osteoclast Activity. 2005 , 34-57	3
1163	Myeloma bone disease. 2005 , 10 Suppl 1, 19-24	25
1162	Osteoclast responses to lipopolysaccharide, parathyroid hormone and bisphosphonates in neonatal murine calvaria analyzed by laser scanning confocal microscopy. 2005 , 53, 1525-37	10
1161	Differential regulation of osteoblast activity by Th cell subsets mediated by parathyroid hormone and IFN-gamma. 2005 , 175, 8287-95	27
1160	Osteoporosis and integrins. 2005 , 90, 2466-8	22
1159	Transcription in the osteoblast: regulatory mechanisms utilized by parathyroid hormone and transforming growth factor-beta. 2005 , 80, 287-321	12
1158	Genetics and Mutations Affecting Osteoclast Development and Function. 2005 , 91-107	1
1157	Effects of osteoprotegerin administration on osteoclast differentiation and trabecular bone structure in osteoprotegerin-deficient mice. 2005 , 54, 467-77	10
1156	Osteoimmunological insight into bone damage in rheumatoid arthritis. 2005 , 15, 225-231	12
1155	Treatment of Paget's disease--taming the wild osteoclast. 2005 , 353, 872-5	20
1154	Osteoprotegerin and diabetic macroangiopathy. 2005 , 37 Suppl 1, 90-4	21
1153	Multiple myeloma: an update of developments in targeted therapy. 2005 , 5, 379-89	2
1152	Magic bullets to kill nasty osteoclasts. 2005 , 146, 3233-4	4
1151	Overview of osteoporosis: pathophysiology and determinants of bone strength. 2005 , 8-14	

1150	Advances in the management of myeloma bone disease. 2005 , 6, 2781-91	3
1149	Receptor activator of NF-kappaB ligand enhances the activity of macrophages as antigen presenting cells. 2005 , 37, 524-32	16
1148	Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. 2005 , 175, 5809-16	95
1147	Suppressors of cytokine signaling-1 and -3 regulate osteoclastogenesis in the presence of inflammatory cytokines. 2005 , 174, 3024-31	37
1146	P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. 2005 , 280, 16909-15	87
1145	Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. 2005 , 280, 41155-64	83
1144	IL-1 receptor-associated kinase M is a central regulator of osteoclast differentiation and activation. 2005 , 201, 1169-77	55
1143	Cellular interactions in lymph node development. 2005 , 174, 21-5	105
1142	Receptor activator of NF-kappaB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4. 2005 , 280, 43064-72	27
1141	Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. 2005 , 280, 35209-16	186
1140	RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro. 2005 , 289, F1005-11	27
1139	Bone Metastasis. 2005 ,	1
1138	Osteoclast: Origin and Differentiation. 2005 , 1-23	6
1137	The role of the sympathetic nervous system in controlling bone metabolism. 2005 , 9, 931-40	59
1136	Osteoprotegerin and bone mineral density in hemodiafiltration patients. 2005 , 27, 531-9	13
1135	A RANKL-inducible gene Znf216 in osteoclast differentiation. 2005 , 25, 199-216	11
1134	Partial rescue of B cells in microphthalmic osteopetrotic marrow by loss of response to type I IFNs. 2005 , 17, 1495-503	3
1133	Integration/Interaction of Oncologic Growth. 2005 ,	3

1132	Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. 2005 , 90, 2964-71	77
1131	NF- κ B is essential for the recruitment of RNA polymerase II and inducible transcription of several CCAAT box-containing genes. 2005 , 25, 512-22	71
1130	IKK β as a target for treatment of inflammation induced bone loss. 2005 , 64 Suppl 4, iv81-5	17
1129	A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. 2005 , 106, 852-9	620
1128	G(-) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. 2005 , 54, 1477-86	77
1127	Advances in osteoclast differentiation and function. 2005 , 5, 347-55	22
1126	Potassium channel-blockers as therapeutic agents to interfere with bone resorption of periodontal disease. 2005 , 84, 488-99	28
1125	Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. 2005 , 280, 11395-403	99
1124	TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF- κ B activation in endothelial cells. 2005 , 175, 531-40	145
1123	Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. 2005 , 175, 6211-8	52
1122	Gamma interferon positively modulates Actinobacillus actinomycetemcomitans-specific RANKL+ CD4+ Th-cell-mediated alveolar bone destruction in vivo. 2005 , 73, 3453-61	74
1121	I κ B kinase (IKK) β , but not IKK α , is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. 2005 , 201, 1677-87	215
1120	Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis. 2005 , 175, 7193-201	55
1119	Identification of an alternatively spliced variant of Ca ²⁺ -promoted Ras inactivator as a possible regulator of RANKL shedding. 2005 , 280, 41700-6	26
1118	Bone metabolism and growth hormone deficiency. Experimental and clinical aspects. 2005 , 33, 146-160	1
1117	Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts. 2005 , 15, 827	0
1116	Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?. 2005 , 20, 566-70	33
1115	The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. 2005 , 146, 3235-43	87

1114	Prostaglandin E2 strongly inhibits human osteoclast formation. 2005 , 146, 5204-14	76
1113	Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. 2005 , 90, 6323-31	181
1112	Macrophages that have phagocytosed particles are capable of differentiating into functional osteoclasts. 2005 , 15, 346-351	4
1111	Infliximab acts directly on human osteoclast precursors and enhances osteoclast formation induced by receptor activator of nuclear factor B ligand in vitro. 2005 , 15, 97-103	12
1110	Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health. 2005 , 59 Suppl 1, S225-8	12
1109	Molecular and Biological Mechanisms of Bone Metastasis. 2005 , 3, 214-226	31
1108	An introduction to death receptors in apoptosis. 2005 , 3, 268-77	51
1107	Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. 2005 , 182, 175-80	99
1106	Detection of receptor activator of NF-kappa beta ligand in apical periodontitis. 2005 , 31, 17-8	28
1105	In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?. 2005 , 3, 553-80	88
1104	Influence of Occlusal Stimuli on the Remodelling of Alveolar Bone in a Rat Hypofunction-Recovery Model. 2005 , 47, 321-334	17
1103	Pathophysiology of age-related bone loss and osteoporosis. 2005 , 34, 1015-30, xi	224
1102	Cannabinoids as Therapeutics. 2005 ,	13
1101	T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients. 2005 , 76, 1675-80	68
1100	Effects of positive pressure in odontogenic keratocysts. 2005 , 84, 913-8	38
1099	Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. 2005 , 65, 9943-52	151
1098	LTB4 can directly stimulate human osteoclast formation from PBMC independent of RANKL. 2005 , 33, 391-403	18
1097	Mechanisms of Disease: the link between RANKL and arthritic bone disease. 2005 , 1, 47-54	140

1096	Role of matrix Gla protein in parathyroid hormone inhibition of osteoblast mineralization. 2005 , 181, 166-75	30
1095	Osteoprotegerin (OPG) and receptor activator of NF- κ B ligand (RANK-L) serum levels in patients on chronic hemodialysis. 2005 , 28, 534-9	21
1094	Ascorbic acid inhibits osteoclastogenesis of RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand (RANKL) in vitro. 2005 , 28, 253-60	26
1093	The cytolethal distending toxin induces receptor activator of NF- κ B ligand expression in human gingival fibroblasts and periodontal ligament cells. 2005 , 73, 342-51	75
1092	Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. 2005 , 12, 549-83	172
1091	Crystal structure of murine 11 beta-hydroxysteroid dehydrogenase 1: an important therapeutic target for diabetes. 2005 , 44, 6948-57	67
1090	The RANKL/OPG system and bone mineral density in patients with chronic liver disease. 2005 , 43, 973-83	81
1089	Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures. 2005 , 33, 749-55	19
1088	Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. 2005 , 36, 945-54	110
1087	IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. 2005 , 77, 615-26	85
1086	Role of endocrine-immune dysregulation in osteoporosis, sarcopenia, frailty and fracture risk. 2005 , 26, 181-201	80
1085	Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women. 2005 , 51, 270-9	59
1084	Modulation of osteoclast formation. 2005 , 328, 739-45	88
1083	Mechanisms of sex steroid effects on bone. 2005 , 328, 688-96	295
1082	RANK ligand and interferon gamma differentially regulate cathepsin gene expression in pre-osteoclastic cells. 2005 , 328, 756-63	36
1081	Osteoporosis with increased osteoclastogenesis in hematopoietic cell-specific STAT3-deficient mice. 2005 , 328, 800-7	53
1080	Hypoxic stress enhances osteoclast differentiation via increasing IGF2 production by non-osteoclastic cells. 2005 , 328, 885-94	38
1079	Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis. 2005 , 329, 839-45	41

1078	Tumor necrosis factor-alpha induces differentiation of human peripheral blood mononuclear cells into osteoclasts through the induction of p21(WAF1/Cip1). 2005 , 330, 1080-6	24
1077	Death of osteocytes turns off the inhibition of osteoclasts and triggers local bone resorption. 2005 , 335, 1095-101	94
1076	Ascorbic acid promotes osteoclastogenesis from embryonic stem cells. 2005 , 335, 1239-46	31
1075	Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. 2005 , 338, 687-93	63
1074	Regulatory roles and molecular signaling of TNF family members in osteoclasts. 2005 , 350, 1-13	108
1073	The insulin-like growth factor-I gene and osteoporosis: a critical appraisal. 2005 , 361, 38-56	129
1072	A bio-assay for effectors of osteoclast differentiation in serum from patients with bone disease. 2005 , 356, 154-63	6
1071	Effect of oral contraceptive treatment on bone mass acquisition in skeletally immature young female rats. 2005 , 71, 362-71	8
1070	Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. 2005 , 5, 618-25	198
1069	The causes and treatment of bone loss associated with carcinoma of the breast. 2005 , 31, 115-42	55
1068	Cytokine responses of human gingival fibroblasts to Actinobacillus actinomycetemcomitans cytolethal distending toxin. 2005 , 30, 56-63	71
1067	Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. 2005 , 8, 751-64	1242
1066	EBF2 regulates osteoblast-dependent differentiation of osteoclasts. 2005 , 9, 757-67	95
1065	Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. 2005 , 68, 117-25	56
1064	IL-1-induced receptor activator of NF-kappa B ligand in human periodontal ligament cells involves ERK-dependent PGE2 production. 2005 , 36, 267-75	55
1063	Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. 2005 , 36, 159-72	136
1062	An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. 2005 , 36, 542-8	28
1061	Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. 2005 , 36, 727-35	41

1060	Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. 2005 , 36, 840-53	175
1059	Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. 2005 , 37, 87-95	42
1058	SOST is a target gene for PTH in bone. 2005 , 37, 148-58	520
1057	Prostate cancer mediates osteoclastogenesis through two different pathways. 2005 , 223, 121-8	26
1056	Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. 2005 , 579, 832-8	50
1055	Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint. 2005 , 37, 247-55	26
1054	Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review. 2005 , 65, 1223-38	13
1053	In vitro and in vivo biological responses to a novel radiopacifying agent for bone cement. 2005 , 2, 71-8	24
1052	Immunolocalization of receptor activator of NF kappa B ligand in rat periapical lesions. 2005 , 31, 574-7	41
1051	The tissue, cellular, and molecular regulation of orthodontic tooth movement: 100 years after Carl Sandstedt. 2006 , 28, 221-40	308
1050	Osteoclasts; culprits in inflammatory osteolysis. 2006 , 8, 201	107
1049	Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction. 2005 , 7, R65-70	64
1048	Inhibitory effect of ribbon-type NF-kappaB decoy oligodeoxynucleotides on osteoclast induction and activity in vitro and in vivo. 2006 , 8, R103	14
1047	Rheumatoid Arthritis and other Inflammatory Joint Pathologies. 2006 , 843-869	1
1046	Pepstatin A, an aspartic proteinase inhibitor, suppresses RANKL-induced osteoclast differentiation. 2006 , 139, 583-90	15
1045	Biology of Langerhans cells and Langerhans cell histiocytosis. 2006 , 254, 1-43	58
1044	Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors. 2006 , 4, 473-82	6
1043	Increase in RANKL: OPG ratio in synovia of patients with temporomandibular joint disorder. 2006 , 85, 627-32	29

1042	The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. 2006 , 4, 801-11	121
1041	Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone. 2006 , 168, 551-61	14
1040	B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. 2006 , 169, 987-98	383
1039	An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. 2006 , 169, 2236-44	121
1038	Bone density and markers of bone remodeling in type 1 male diabetic patients. 2006 , 32, 453-8	47
1037	Cutaneous metastasis of primary appendicular osteosarcoma in a dog. 2006 , 35, 358-61	6
1036	Immune modulation by mesenchymal stem cells. 2006 , 312, 2169-79	280
1035	Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). 2006 , 67, 139-41	18
1034	Response to bortezomib and activation of osteoblasts in multiple myeloma. 2006 , 7, 109-14	40
1033	Differentiating primary human cells in rapid-throughput discovery applications. 2007 , 356, 121-8	8
1032	Denosumab in postmenopausal women with low bone mineral density. 2006 , 354, 821-31	931
1031	Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models. 2006 , 19, 399-412	8
1030	Selenite-induced apoptosis of osteoclasts mediated by the mitochondrial pathway. 2006 , 160, 143-50	48
1029	High expression levels of receptor activator of nuclear factor-kappa B ligand associated with human chronic periodontitis are mainly secreted by CD4+ T lymphocytes. 2006 , 77, 1772-80	57
1028	Osteoimmunology: interplay between the immune system and bone metabolism. 2006 , 24, 33-63	492
1027	Profiling the cytokines in gingival crevicular fluid using a cytokine antibody array. 2006 , 77, 856-64	80
1026	Osteoclast and its roles in calcium metabolism and bone development and remodeling. 2006 , 343, 345-50	56
1025	Tetraspanin CD9 regulates osteoclastogenesis via regulation of p44/42 MAPK activity. 2006 , 347, 178-84	22

1024	Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. 2006 , 347, 124-32	42
1023	Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. 2006 , 347, 460-7	71
1022	Ca ²⁺ stimulates COX-2 expression through calcium-sensing receptor in fibroblasts. 2006 , 351, 808-14	34
1021	Human osteoblasts produce cathepsin K. 2006 , 38, 769-77	58
1020	Long wave ultrasound may enhance bone regeneration by altering OPG/RANKL ratio in human osteoblast-like cells. 2006 , 39, 283-8	41
1019	OPG/membranous-RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. 2006 , 39, 706-15	52
1018	Megakaryocyte-mediated inhibition of osteoclast development. 2006 , 39, 991-999	66
1017	Oscillatory fluid flow-induced shear stress decreases osteoclastogenesis through RANKL and OPG signaling. 2006 , 39, 1043-1047	107
1016	Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism. 2006 , 39, 1352-60	24
1015	Calcineurin/NFAT signaling in osteoblasts regulates bone mass. 2006 , 10, 771-82	266
1014	Bone markers in multiple myeloma. 2006 , 42, 1544-53	46
1013	Myeloma bone disease and treatment options. 2006 , 42, 1554-63	31
1012	The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. 2006 , 42, 1564-73	171
1011	Association of TNFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women. 2006 , 55, 219-26	25
1010	Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved. 2006 , 6, 1833-46	21
1009	The stem cell niches in bone. 2006 , 116, 1195-201	576
1008	NFATc1 expression in the developing heart valves is responsive to the RANKL pathway and is required for endocardial expression of cathepsin K. 2006 , 292, 407-17	45
1007	Receptor activator NFkappaB-ligand and osteoprotegerin protein expression in human periapical cysts and granulomas. 2006 , 102, 404-9	49

1006	The Vitamin D Hormone and its Nuclear Receptor: Mechanisms Involved in Bone Biology. 2006 , 307-325	1
1005	[Osteoclasts activation by bacterial endotoxins during periodontal diseases]. 2006 , 22, 614-20	0
1004	RANK-Fc Gene Therapy in Mouse Model of Osteoporosis. 2006 , 21, 189	
1003	Osteoporosis and Cardiovascular Disease in the Elderly. 2006 , 703-712	
1002	The role of mineral metabolism and inflammation on dialysis vascular access failure. 2006 , 7, 77-82	10
1001	Bone Resorption. 2006 ,	
1000	The Role of RANK, RANK Ligand and Osteoprotegerin in the Lytic Effects and Growth of Bone Metastases. 2006 , 51-62	
999	Osteoblastic Metastases. 2006 , 41-50	
998	Current topics in pharmacological research on bone metabolism: osteoclast differentiation regulated by glycosphingolipids. 2006 , 100, 195-200	23
997	Osteosarcoma: Current status of immunotherapy and future trends (Review). 2006 , 15, 693	8
996	Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. 2006 , 107, 2686-93	84
995	Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification. 2006 , 54, 395-401	33
994	Selective upregulation of the ADP-ribosyl cyclases CD38 and CD157 by TNF but not by RANK-L reveals differences in downstream signaling. 2006 , 291, F557-66	20
993	The RANKL/OPG System Is Activated in Inflammatory Bowel Disease and Relates to the State of Bone Loss. 2006 , 2006, 160-161	
992	Genistein modulates the effects of parathyroid hormone in human osteoblastic SaOS-2 cells. 2006 , 95, 1039-47	32
991	Alterations in the phenotype and function of immune cells in ovariectomy-induced osteopenic mice. 2006 , 21, 880-7	22
990	Histologie et cytologie de l'os normal. 2006 , 1, 1-6	
989	Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation. 2006 , 82, 1449-56	11

988	Cytokines regulating osteoclast formation and function. 2006 , 18, 411-8	65
987	Osteoclasts, rheumatoid arthritis, and osteoimmunology. 2006 , 18, 419-26	157
986	Estrogen receptor agonists and immune system in ovariectomized mice. 2006 , 19, 807-19	18
985	Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation. 2006 , 20, 383-8	17
984	The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. 2006 , 17, 212-9	307
983	Transforming growth factor-beta stimulates interleukin-11 production by human periodontal ligament and gingival fibroblasts. 2006 , 33, 165-71	19
982	Expression and function of death receptors and their natural ligands in the intestine. 2000 , 915, 162-70	29
981	RANKL and cathepsin K in diffuse sclerosing osteomyelitis of the mandible. 2006 , 35, 620-5	28
980	Effect of interleukin-10 on gene expression of osteoclastogenic regulatory molecules in the rat dental follicle. 2006 , 114, 42-9	67
979	Effects of growth factors and cytokines on osteoblast differentiation. 2006 , 41, 48-72	168
978	How we got attached to Actinobacillus actinomycetemcomitans: A model for infectious diseases. 2006 , 42, 114-57	112
977	Maturation-state dependent response of human periodontal ligament cells to an intermittent parathyroid hormone exposure in vitro. 2006 , 41, 62-72	17
976	Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts. 2006 , 41, 288-96	33
975	RANKL in human periapical granuloma: possible involvement in periapical bone destruction. 2006 , 12, 283-9	67
974	Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease. 2006 , 133, 93-7	14
973	Balance of inflammatory response in stable gingivitis and progressive periodontitis lesions. 2006 , 144, 35-40	104
972	Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. 2006 , 64, 652-8	65
971	Mechanisms of osteoporosis in spinal cord injury. 2006 , 65, 555-65	121

970	Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. 2006 , 8, 615-22	205
969	Microenvironmental niches in the bone marrow required for B-cell development. 2006 , 6, 107-16	347
968	Regulation of cancer cell migration and bone metastasis by RANKL. 2006 , 440, 692-6	603
967	A novel ubiquitin-binding protein ZNF216 functioning in muscle atrophy. 2006 , 25, 554-64	103
966	NFkappaB decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts. 2006 , 13, 933-41	22
965	Direct maxacalcitol injection into hyperplastic parathyroids improves skeletal changes in secondary hyperparathyroidism. 2006 , 70, 486-95	8
964	Prevention and treatment of osteoporosis in inflammatory bowel disease. 2006 , 12, 797-813	62
963	Expression of RANKL and OPG in middle ear cholesteatoma tissue. 2006 , 116, 1180-4	27
962	A role for the immunomodulatory molecules CD200 and CD200R in regulating bone formation. 2006 , 105, 150-8	21
961	OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis. 2006 , 39, 617-22	7
960	Genetic background influences metabolic response to dietary phosphorus restriction. 2006 , 17, 385-95	29
959	Retrovirus-mediated gene transfer of receptor activator of nuclear factor-kappaB-Fc prevents bone loss in ovariectomized mice. 2006 , 24, 1798-805	30
958	M-CSF, c-Fms, and signaling in osteoclasts and their precursors. 2006 , 1068, 110-6	102
957	Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling. 2006 , 1068, 143-64	79
956	The regulation of cathepsin K gene expression. 2006 , 1068, 165-72	80
955	Estrogen regulation of immune cell bone interactions. 2006 , 1068, 256-74	67
954	Does TNF have anti-osteoclastogenic actions?. 2006 , 1068, 234-9	2
953	Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis. 2006 , 21, 876-85	44

952	Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation. 2006 , 21, 1003-11	147
951	RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. 2006 , 21, 1339-49	104
950	RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis. 2006 , 21, 1946-54	54
949	Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. 2007 , 22, 55-63	68
948	Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. 2006 , 41, 354-60	93
947	The activating protein-1 transcriptional complex. 2006 , 4, 107-122	4
946	Bone disease in multiple myeloma. 2006 , 23, 431-41	9
945	Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats. 2006 , 23, 167-75	25
944	Emerging and future therapies for the treatment of bone loss associated with chronic inflammation. 2006 , 14, 193-7	19
943	Rac1 GTPase regulates osteoclast differentiation through TRANCE-induced NF-kappa B activation. 2006 , 281, 55-61	22
942	Arthritis -- a nightmare for bone. 2006 , 118, 11-5	1
941	Rheumatoid arthritis: inflammation and bone loss. 2006 , 156, 34-41	22
940	Uremic toxin and bone metabolism. 2006 , 24, 172-5	20
939	Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. 2007 , 25, 36-45	98
938	Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major. 2007 , 25, 60-7	16
937	Stimulation of osteoclast formation by inflammatory synovial fluid. 2006 , 449, 69-77	18
936	Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. 2006 , 118, 568-77	95
935	Usefulness of osteoprotegerin in assessing responses to neridronate treatment in Paget's disease of bone. 2006 , 7, 192-194	1

934	Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?. 2006 , 17, 724-30	11
933	Osteoprotegerin and bone mineral density in hemodialysis patients. 2006 , 17, 841-6	19
932	Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. 2007 , 86, 23-30	28
931	Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis. 2006 , 55, 32-9	15
930	Senile osteoporosis: is it an immune-mediated disease?. 2006 , 55, 399-404	49
929	Biomaterials and Bone Remodeling: The Physiologic Process Required for Biologization of Bone Substitutes. 2006 , 32, 102-106	6
928	[Pathophysiology and pathomorphology of osteoporosis]. 2006 , 46, 831-8	2
927	B cells play an important role in lipopolysaccharide-induced bone resorption. 2006 , 78, 125-32	23
926	Osteoprotegerin as a potential therapy for osteoporosis. 2006 , 8, 50-4	10
925	Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. 2006 , 312, 1909-23	58
924	Upregulation of ADAM19 in chronic allograft nephropathy. 2006 , 6, 1673-81	15
923	Role of RANK ligand in normal and pathologic bone remodeling and the therapeutic potential of novel inhibitory molecules in musculoskeletal diseases. 2006 , 55, 15-8	13
922	Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. 2006 , 54, 1151-64	77
921	Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. 2006 , 54, 1463-72	42
920	LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. 2006 , 54, 1451-62	75
919	The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. 2006 , 54, 1772-7	141
918	Buried alive: how osteoblasts become osteocytes. 2006 , 235, 176-90	474
917	Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation. 2006 , 77, 75-83	57

916	Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications. 2006 , 97, 226-32	35
915	Serotonin and fluoxetine modulate bone cell function in vitro. 2006 , 98, 139-51	126
914	Modeled gravitational unloading triggers differentiation and apoptosis in preosteoclastic cells. 2006 , 98, 65-80	27
913	Leptin effect on RANKL and OPG expression in MC3T3-E1 osteoblasts. 2006 , 98, 1123-9	37
912	Fluid flow induces Rankl expression in primary murine calvarial osteoblasts. 2006 , 98, 1271-83	29
911	Modulation of mouse RANKL gene expression by Runx2 and PKA pathway. 2006 , 98, 1629-44	38
910	Involvement of CSF-1 in generating a stroma-independent hematopoietic stem cell line. 2006 , 206, 556-62	
909	Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides. 2006 , 207, 244-50	49
908	Active caspase-3 is required for osteoclast differentiation. 2006 , 209, 836-44	56
907	Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. 2006 , 107, 289-98	186
906	Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma. 2006 , 119, 146-51	17
905	Osteoclastogenesis in the nonadherent cell population of human bone marrow is inhibited by rhBMP-2 alone or together with rhVEGF. 2006 , 24, 29-36	17
904	Implant wear induces inflammation, but not osteoclastic bone resorption, in RANK(-/-) mice. 2006 , 24, 1575-86	55
903	Map kinase c-JUN N-terminal kinase mediates PMMA induction of osteoclasts. 2006 , 24, 1349-57	24
902	The new bone biology: pathologic, molecular, and clinical correlates. 2006 , 140, 2646-706	226
901	Therapeutic approaches in bone pathogenesis: targeting the IKK/NF- κ B axis. 2006 , 1, 133-146	3
900	Anti-RANKL therapy--implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density. 2006 , 21, 2075-7	14
899	Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. 2006 , 73, 43-84	98

898	Osteostat/tumor necrosis factor superfamily 18 inhibits osteoclastogenesis and is selectively expressed by vascular endothelial cells. 2006 , 147, 70-8	19
897	The roles of parathyroid hormone and calcitonin in bone remodeling: prospects for novel therapeutics. 2006 , 6, 59-76	49
896	Aromatase inhibitors and bone health in women with breast cancer. 2006 , 24, 5305-12	94
895	Murine osteoclast formation and function: differential regulation by humoral agents. 2006 , 147, 1979-85	75
894	Infliximab for rheumatoid arthritis. 2006 , 2, 193-207	5
893	Prostaglandins and Proinflammatory Cytokines. 2006 , 115-128	3
892	Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling. 2006 , 12, 6274s-6278s13	
891	Selective Estrogen Receptor Modulators. 2006 ,	1
890	Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. 2006 , 45, 1218-22	44
889	Regulation of osteoclast function and bone mass by RAGE. 2006 , 203, 1067-80	128
888	Targeting pathways mediating bone disease. 2006 , 7, 423-9	5
887	Molecular determinants of vascular calcification: a bench to bedside view. 2006 , 6, 515-24	27
886	The hemoglobin receptor protein of porphyromonas gingivalis inhibits receptor activator NF-kappaB ligand-induced osteoclastogenesis from bone marrow macrophages. 2006 , 74, 2544-51	17
885	Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation. 2006 , 12, 662-8	61
884	RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. 2006 , 45, 1068-76	113
883	1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation. 2006 , 4, 275-81	19
882	Plasma osteoprotegerin is associated with mortality in hemodialysis patients. 2006 , 17, 262-70	138
881	Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. 2006 , 66, 3620-8	66

880	Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. 2006 , 29, 1664-6	58
879	The role of the interleukin-6/gp130 signaling pathway in bone metabolism. 2006 , 74, 341-55	21
878	Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. 2006 , 154, 373-7	18
877	The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. 2006 , 20, 2562-4	157
876	Treatment for myeloma bone disease. 2006 , 12, 6279s-6284s	31
875	Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling. 2006 , 47, 1739-48	62
874	alpha-Lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis. 2006 , 176, 111-7	76
873	Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE ^{-/-} mice. 2006 , 26, 2117-24	238
872	Proteomic analysis of lysosomal acid hydrolases secreted by osteoclasts: implications for lytic enzyme transport and bone metabolism. 2006 , 5, 134-43	61
871	A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. 2006 , 5, 2634-43	87
870	Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. 2006 , 26, 1002-13	92
869	Hodgkin's lymphoma: molecular targets and novel treatment strategies. 2006 , 2, 533-51	4
868	Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. 2006 , 26, 6469-86	192
867	Protective and destructive immunity in the periodontium: Part 2--T-cell-mediated immunity in the periodontium. 2006 , 85, 209-19	53
866	Involvement of aquaporin 9 in osteoclast differentiation. 2006 , 281, 19305-9	27
865	A novel receptor activator of NF-kappaB (RANK) cytoplasmic motif plays an essential role in osteoclastogenesis by committing macrophages to the osteoclast lineage. 2006 , 281, 4678-90	38
864	Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. 2006 , 26, 6453-68	147
863	Hormone Replacement Therapy in Rheumatoid Arthritis. 2006 , 2, 251-260	2

862	Membrane-bound prostaglandin E synthase-1-mediated prostaglandin E2 production by osteoblast plays a critical role in lipopolysaccharide-induced bone loss associated with inflammation. 2006 , 177, 1879-85	99
861	Glucocorticoids suppress bone formation via the osteoclast. 2006 , 116, 2152-60	281
860	Molecular networks orchestrating GALT development. 2006 , 308, 19-57	7
859	A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. 2006 , 12, 1221-8	413
858	Regulation of osteoclast differentiation and function by interleukin-1. 2006 , 74, 357-70	63
857	The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. 2006 , 16, 583-91	90
856	Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. 2006 , 3, 41-9	113
855	Salivary biomarkers of existing periodontal disease: a cross-sectional study. 2006 , 137, 322-9	244
854	Immune interactions with CD4+ T cells promote the development of functional osteoclasts from murine CD11c+ dendritic cells. 2006 , 177, 3314-26	113
853	Identification and characterization of the precursors committed to osteoclasts induced by TNF-related activation-induced cytokine/receptor activator of NF-kappa B ligand. 2006 , 177, 4360-8	36
852	Bacterial-responsive B lymphocytes induce periodontal bone resorption. 2006 , 176, 625-31	107
851	Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. 2006 , 281, 36846-55	183
850	Heparin synergistically enhances interleukin-11 signaling through up-regulation of the MAPK pathway. 2006 , 281, 20780-20787	16
849	Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts. 2006 , 25, 475-83	31
848	An antioxidant modulates expression of receptor activator of NF-kappaB in asthma. 2006 , 38, 217-29	18
847	RANK ligand inhibition with denosumab for the management of osteoporosis. 2006 , 6, 1041-50	38
846	Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. 2006 , 66, 4816-25	114
845	CGRP inhibits osteoprotegerin production in human osteoblast-like cells via cAMP/PKA-dependent pathway. 2006 , 291, C529-37	48

844	The effect of osteoclastic activity on tendon-to-bone healing: an experimental study in rabbits. 2007 , 89, 2250-9	35
843	Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. 2007 , 282, 31601-9	88
842	The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis. 2007 , 178, 3379-89	171
841	Protein inhibitor of activated STAT 3 modulates osteoclastogenesis by down-regulation of NFATc1 and osteoclast-associated receptor. 2007 , 178, 5588-94	42
840	MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. 2007 , 282, 15921-9	138
839	Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. 2007 , 179, 7497-505	56
838	Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. 2007 , 282, 33098-106	160
837	The effect of class a scavenger receptor deficiency in bone. 2007 , 282, 4653-4660	17
836	Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. 2007 , 30, 3122-4	26
835	Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. 2007 , 9, 357-63	37
834	Androgen decreases osteoprotegerin expression in prostate cancer cells. 2007 , 10, 160-6	2
833	The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB ligand with bone mineral density in older adults: the Rancho Bernardo study. 2007 , 156, 555-62	59
832	Rheumatoid synovial endothelial cells produce macrophage colony-stimulating factor leading to osteoclastogenesis in rheumatoid arthritis. 2007 , 46, 597-603	41
831	Molecular biology of otosclerosis. 2007 , 65, 68-74	12
830	The Dissection of Human Autosomal Recessive Osteopetrosis Identifies an Osteoclast-Poor Form due to RANKL Deficiency. 2007 , 6, 3027-3033	11
829	Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. 2007 , 21, 1129-35	28
828	Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. 2007 , 148, 2778-87	39
827	Transcriptional control of receptor activator of nuclear factor-kappaB ligand by the protein kinase A activator forskolin and the transmembrane glycoprotein 130-activating cytokine, oncostatin M, is exerted through multiple distal enhancers. 2007 , 21, 197-214	69

826	Methylation status of a single CpG locus 3 bases upstream of TATA-box of receptor activator of nuclear factor-kappaB ligand (RANKL) gene promoter modulates cell- and tissue-specific RANKL expression and osteoclastogenesis. 2007 , 21, 148-58	59
825	The circadian rhythm of osteoprotegerin and its association with parathyroid hormone secretion. 2007 , 92, 3230-8	43
824	RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. 2007 , 27, 1442-54	99
823	Effects of Mechanical Strain on Osteoblastic Precursor Cells in a Three-Dimensional Scaffold. 2007 , 330-332, 1181-1184	
822	Role of osteoprotegerin in arterial calcification: development of new animal model. 2007 , 27, 2058-64	60
821	Molecular mechanism of bone destruction in rheumatoid arthritis. 2007 , 2, 61-72	2
820	CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. 2007 , 92, 4514-21	179
819	Colorectal Cancer and Bone Tissue: Fantastic Relations and Where to Find Them. 2020 , 12,	2
818	Elevated Osteoprotegerin Concentration Predicts Increased Risk of Cardiovascular Mortality in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. 2020 , 45, 565-575	8
817	Preparation of osteogenic matrices from cultured cells. 2020 , 156, 15-43	3
816	Knockdown of Tcirg1 inhibits large-osteoclast generation by down-regulating NFATc1 and IP3R2 expression. 2020 , 15, e0237354	1
815	JAK/STAT pathway and molecular mechanism in bone remodeling. 2020 , 47, 9087-9096	5
814	Role of MicroRNAs in Bone Pathology during Chikungunya Virus Infection. 2020 , 12,	4
813	Isoliquiritigenin Derivatives Inhibit RANKL-Induced Osteoclastogenesis by Regulating p38 and NF- κ B Activation in RAW 264.7 Cells. 2020 , 25,	7
812	Accumulation of synovial fluid CD19CD24CD27 B cells was associated with bone destruction in rheumatoid arthritis. 2020 , 10, 14386	4
811	Clinical and Molecular Genetics of Primary Hyperparathyroidism. 2020 , 52, 578-587	1
810	Bone Marrow Microvasculature. 2020 , 10, 1009-1046	4
809	Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor- κ B Ligand with a Superior Therapeutic Index. 2020 , 63, 12043-12059	0

808	Zebrafish: A Suitable Tool for the Study of Cell Signaling in Bone. 2020 , 9,	3
807	Optimizing skeletal-related events prevention in patients with advanced prostate cancer. 2020 , 16 Suppl 3, 4-6	0
806	LAMP-2 Is Involved in Surface Expression of RANKL of Osteoblasts In Vitro. 2020 , 21,	3
805	Impact of iron overload on bone remodeling in thalassemia. 2020 , 15, 143	3
804	B cell acute lymphoblastic leukemia cells mediate RANK-RANKL-dependent bone destruction. 2020 , 12,	7
803	Osteoblast-Osteoclast Communication and Bone Homeostasis. 2020 , 9,	106
802	Metallic additive manufacturing for bone-interfacing implants. 2020 , 15, 050801	6
801	Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2. 2020 , 21,	7
800	Chemokines and Bone. 2020 , 262, 231-258	2
799	Insight into the divergent role of TRAIL in non-neoplastic neurological diseases. 2020 , 24, 11070-11083	3
798	Soluble RANKL exaggerates hindlimb suspension-induced osteopenia but not muscle protein balance. 2021 , 39, 1860-1869	0
797	Differential Gene Expression Changes in Human Primary Dental Pulp Cells Treated with Biodentine and TheraCal LC Compared to MTA. 2020 , 8,	0
796	Microbial Stimulation Reverses the Age-Related Decline in M Cells in Aged Mice. 2020 , 23, 101147	14
795	What is the relationship between bone turnover markers and skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma? A systematic review and meta-regression analysis. 2020 , 12, 100272	2
794	Innovation in medical imaging to improve disease staging, therapeutic intervention, and clinical outcomes. 2020 , 306, 75-84	2
793	Anthocyanins and anthocyanin-rich food as antioxidants in bone pathology. 2020 , 145-158	1
792	Shortening of Overall Orthodontic Treatment Duration with Low-Intensity Pulsed Ultrasound (LIPUS). 2020 , 9,	6
791	Tea extract increases cell fusion via regulation of cell surface DC-STAMP. 2020 , 22, 100759	2

790	Gaucher disease-associated alterations in mesenchymal stem cells reduce osteogenesis and favour adipogenesis processes with concomitant increased osteoclastogenesis. 2020 , 130, 274-282	2
789	Switching Homes: How Cancer Moves to Bone. 2020 , 21,	5
788	Hypoxia in bone metastasis and osteolysis. 2020 , 489, 144-154	7
787	MiR-106b inhibition suppresses inflammatory bone destruction of wear debris-induced periprosthetic osteolysis in rats. 2020 , 24, 7490-7503	6
786	Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy. 2020 , 8, 325	14
785	Cladophora glomerata enriched by biosorption with Mn(II) ions alleviates lipopolysaccharide-induced osteomyelitis-like model in MC3T3-E1, and 4B12 osteoclastogenesis. 2020 , 24, 7282-7300	6
784	New perspectives on traumatic bone infections. 2020 , 23, 314-318	4
783	Upregulation of miR-941 in Circulating CD14+ Monocytes Enhances Osteoclast Activation via WNT16 Inhibition in Patients with Psoriatic Arthritis. 2020 , 21,	2
782	Effect of GNAQ alteration on RANKL-induced osteoclastogenesis in human non-small-cell lung cancer. 2020 , 9, 29-35	7
781	RANK Ligand Helps Immunity to by Skewing M2-Like Into M1 Macrophages. 2020 , 11, 886	6
780	The RNA-binding protein Cpeb4 is a novel positive regulator of osteoclast differentiation. 2020 , 528, 621-627	3
779	Adipose-derived mesenchymal stromal cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis. 2020 , 92, e12877	3
778	RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling. 2020 , 2020, 6910312	46
777	Associations among Bone Mineral Density, Physical Activity and Nutritional Intake in Middle-Aged Women with High Levels of Arterial Stiffness: A Pilot Study. 2020 , 17,	2
776	Glyburide inhibits the bone resorption induced by traumatic occlusion in rats. 2020 , 55, 464-471	4
775	Postnatal Conditional Deletion of Bmal1 in Osteoblasts Enhances Trabecular Bone Formation Via Increased BMP2 Signals. 2020 , 35, 1481-1493	4
774	Endogenous parathyroid hormone (PTH) signals through osteoblasts via RANKL during fracture healing to affect osteoclasts. 2020 , 525, 850-856	10
773	RANK-RANKL signaling upregulates Il-10 mRNA expression in mucosal Candida infection in vivo. 2020 , 149, 104285	0

772	Chitosan derived nitrogen-doped carbon dots suppress osteoclastic osteolysis via downregulating ROS. 2020 , 12, 16229-16244	10
771	The osteoclast cytoskeleton - current understanding and therapeutic perspectives for osteoporosis. 2020 , 133,	14
770	Therapeutic effects of triptolide from <i>Tripterygium wilfordii</i> Hook. f. on interleukin-1-beta-induced osteoarthritis in rats. 2020 , 883, 173341	4
769	Antiresorptive activity of osteoprotegerin requires an intact heparan sulfate-binding site. 2020 , 117, 17187-17194	4
768	Controversy of physiological vs. pharmacological effects of BMP signaling: Constitutive activation of BMP type IA receptor-dependent signaling in osteoblast lineage enhances bone formation and resorption, not affecting net bone mass. 2020 , 138, 115513	3
767	Cellular Communication in Bone Homeostasis and the Related Anti-osteoporotic Drug Development. 2020 , 27, 1151-1169	7
766	Collagen Extract Derived from Yeonsan Ogye Chicken Increases Bone Microarchitecture by Suppressing the RANKL/OPG Ratio via the JNK Signaling Pathway. 2020 , 12,	2
765	Phosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: A potential combination therapy with alendronate. 2020 , 257, 118033	3
764	A20 inhibits osteoclastogenesis via TRAF6-dependent autophagy in human periodontal ligament cells under hypoxia. 2020 , 53, e12778	13
763	Murine osteoclastogenesis suppression using conditioned media produced by melanoma or activated and non-activated Jurkat-E6 cells. 2020 , 44, 1184-1192	0
762	Destroy to Rebuild: The Connection Between Bone Tissue Remodeling and Matrix Metalloproteinases. 2020 , 11, 47	26
761	Non-coenzyme role of vitamin B1 in RANKL-induced osteoclastogenesis and ovariectomy induced osteoporosis. 2020 , 121, 3526-3536	2
760	Oral biosciences: The annual review 2019. 2020 , 62, 1-8	
759	RANKL biology: bone metabolism, the immune system, and beyond. 2020 , 40, 2	98
758	A two-herb formula inhibits osteoclastogenesis and suppresses NF-kB and MAPK pathways. 2020 , 252, 112625	5
757	Impact of periodontal treatment on the RANKL/OPG ratio in crevicular fluid. 2020 , 15, e0227757	9
756	A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab. 2020 , 35, 1014-1021	10
755	A Sub-Clone of RAW264.7-Cells Form Osteoclast-Like Cells Capable of Bone Resorption Faster than Parental RAW264.7 through Increased De Novo Expression and Nuclear Translocation of NFATc1. 2020 , 21,	3

754	Flavonoids compounds from <i>Tridax procumbens</i> inhibit osteoclast differentiation by down-regulating c-Fos activation. 2020 , 24, 2542-2551	8
753	Osteoprotegerin-dependent M cell self-regulation balances gut infection and immunity. 2020 , 11, 234	19
752	New Function of RUNX2 in Regulating Osteoclast Differentiation via the AKT/NFATc1/CTSK Axis. 2020 , 106, 553-566	6
751	Cytokines and Bone: Osteoimmunology. 2020 , 262, 177-230	10
750	Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis. 2020 , 80, 698-714	4
749	Alterations in osteocyte mediated osteoclastogenesis during estrogen deficiency and under ROCK-II inhibition: An in vitro study using a novel postmenopausal multicellular niche model. 2020 , 392, 112005	7
748	Pregnenolone Inhibits Osteoclast Differentiation and Protects Against Lipopolysaccharide-Induced Inflammatory Bone Destruction and Ovariectomy-Induced Bone Loss. 2020 , 11, 360	7
747	Osteoimmunology - Bidirectional dialogue and inevitable union of the fields of bone and immunity. 2020 , 96, 159-169	5
746	The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1. 2020 , 83, 106429	4
745	Electrochemical immunoplatfrom to improve the reliability of breast cancer diagnosis through the simultaneous determination of RANKL and TNF in serum. 2020 , 314, 128096	12
744	Results of advanced core decompression in patients with osteonecrosis of the femoral head depending on age and sex-a prospective cohort study. 2020 , 15, 124	3
743	Juvenile Paget's Disease From Heterozygous Mutation of SP7 Encoding Osterix (Specificity Protein 7, Transcription Factor SP7). 2020 , 137, 115364	7
742	Estrogen and bones after menopause: a reappraisal of data and future perspectives. 2021 , 20, 13-21	4
741	Osteoclast formation at the bone marrow/bone surface interface: Importance of structural elements, matrix, and intercellular communication. 2021 , 112, 8-15	12
740	"Take My Bone Away?" Hypoxia and bone: A narrative review. 2021 , 236, 721-740	9
739	Notch signaling: Its essential roles in bone and craniofacial development. 2021 , 8, 8-24	18
738	Cinchonine inhibits osteoclast differentiation by regulating TAK1 and AKT, and promotes osteogenesis. 2021 , 236, 1854-1865	5
737	Role of histone deacetylases in bone development and skeletal disorders. 2021 , 143, 115606	5

736	RANKL as a key figure in bridging between the bone and immune system: Its physiological functions and potential as a pharmacological target. 2021 , 218, 107682	7
735	Delineating role of NF- κ B and interacting cytokines during prostate cancer-induced osteoclastogenesis. 2021 , 122, 259-276	1
734	RANKL as a target for the treatment of osteoporosis. 2021 , 39, 91-105	13
733	Impact of MGUS and myeloma on skeletal health. 2021 , 1421-1437	
732	In vitro biological response of human osteoblasts in 3D chitosan sponges with controlled degree of deacetylation and molecular weight. 2021 , 254, 117434	15
731	Osteoblastic monocyte chemoattractant protein-1 (MCP-1) mediation of parathyroid hormone's anabolic actions in bone implicates TGF- β signaling. 2021 , 143, 115762	3
730	Sarcoma. 2021 ,	
729	Liver X receptors and skeleton: Current state-of-knowledge. 2021 , 144, 115807	2
728	Bad to the bone: B cell acute lymphoblastic leukemia cells mediate bone destruction. 2020 , 8, 1835423	
727	The impact of cholecalciferol on markers of vascular calcification in hemodialysis patients: A randomized placebo controlled study. 2021 , 31, 626-633	5
726	The role of the RANKL/RANK/OPG system in the central nervous systems (CNS). 2021 , 39, 64-70	1
725	Mineral trioxide aggregate (MTA) inhibits osteoclastogenesis and osteoclast activation through calcium and aluminum activities. 2021 , 25, 1805-1814	1
724	Three-year results of denosumab treatment for osteoporosis in women with rheumatoid arthritis and primary osteoporosis: A clinical observational study. 2021 , 31, 600-606	3
723	Parathyroid hormone and parathyroid hormone-related protein. 2021 , 191-214	
722	FGF23 and bone disease. 2021 , 99-113	
721	Scope assisted ankle arthrodesis in a young male with hemophilic arthritis: A case study. 2021 , 1, 100035	
720	On the evolution and contemporary roles of bone remodeling. 2021 , 727-772	1
719	The Role of Osteoclasts in Psoriatic Arthritis. 2021 , Publish Ahead of Print,	

718	Osteoporosis associated with rheumatologic disorders. 2021 , 1309-1324	
717	Focus on Osteosclerotic Progression in Primary Myelofibrosis. 2021 , 11,	2
716	Biologics Targeting Immune Modulation in Inflammatory Disorders. 2021 ,	
715	Dietary Salt Accelerates Orthodontic Tooth Movement by Increased Osteoclast Activity. 2021 , 22,	1
714	Control of Bone Matrix Properties by Osteocytes. 2020 , 11, 578477	11
713	Extracellular Vesicle-Mediated Bone Remodeling and Bone Metastasis: Implications in Prostate Cancer. 2021 , 97, 297-361	2
712	Mechanisms of Bone Fragility: From Osteogenesis Imperfecta to Secondary Osteoporosis. 2021 , 22,	14
711	Discovery of the RANKL/RANK/OPG system. 2021 , 39, 2-11	14
710	An update on vascular calcification and potential therapeutics. 2021 , 48, 887-896	11
709	Dental pulp-derived stem cells inhibit osteoclast differentiation by secreting osteoprotegerin and deactivating AKT signalling in myeloid cells. 2021 , 25, 2390-2403	3
708	Immobilization osteoporosis. 2021 , 991-1032	0
707	Therapy of Myeloma Bone Disease. 2021 , 111-137	
706	RANKL as the master regulator of osteoclast differentiation. 2021 , 39, 13-18	11
705	'Educated' Osteoblasts Reduce Osteoclastogenesis in a Bone-Tumor Mimetic Microenvironment. 2021 , 13,	1
704	Cigarette Smoke-Induced Lymphoid Neogenesis in COPD Involves IL-17/RANKL Pathway. 2020 , 11, 588522	4
703	Monocyte/Macrophage Lineage Cells From Fetal Erythromyeloid Progenitors Orchestrate Bone Remodeling and Repair. 2021 , 9, 622035	7
702	Is Inflammation a Friend or Foe for Orthodontic Treatment?: Inflammation in Orthodontically Induced Inflammatory Root Resorption and Accelerating Tooth Movement. 2021 , 22,	15
701	Effects of premature contact in maxillary alveolar bone in rats: relationship between experimental analyses and a micro scale FEA computational simulation study. 2021 , 25, 5479-5492	

700	Role of the RANK/RANKL/OPG and Wnt/ β Catenin Systems in CKD Bone and Cardiovascular Disorders. 2021 , 108, 439-451	17
699	Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression. 2021 , 27, 19	1
698	Osteoimmunological insights into the pathogenesis of ankylosing spondylitis. 2021 , 236, 6090-6100	4
697	Zebrafish Mutants Display Osteoclast Over-Activation and Bone Deformity Resembling Osteolysis in MCTO Patients. 2021 , 11,	1
696	Extract and 17 β Estradiol Suppresses Ovariectomy Induced Osteoporosis in Female Rats. 2021 , 24, 434-444	1
695	The role of statins in the differentiation and function of bone cells. 2021 , 51, e13534	12
694	The Pathophysiology of Osteoporosis after Spinal Cord Injury. 2021 , 22,	2
693	Chemokine C-C motif ligand 8 in periodontal ligament during orthodontic tooth movement. 2021 , 123, 104996	2
692	Maintaining homeostatic control of periodontal bone tissue. 2021 , 86, 157-187	22
691	Protocatechualdehyde inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclastogenesis and attenuates lipopolysaccharide-induced inflammatory osteolysis. 2021 , 35, 3821-3835	1
690	Flagellin/TLR5 Stimulate Myeloid Progenitors to Enter Lung Tissue and to Locally Differentiate Into Macrophages. 2021 , 12, 621665	0
689	Biological Evaluation and Transcriptomic Analysis of Corylin as an Inhibitor of Osteoclast Differentiation. 2021 , 22,	1
688	Denosumab Recovers Aortic Arch Calcification During Long-Term Hemodialysis. 2021 , 6, 605-612	8
687	Salubrinal Alleviates Collagen-Induced Arthritis through Promoting P65 Degradation in Osteoclastogenesis. 2021 , 22,	0
686	Bone resorption goes green. <i>Cell</i> , 2021 , 184, 1137-1139	56.2 3
685	Inhibition of osteoclast activities by SCPC bioceramic promotes osteoblast-mediated graft resorption and osteogenic differentiation. 2021 , 109, 1714-1725	1
684	Bone marrow niches in the regulation of bone metastasis. 2021 , 124, 1912-1920	13
683	Osteoclast-derived small extracellular vesicles induce osteogenic differentiation via inhibiting ARHGAP1. 2021 , 23, 1191-1203	7

682	Structural and Functional Changes of Hands and Legs in Early Rheumatoid Arthritis. 2021 , 57,	
681	Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics. 2021 , 22,	12
680	Development of a method for the identification of receptor activator of nuclear factor- κ B populations in vivo. 2021 , 63, 45-51	
679	Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people. 2021 , 33, 759-773	23
678	Hypoxia-inducible factor-2 β mediates senescence-associated intrinsic mechanisms of age-related bone loss. 2021 , 53, 591-604	4
677	Impact of Cigarette Smoking on the Risk of Osteoporosis in Inflammatory Bowel Diseases. 2021 , 10,	1
676	Bone Aging, Cellular Senescence, and Osteoporosis. 2021 , 5, e10488	14
675	A non-immunological role for Interferon-inducible lysosomal thiol reductase (GILT) in osteoclastic bone resorption. 2021 , 7,	0
674	6'-O-Galloyl paeoniflorin Attenuates Osteoclastogenesis and Relieves Ovariectomy-Induced Osteoporosis by Inhibiting Reactive Oxygen Species and MAPKs/c-Fos/NFATc1 Signaling Pathway. 2021 , 12, 641277	2
673	RANK promotes colorectal cancer migration and invasion by activating the Ca-calcineurin/NFATc1-ACP5 axis. 2021 , 12, 336	6
672	Postnatal expression and possible function of RANK and RANKL in the murine inner ear. 2021 , 145, 115837	2
671	Interleukin-1 induces receptor activator of nuclear factor- κ B ligand-independent osteoclast differentiation in RAW264.7 cells. 2021 , 21, 640	2
670	RANKL regulates male reproductive function. 2021 , 12, 2450	3
669	Effects of estrogen deficiency during puberty on maxillary and mandibular growth and associated gene expression - an μ CT study on rats. 2021 , 17, 14	2
668	Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women. 2021 , 12, 588095	0
667	Osteoporosis Therapy: Mechanistic Antiresorptives. 1-24	
666	TPCA-1 negatively regulates inflammation mediated by NF- κ B pathway in mouse chronic periodontitis model. 2021 , 36, 192-201	2
665	The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma. 2021 , 22,	11

664	The estrogen-related receptor β modulator, GSK5182, inhibits osteoclast differentiation and accelerates osteoclast apoptosis. 2021 , 54, 266-271	0
663	Role of Biomolecules in Osteoclasts and Their Therapeutic Potential for Osteoporosis. 2021 , 11,	7
662	Characterization and Function of Tumor Necrosis Factor and Interleukin-6-Induced Osteoclasts in Rheumatoid Arthritis. 2021 , 73, 1145-1154	10
661	Endocrine role of bone in the regulation of energy metabolism. 2021 , 9, 25	5
660	Autosomal recessive osteopetrosis: mechanisms and treatments. 2021 , 14,	5
659	Deletion of a putative promoter-proximal Tnfsf11 regulatory region in mice does not alter bone mass or Tnfsf11 expression in vivo. 2021 , 16, e0250974	2
658	Efficacy of Pulsed Electromagnetic Fields on Experimental Osteopenia in Rodents: A Systematic Review. 2021 , 42, 415-431	0
657	Denosumab e cambio di paradigma nella terapia dell'osteoporosi. 2021 , 22, 253-257	
656	Ginkgolide B monotherapy reverses osteoporosis by regulating oxidative stress-mediated bone homeostasis. 2021 , 168, 234-246	3
655	Total glycosides and polysaccharides of <i>Cistanche deserticola</i> prevent osteoporosis by activating Wnt/ β -catenin signaling pathway in SAMP6 mice. 2021 , 271, 113899	5
654	Hepcidin contributes to Swedish mutant APP-induced osteoclastogenesis and trabecular bone loss. 2021 , 9, 31	3
653	New Therapeutic Tools to Shape Monocyte Functional Phenotypes in Leishmaniasis. 2021 , 12, 704429	0
652	Celastrol Attenuates RANKL-Induced Osteoclastogenesis and Reduces Titanium Particle-Induced Osteolysis and Ovariectomy-Induced Bone Loss. 2021 , 12, 682541	2
651	RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway. 2021 , 11, 12186	1
650	Systems genetics in diversity outbred mice inform BMD GWAS and identify determinants of bone strength. 2021 , 12, 3408	6
649	RANKL from bone marrow adipose lineage cells promotes osteoclast formation and bone loss. 2021 , 22, e52481	21
648	Impact of Leptin on Periodontal Ligament Fibroblasts during Mechanical Strain. 2021 , 22,	1
647	The Role of BMP Signaling in Osteoclast Regulation. 2021 , 9,	3

646	Osteoclast-Mediated Cell Therapy as an Attempt to Treat Elastin Specific Vascular Calcification. 2021 , 26,	1
645	Osteocytes regulate neutrophil development through IL-19: a potent cytokine for neutropenia treatment. 2021 , 137, 3533-3547	3
644	Purification and Biological Function of Caldecrin. 2021 , 8,	0
643	7,8-Dihydroxyflavone modulates bone formation and resorption and ameliorates ovariectomy-induced osteoporosis. 2021 , 10,	5
642	[80 milestones in rheumatology from 80 years-IV. 2000-2020]. 2021 , 80, 528-538	
641	Menaquinone 4 Reduces Bone Loss in Ovariectomized Mice through Dual Regulation of Bone Remodeling. 2021 , 13,	1
640	Imaging of bone and joints in vivo: pathological osteoclastogenesis in arthritis. 2021 , 33, 679-686	1
639	Bone marrow adipose tissue: Role in bone remodeling and energy metabolism. 2021 , 35, 101545	3
638	Lunate bone loss associated with infection. 2021 , 34, 100431	
637	Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis?. 2021 , 22,	1
636	Bovine Colostrum Supplementation Improves Bone Metabolism in an Osteoporosis-Induced Animal Model. 2021 , 13,	1
635	Multiple versus solitary giant cell lesions of the jaw: Similar or distinct entities?. 2021 , 149, 115935	0
634	A systematic dissection of human primary osteoblasts at single-cell resolution. 2021 , 13, 20629-20650	2
633	The association of OPG polymorphisms with risk of osteoporotic fractures: A systematic review and meta-analysis. 2021 , 100, e26716	0
632	Osteoimmunology as an intrinsic part of immunology. 2021 , 33, 673-678	1
631	The hidden secrets of soluble RANKL in bone biology. 2021 , 144, 155559	2
630	Protective Effect of > Gene Polymorphism on Coronary Outcome of Kawasaki Disease in Southern Chinese Population. 2021 , 12, 691282	
629	Bioengineered Fluorescent Nanoprobe Conjugates for Tracking Human Bone Cells: In Vitro Biocompatibility Analysis. 2021 , 14,	0

628	Mutations in the osteoprotegerin-encoding gene are associated with temporomandibular joint ankylosis. 2021 ,	0
627	The Role of RANKL and Involvement of Cementum in Orthodontic Root Resorption. 2021 , 11, 7244	0
626	Undenatured Type II Collagen Relieves Bone Impairment through Improving Inflammation and Oxidative Stress in Ageing db/db Mice. 2021 , 26,	1
625	Common Variants of the gene Are Associated with Osteoporosis Risk: A Meta-Analysis. 2021 , 25, 600-610	0
624	Ferulic acid attenuates osteoporosis induced by glucocorticoid through regulating the GSK-3 β /Lrp-5/ERK signalling pathways. 2021 , 108, 317-341	1
623	High levels of osteoprotegerin are associated with coronary artery calcification in patients suspected of a chronic coronary syndrome. 2021 , 11, 18946	1
622	TNF-Polarized Macrophages Produce Insulin-like 6 Peptide to Stimulate Bone Formation in Rheumatoid Arthritis in Mice. 2021 ,	2
621	Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone. 2021 , 12, 868	3
620	Immunization With RANKL Inhibits Osteolytic Bone Metastasis in Breast Cancer. 2022 , 45, 1-12	1
619	Plasma Membrane Receptors Involved in the Binding and Response of Osteoclasts to Noncellular Components of the Bone. 2021 , 22,	0
618	Osteomorphs as a tool for personalized medicine. 2021 , 32, 655-656	0
617	Myeloma-Bone Interaction: A Vicious Cycle via TAK1-PIM2 Signaling. 2021 , 13,	0
616	Peiminine Suppresses RANKL-Induced Osteoclastogenesis by Inhibiting the NFATc1, ERK, and NF- κ B Signaling Pathways. 2021 , 12, 736863	3
615	RANK- NFATc1 signaling forms positive feedback loop on rank gene expression via functional NFATc1 responsive element in rank gene promoter. 2021 , 572, 86-91	1
614	Controlled release of dopamine coatings on titanium bidirectionally regulate osteoclastic and osteogenic response behaviors. 2021 , 129, 112376	4
613	The polypeptide OP3-4 induced osteogenic differentiation of bone marrow mesenchymal stem cells via protein kinase B/glycogen synthase kinase 3 β /E-catenin pathway and promoted mandibular defect bone regeneration. 2021 , 130, 105243	2
612	HIV and Menopause are Independently Associated with Lower Bone Mineral Density: Results from the Women's Interagency HIV Study. 2021 ,	3
611	Bone physiological microenvironment and healing mechanism: Basis for future bone-tissue engineering scaffolds. 2021 , 6, 4110-4140	48

- 610 Osteoprotegerin (OPG) mediates the anti-carcinogenic effects of normal breast fibroblasts and targets cancer stem cells through inhibition of the Eatenin pathway. **2021**, 520, 374-384 1
- 609 Bone-targeted pH-responsive cerium nanoparticles for anabolic therapy in osteoporosis. **2021**, 6, 4697-4706 9
- 608 Aspects of intercellular communication in bone and implications in therapy. **2021**, 153, 116148 0
- 607 Anti-osteoblastogenic, pro-inflammatory and pro-angiogenic effect of extracellular vesicles isolated from the human osteosarcoma cell line MNNG/HOS. **2021**, 153, 116130 1
- 606 Tanshinone IIA attenuates polyethylene-induced osteolysis in a mouse model: The key role of miR-155-5p/FOXO3 axis. **2021**, 87, 104784
- 605 Osteoclast-rich lesions of bone. **2022**, 631-647
- 604 Osteocytes and bone tumor niche. **2022**, 171-178
- 603 Bone niche and bone metastases. **2022**, 107-119
- 602 Osteomimicry. **2022**, 129-143
- 601 Immune functions of osteoclasts. **2022**, 179-188
- 600 Therapies of bone metastases in castration-resistant prostate cancer. **2022**, 967-975
- 599 Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases. **2022**, 943-955
- 598 Human immunodeficiency virus and osteoporosis. **2021**, 1217-1238
- 597 RANKL and RANK in extracellular vesicles: surprising new players in bone remodeling. **2021**, 2, 18-28 3
- 596 Bones and Rheumatology. **2021**, 209-239
- 595 Uterine leiomyosarcomas with osteoclast-like giant cells associated with high expression of RUNX2 and RANKL. **2021**, 478, 893-904 1
- 594 Cytokines and the pathogenesis of osteoporosis. **2021**, 799-831
- 593 Osteoblast biology: developmental origin and interactive nature of osteoblasts. **2021**, 111-134

592	Development of the skeleton. 2021 , 39-73	
591	Targeting cancer metastasis with antibody therapeutics. 2021 , 13, e1698	9
590	Mathematical Modeling of Tumor Malignancy in Bone Microenvironment. 2021 , 235-241	
589	Flagging fusion: Phosphatidylserine signaling in cell-cell fusion. 2021 , 296, 100411	17
588	Molecular mechanisms of osteolytic bone metastases. 2000 , 88, 2892-2898	4
587	The skeleton: stone bones and stoned heads?. 2005 , 201-206	9
586	Novel signaling pathways and therapeutic targets in osteoclasts. 2007 , 602, 93-6	5
585	Control of osteoclast activity and bone loss by IKK subunits: new targets for therapy. 2007 , 602, 125-34	14
584	RANKL inhibition: from mice to men (and women). 2007 , 602, 143-50	22
583	Ectodomain shedding of receptor activator of NF-kappaB ligand. 2007 , 602, 15-21	14
582	RANK(L) as a key target for controlling bone loss. 2009 , 647, 130-45	29
581	Toxicity of Bone-Targeted Agents in Malignancy. 2013 , 531-567	1
580	Breast Cancer. 2013 , 29-117	1
579	Potential Therapeutic Targets for Bone Metastasis. 2004 , 187-210	1
578	Bone Homeostasis: An Emerging Role for the Renin-Angiotensin System. 2007 , 179-195	1
577	Biphosphonates In The Management Of Metastatic Bone Disease. 2009 , 195-231	1
576	Pathophysiology of Bone Metastases. 2009 , 31-50	3
575	Bone Biomarkers in Research and Clinical Practice. 2009 , 93-116	2

574	Bone loss in the spondyloarthropathies: role of osteoclast, RANKL, RANK and OPG in the spondyloarthropathies. 2009 , 649, 85-99	12
573	RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies. 2009 , 649, 100-13	32
572	Eph and ephrin interactions in bone. 2010 , 658, 95-103	31
571	TNF conference 2009: beyond bones - RANKL/RANK in the immune system. 2011 , 691, 5-22	6
570	Opg, RANKL, and RANK in cancer metastasis: expression and regulation. 2004 , 118, 149-72	27
569	Cartilage Cells. 2004 , 219-228	1
568	Central control of bone mass: brainstorming of the skeleton. 2001 , 496, 85-94	13
567	In vitro investigation of the roles of the proinflammatory cytokines tumor necrosis factor- α and interleukin-1 in murine osteoclastogenesis. 2014 , 1155, 109-23	13
566	Attenuation of Osteoporosis by n-3 Lipids and Soy Protein. 2004 , 575-592	1
565	Bone Structure, Development and Bone Biology. 2009 , 1-50	11
564	Death Receptors in Multiple Myeloma and Therapeutic Opportunities. 2008 , 393-419	4
563	Embryonic stem cells for osteo-degenerative diseases. 2011 , 690, 1-30	8
562	Generation of human osteoclasts from peripheral blood. 2012 , 816, 159-75	24
561	Rodent osteoclast cultures. 2012 , 816, 103-17	24
560	RANKL-based osteoclastogenic assays from murine bone marrow cells. 2014 , 1130, 307-313	13
559	Drug therapy of osteoporosis. 2008 , 5-15	1
558	Osteoimmunological Aspects of Periodontal Diseases. 2016 , 289-321	3
557	Bone and the Immune System. 2017 , 363-398	4

556	Combination and Sequential Osteoanabolic/Antiresorptive Therapy in Osteoporosis Treatment. 2020 , 363-374	1
555	Physiology of Bone Formation, Remodeling, and Metabolism. 2012 , 29-57	103
554	The role of bone microenvironment, vitamin D and calcium. 2012 , 192, 33-64	9
553	Basics of Bone Biology. 2012 , 1-26	4
552	Cytokines. 2009 , 155-276	3
551	Molecules Regulating Macrophage Fusions. 2011 , 233-248	3
550	Cytokines. 2003 , 183-299	1
549	The Role of Autoantibodies in Bone Metabolism and Bone Loss. 2018 , 102, 522-532	3
548	Osteoimmunological insight into bone damage in rheumatoid arthritis. 2005 , 15, 225-31	7
547	Macrophages that have phagocytosed particles are capable of differentiating into functional osteoclasts. 2005 , 15, 346-51	3
546	Regulation of osteoclast function. 2012 , 22, 167-77	31
545	Role of FK506 binding protein 5 (FKBP5) in osteoclast differentiation. 2013 , 23, 1133-9	4
544	Cytokine Gene Therapy in Bone Remodeling. 2010 , 365-374	1
543	Cytokines and Bone Remodeling. 2010 , 453-490	1
542	The rheumatoid joint: Synovitis and tissue destruction. 2015 , 768-784	1
541	The Cells of Bone. 2006 , 221-258	2
540	The Vitamin D Hormone and its Nuclear Receptor: Mechanisms Involved in Bone Biology. 2006 , 307-325	2
539	Cellular Actions of Parathyroid Hormone on Osteoblast and Osteoclast Differentiation. 2001 , 199-211	5

538	Cells of Bone. 2002 , 109-126	14
537	Renal and Skeletal Actions of Parathyroid Hormone (PTH) and PTH-Related Protein. 2002 , 483-514	5
536	The Vitamin D Receptor. 2001 , 197-243	1
535	Bone and the Immune System. 2005 , 91-109	1
534	Vitamin D and Osteoclastogenesis. 2005 , 665-685	9
533	Parathyroid Hormone and Parathyroid Hormone-Related Protein. 2008 , 283-316	1
532	Osteoclast Biology. 2001 , 73-105	5
531	Glucocorticoid-Induced Osteoporosis. 2001 , 169-193	4
530	Parathyroid Hormone and Parathyroid Hormone-Related Peptide in the Regulation of Calcium Homeostasis and Bone Development. 2010 , 1040-1073	4
529	Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation. 2020 , 159, 104944	13
528	Chronic recurrent multifocal osteomyelitis (CRMO): evidence for a susceptibility gene located on chromosome 18q21.3-18q22.	3
527	Characterization of osteoclast precursors in human blood. 2000 , 111, 501-12	100
526	Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. 2000 , 97, 3370-5	280
525	McCune-Albright syndrome: new insights. 1999 , 6, 119-125	31
524	Circulating osteoprotegerin is associated with age and systolic blood pressure, but not with lipid profile or fasting glucose, in postmenopausal women. 2008 , 15, 180-4	11
523	Bone Health and Osteoporosis Prevention and Treatment. 2020 , 63, 770-787	1
522	Association of a single nucleotide polymorphism of RANK gene with blood pressure in Spanish women. 2020 , 99, e22436	1
521	Systems genetics analyses in Diversity Outbred mice inform human bone mineral density GWAS and identify Qsox1 as a novel determinant of bone strength.	1

520	Genetic analysis of apoptotic and survival signals. 1999 , 64, 335-42	5
519	Endogenous n-3 fatty acids protect ovariectomy induced bone loss by attenuating osteoclastogenesis. 2009 , 13, 1833-44	35
518	Osteoprotegerin. 2001 , 60 Suppl 3, iii81-4	7
517	Single gene mutations and variations affecting bone turnover and strength: a selective 2006 update. 2006 , 3, 11-29	3
516	Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review. 2019 , 60, 364-378	15
515	Osteoprotective action of low-salt diet requires myeloid cell-derived NFAT5. 2019 , 4,	6
514	IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. 2001 , 107, 1375-85	146
513	Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. 2000 , 106, R59-67	380
512	Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. 2000 , 106, 1229-37	509
511	Interactions between immune and bone cells: new insights with many remaining questions. 2000 , 106, 749-52	114
510	Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. 2001 , 107, 1235-44	364
509	Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. 2001 , 108, 971-9	139
508	Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. 2003 , 111, 821-31	187
507	Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. 2003 , 111, 1221-30	257
506	Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. 2003 , 111, 821-831	393
505	Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. 2003 , 111, 1221-1230	524
504	RANKing c-Jun in osteoclast development. 2004 , 114, 463-465	73
503	A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. 2006 , 116, 1525-34	100

502	Paget disease of bone. 2005 , 115, 200-8	240
501	FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner. 2005 , 115, 2742-51	73
500	M-CSF mediates TNF-induced inflammatory osteolysis. 2005 , 115, 3418-27	219
499	Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. 2006 , 116, 2880-91	91
498	NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. 2009 , 119, 3024-34	120
497	Activating transcription factor 4 regulates osteoclast differentiation in mice. 2010 , 120, 2755-66	61
496	Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice. 2011 , 121, 628-39	79
495	OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. 2011 , 121, 3505-16	147
494	Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. 2000 , 105, 823-32	164
493	Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. 2000 , 105, 607-14	110
492	M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss. 2000 , 105, 1279-87	83
491	Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. 2000 , 105, 433-40	555
490	Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. 2000 , 105, 935-43	208
489	Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. 2000 , 105, 1833-8	114
488	Inflammatory osteolysis: a conspiracy against bone. 2017 , 127, 2030-2039	124
487	Paracrine osteoprotegerin and Eatenin stabilization support synovial sarcomagenesis in periosteal cells. 2018 , 128, 207-218	8
486	Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Secretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease. 1999 , 94, 3883-3888	5
485	Intramedullary and extramedullary B lymphopoiesis in osteopetrotic mice. 2000 , 95, 3363-3370	6

484	An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor κ B ligand. 2000 , 96, 4335-4343	7
483	Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. 2000 , 96, 1873-1878	6
482	Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α 4-integrin enhances production of osteoclast-stimulating activity. 2000 , 96, 1953-1960	6
481	High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. 2002 , 72, 643-649	15
480	Etiology and Pathogenesis of Osteoporosis. 2002 , 3-18	2
479	MEF2C Interacts With c-FOS in PTH-Stimulated Mmp13 Gene Expression in Osteoblastic Cells. 2017 , 158, 3778-3791	11
478	A role for TGFbeta(1) in osteoclast differentiation and survival. 2000 , 113, 2445-2453	161
477	The cell biology of osteoclast function. 2000 , 113, 377-381	459
476	Role of Osterix and MicroRNAs in Bone Formation and Tooth Development. 2016 , 22, 2934-42	22
475	Treatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies. 2018 , 24, 8758-8766	9
474	SC-19220, Antagonist of Prostaglandin E2 Receptor EP1, Inhibits Osteoclastogenesis by RANKL. 2005 , 20, 15-22	20
473	Mice Lacking the Integrin 5 Subunit Have Accelerated Osteoclast Maturation and Increased Activity in the Estrogen-Deficient State. 2005 , 20, 58-66	46
472	cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by suppressing leptin. 2008 , 3, e1540	100
471	Osteopenia due to enhanced cathepsin K release by BK channel ablation in osteoclasts. 2011 , 6, e21168	8
470	Pathway-based association analyses identified TRAIL pathway for osteoporotic fractures. 2011 , 6, e21835	12
469	Modulation of Wnt5a expression by periodontopathic bacteria. 2012 , 7, e34434	42
468	Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma. 2012 , 7, e41127	23
467	c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions. 2012 , 7, e46900	16

466	Fas-independent T-cell apoptosis by dendritic cells controls autoimmune arthritis in MRL/lpr mice. 2012, 7, e48798	17
465	Bone formation and resorption are both increased in experimental autoimmune arthritis. 2012, 7, e53034	10
464	1,25-dihydroxyvitamin D and the vitamin D receptor gene polymorphism Apa1 influence bone mineral density in primary hyperparathyroidism. 2013, 8, e56019	12
463	Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia. 2013, 8, e57322	50
462	Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF- κ B/c-Fos/NFATc1 Pathways. 2013, 8, e59171	37
461	RANKL signaling and osteoclastogenesis is negatively regulated by cardamomin. 2013, 8, e64118	16
460	Loss of protein kinase C- β protects against LPS-induced osteolysis owing to an intrinsic defect in osteoclastic bone resorption. 2013, 8, e70815	18
459	Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGF β . 2013, 8, e78043	38
458	Sex and genetic factors determine osteoblastic differentiation potential of murine bone marrow stromal cells. 2014, 9, e86757	37
457	Increased osteoclastogenesis in mice lacking the carcinoembryonic antigen-related cell adhesion molecule 1. 2014, 9, e114360	1
456	The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease. 2015, 10, e0126153	15
455	Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone. 2015, 10, e0138189	168
454	Sympathetic Neurotransmitters Modulate Osteoclastogenesis and Osteoclast Activity in the Context of Collagen-Induced Arthritis. 2015, 10, e0139726	13
453	Decreased Bone Mineral Density Is an Independent Predictor for the Development of Atherosclerosis: A Systematic Review and Meta-Analysis. 2016, 11, e0154740	48
452	Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing. 2016, 11, e0157754	15
451	OCLI-023, a Novel Pyrimidine Compound, Suppresses Osteoclastogenesis In Vitro and Alveolar Bone Resorption In Vivo. 2017, 12, e0170159	14
450	Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. 2017, 12, e0184904	19
449	EFFECT OF PROPOLIS ON BONE LOSS PREVENTION- A REVIEW. 2017, 6, 6785-6790	1

448	Up-Regulation of RANK Expression via ERK1/2 by Insulin Contributes to the Enhancement of Osteoclast Differentiation. 2017 , 40, 371-377	12
447	Oleylethanolamide Exhibits GPR119-Dependent Inhibition of Osteoclast Function and GPR119-Independent Promotion of Osteoclast Apoptosis. 2020 , 43, 340-349	3
446	RANK Signaling Pathways and Key Molecules Inducing Osteoclast Differentiation. 2017 , 23, 295-302	4
445	The Effects of Exercise Intensity Difference on Bone Metabolic Markers and Cytokines of the RANKL/RANK/OPG System in Korean Osteopenia Elderly Women. 2017 , 26, 87-95	2
444	Effect of enhanced masticatory force on OPG, RANKL and MGF in alveolar bone of ovariectomized rats. 2020 , 28, e20190409	3
443	1,25-Dihydroxy-19-nor-vitamin D(2), a vitamin D analog with reduced bone resorbing activity in vitro. 2000 , 11, 1857-1864	24
442	Caffeic Acid Inhibits NFkappaB Activation of Osteoclastogenesis Signaling Pathway. 2011 , 3, 216	4
441	Plasma proteomic profiling of young and old mice reveals cadherin-13 prevents age-related bone loss. 2020 , 12, 8652-8668	4
440	Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. 2017 , 8, 20394-20409	21
439	Cyclophosphamide causes osteoporosis in C57BL/6 male mice: suppressive effects of cyclophosphamide on osteoblastogenesis and osteoclastogenesis. 2017 , 8, 98163-98183	11
438	Effects of 12-week combined exercise on RANKL/RANK/OPG signaling and bone-resorption cytokines in healthy college females. 2019 , 23, 13-20	4
437	Brain and bone: central regulation of bone mass. A new paradigm in skeletal biology. 2001 , 83, 1871-6	22
436	The Effect of Osteoclastic Activity on Tendon-to-Bone Healing. 2007 , 89, 2250-2259	3
435	Infliximab (Remicade) in the treatment of psoriatic arthritis. 2006 , 2, 389-400	8
434	Understanding and targeting osteoclastic activity in prostate cancer bone metastases. 2013 , 13, 626-39	46
433	Effects of insulin-like growth factor-induced Wharton jelly mesenchymal stem cells toward chondrogenesis in an osteoarthritis model. 2018 , 21, 745-752	9
432	RANK signaling pathways as potent and specific therapeutic targets for bone erosion in rheumatoid arthritis. 2006 , 1, 567-578	1
431	[Osteoporosis in men]. 2007 , 58, 25-32	2

430	Effects of Carbonic Anhydrase Inhibitor Acetazolamide (AZ) on Osteoclasts and Bone Structure. 2007 , 16, 115-123	11
429	Direct and Indirect Effects of IL-17A on RANKL-Induced Osteoclastogenesis. 2013 , 22, 287-292	6
428	Niches Within the Multiple Myeloma Bone Marrow Microenvironment. 2007 , 61-74	1
427	Plasma osteoprotegerin is associated with testosterone levels but unaffected by pioglitazone treatment in patients with polycystic ovary syndrome. 2013 , 36, 460-5	4
426	VEGF165 promotes the osteolytic bone destruction of ewing's sarcoma tumors by upregulating RANKL. 2009 , 18, 117-25	24
425	Effects of Brown Rice Extract Treated with Lactobacillus sakei Wikim001 on Osteoblast Differentiation and Osteoclast Formation. 2014 , 19, 353-7	2
424	Protocatechuic acid attenuates anterior cruciate ligament transection-induced osteoarthritis by suppressing osteoclastogenesis. 2020 , 19, 232-240	7
423	Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients. 2013 , 28, 668-77	12
422	Modeling of the kinetics of vitamin D(3) in osteoblastic cells. 2013 , 10, 319-44	1
421	Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics. 2015 , 4, 438-54	21
420	[Denosumab for treatment of postmenopausal osteoporosis]. 2011 , 131, 1893-6	2
419	Application of Biomarkers for the Prediction and Diagnosis of Bone Metastasis in Breast Cancer. 2020 , 23, 588-598	5
418	Cellular response within the periodontal ligament on application of orthodontic forces. 2013 , 17, 16-20	21
417	Vitamin D and periodontal health: Current concepts. 2013 , 17, 302-8	23
416	A study on OPG/RANK/RANKL axis in osteoporotic bile duct-ligated rats and the involvement of nitrenergic and opioidergic systems. 2018 , 13, 239-249	16
415	Serum, saliva, and GCF concentration of RANKL and osteoprotegerin in smokers versus nonsmokers with chronic periodontitis. 2016 , 5, 80	13
414	Biological response at the cellular level within the periodontal ligament on application of orthodontic force - An update. 2012 , 1, 2-10	18
413	Gingival Crevicular Fluid Levels of RANKL and OPG After Placement of Collagen Membrane With Simvastatin in the Treatment of Intrabony Defects in Chronic Periodontitis. 2019 , 11, S301-S304	1

412	The Effects of Adiponectin on Bone Metabolism. 2014 , 07, 621-630	1
411	Activation of cannabinoid receptor CB2 regulates LPS-induced pro-inflammatory cytokine production and osteoclastogenic gene expression in human periodontal ligament cells. 2013 , 03, 44-51	4
410	Osteoclast Response to Bioactive Surface Modification of Hydroxyapatite. 2014 , 04, 340-344	4
409	Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. 2014 , 6, 322-43	30
408	The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox. 2018 , 35, 225-232	7
407	Comparative Evaluation of Myeloperoxidase Enzymatic Activity in Gingival Crevicular Fluid of Subjects having Orthodontic Treatment by Different Aligning Arch Wires. 2017 , 18, 977-980	3
406	Bone metastases: When and how lung cancer interacts with bone. 2014 , 5, 149-55	30
405	RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. 2013 , 4, 207-17	33
404	Regulation by Phloroglucinol of Nrf2/Maf-Mediated Expression of Antioxidant Enzymes and Inhibition of Osteoclastogenesis via the RANKL/RANK Signaling Pathway: In Silico study. 2015 , 23, 228-32	6
403	TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. 2002 , 35, 371-6	49
402	Role of LIGHT in the pathogenesis of joint destruction in rheumatoid arthritis. 2017 , 7, 49-57	5
401	Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication. 2012 , 1, 43-53	55
400	Markers of bone metastases in breast and lung cancers. 2012 , 13, 4331-4	6
399	High-phytate/low-calcium diet is a risk factor for crystal nephropathies, renal phosphate wasting, and bone loss. 2020 , 9,	12
398	TPC1 and TPC2 Promote Osteoclastogenesis. 2021 , 30, 333-338	
397	Modulation of osteoclastogenesis through adrenomedullin receptors on osteoclast precursors: initiation of differentiation by asymmetric cell division. 2021 , 101, 1449-1457	0
396	Serum RANKL levels in Chinese patients with ankylosing spondylitis: a meta-analysis. 2021 , 16, 615	0
395	Serum osteoprotegerin levels, endothelial function and carotid intima-media thickness in type 2 diabetic patients. 2021 , 35, 108073	1

- 394 Bone health in pediatric transfusion-dependent beta-thalassemia: Circulating osteoprotegerin and RANKL system. **2022**, 69, e29377 0
- 393 Blockade of cytokine activity by soluble cytokine receptors. **2000**, 157-176
- 392 Osteoklasten: Universelle Zellen der Knochenumstrukturierung. **2000**, 43-61
- 391 ??????????, ??????????. **2000**, 67, 275-275
- 390 New Insights into Aging and Renal Osteodystrophy. **2000**, 137-147
- 389 Cellular and Molecular Mechanisms of Postmenopausal Osteoporosis. **2000**, 134-146
- 388 The Mechanisms of Bone Loss due to Estrogen Deficiency: Possible Role of Increased B-Lymphopoiesis in Bone Resorption. **2000**, 171-183
- 387 ??????????. **2001**, 68, 221-221
- 386 New Approaches to Osteoporosis Therapeutics. **2001**, 769-818
- 385 Use of Transgenic Animals in Skeleton Biology. **2001**, 385-399
- 384 Osteoporose. **2001**, 137-188 1
- 383 Hypercalcemia Due to PTHrP. **2001**, 671-689
- 382 Physiologic Actions of PTH and PTHrP: I. Skeletal Actions. **2001**, 213-226
- 381 Osteolysis Induced by Radio-Opaque Agents. **2001**, 149-161 1
- 380 TRANCE. **2001**, 486-489
- 379 Mouse Genetics as a Tool to Study Bone Development and Physiology. **2001**, 213-219
- 378 Osteoporosis Associated with Rheumatologic Disorders. **2001**, 351-362 1
- 377 Cytokines in Primary Hyperparathyroidism. **2001**, 411-421 1

- 358 PTHrP and skeletal metastasis. **2004**, 118, 125-47 2
- 357 The Role of Tumor-Associated Macrophages in Metastasis-Associated Osteolysis. **2004**, 87-108 1
- 356 OPG, RANK and RANKL in Bone Metastasis and Cancer-Associated Osteolysis. **2004**, 211-240 1
- 355 Cytokine regulation of bone destruction. **2004**, 269-289
- 354 TNF-Related Apoptosis-Inducing Ligand (TRAIL). **2004**, 181-191
- 353 Effects of alpha-Lipoic Acid on Bone Metabolism in Rats with Low Bone Mass. **2005**, 20, 476
- 352 Osteoporosis and Vascular Calcification: Lesson from OPG KO Mice. **2005**, 20, 571
- 351 The Changes in the Serum RANKL and OPG levels after Bone Marrow Transplantation: Association with Bone Mineral Metabolism. **2005**, 20, 40
- 350 [Osteoprotegerin--a neutralizing receptor, protector of bones and a potential antiresorptive agent]. **2005**, 58, 362-7 2
- 349 Mucosal Vaccines for Dental Diseases. **2005**, 1109-1137
- 348 Signaling in Bone. **2006**, 259-271
- 347 Osteoporosi: la scienza di base, inquadramento, classificazione. **2006**, 3-15
- 346 Pathogenesis of Inflammation-Induced Bone Loss. **2006**, 249-263
- 345 P2 Nucleotide Receptor Signaling in Osteoclasts. **2006**, 25-59
- 344 The Role of Receptor Activator of NF- κ B Ligand in Smooth Muscle Cell Proliferation. **2006**, 16, 1066-1070
- 343 The negative role of IdS in osteoclastogenesis. **2007**, 602, 23-31 1
- 342 Pathogenesis of Psoriatic Arthritis. **2007**, 48-60 1
- 341 Expression of RANKL in Osteolytic Membranes. **2007**, 89, 841-848 8

340 RANK ligand et métastases osseuses. **2008**, 133-142

339 Intraarticular Corticosteroids Modulate the Osteoprotegerin/Receptor Activator of Nuclear Factor- κ B Ligand System in the Synovial Fluid in Patients with Rheumatoid Arthritis. **2008**, 43, 227

338 Osteoporosis Associated with Rheumatologic Disorders. **2008**, 1387-1398

1

337 Pathophysiology of Bone Disease in Multiple Myeloma. **2008**, 435-454

336 Alterations in Serum Levels of Receptor Activator of Nuclear Factor- κ B Ligand and Osteoprotegerin in Patients with Head Injury and Fracture. **2008**, 21, 145

1

335 Skeletal Complications: Bone Metabolism and Novel Targeted Agents. **2008**, 1-24

334 Osteoclastic Bone Resorption / Samuel C. Ramage, Mengnai Li, Matthew J. Beckman. **2008**, 2113-2122

333 Skeletal Metastases: Optimal Management Today. **2009**, 17-32

332 The expressions of C-reactive protein and macrophage colony-stimulating factor in gingival tissue of human chronic periodontitis with hypertension. **2009**, 39, 391

1

331 Pathologic Fractures in Children. **2009**, 41-56

330 Biology, Physiology, and Morphology of Bone. **2009**, 71-91

1

329 Bone Structure and Function. **2009**, 1-13

328 Bone pain. **2009**, 493-504

327 The interactions and shared mechanisms of T cells and osteoclasts. **2009**, 29, 239-248

326 Bone Homeostasis: Extracellular Calcium Levels and Their Control.

325 The Basic Biology of Estrogen and Bone. **2010**, 333-350

324 Development of the Skeleton. **2010**, 203-231

323 Parathyroid Hormone and Parathyroid Hormone-Related Protein. **2010**, 245-278

- 322 Bone Development and Remodeling. **2010**, 1111-1135
- 321 Intercellular Communication during Bone Remodeling. **2010**, 509-522 1
- 320 Rol van cytokinen bij de orthodontische verplaatsing van gebitselementen. **2010**, 175-186
- 319 Die Rolle des RANK/RANKL/OPG-Signalwegs im Knochenstoffwechsel. **2010**, 118-121 1
- 318 The Pathophysiologic Role of the Bone Marrow Environment and its Niches in Multiple Myeloma. **2010**, 2811-2819
- 317 Osteoblast Biology. **2010**, 55-112 1
- 316 Effects of Artemisia princeps Extract on Bone Metabolism. **2010**, 39, 363-368 1
- 315 Anti-inflammatory and antiosteoclastogenesis properties of endogenous melanocortin receptor type 3 in experimental arthritis. **2010**, 24, 4835-4843 3
- 314 Aseptic Loosening of Total Hip Implant: Mechanisms of Osteolysis and Potential Therapy. **2010**, 17, 82-88 1
- 313 Identification of osteoclasts in culture. **2011**, 690, 273-84
- 312 Nouveaux acteurs du remodelage osseux, rôle du système immunitaire. **2010**, 194, 1493-1504
- 311 The expression of RANKL, OPG and TNF- α on cells and/or tissues around alveolar bone during early-stage rat tooth germ development. **2011**, 15, 39-43
- 310 Osteoimmunology. **2011**, 169-172
- 309 Effects of Lotus Root Extract on Osteoblast and Osteoclast. **2011**, 603-612
- 308 Mechanobiology of Bone. **2011**, 117-136
- 307 The rheumatoid joint. **2011**, 911-934.e4
- 306 Osteoclasts and Interleukin-17-Producing Helper T Cells in Rheumatoid. **2011**, 75-89
- 305 Denosumab for treatment of osteoporosis in postmenopausal women. **2011**, 1, 1329-1340

- 304 RANKL Inhibition: Clinical Data. **2012**, 217-240
- 303 Osteoimmunological Aspects of Periodontal Diseases. **2012**, 241-273
- 302 RANKL Inhibition: Preclinical Data. **2012**, 197-215 0
- 301 Bone pain. **2012**, 50-60
- 300 The Role of GPR55 in Bone Biology. **2013**, 71-113
- 299 Effects of type 2 diabetes mellitus on expression of macrophage colony-stimulating factor and bone differentiation factors in human chronic periodontitis. **2012**, 36, 104-112
- 298 Role of Bone Disease in the Pathogenesis of Multiple Myeloma. **2013**, 97-120 0
- 297 Adaptive Immune Responses and Bone. **2013**, 7-21
- 296 Intracellular Calcium Signaling for Osteoclast Differentiation. **2013**, 23-30
- 295 Bone Metastasis of Breast Cancer. **2013**, 189-209
- 294 Bone Health: Prevention of Skeletal-Related Events and Palliative Care. **2013**, 935-940
- 293 Metabolic. **2013**, 53-81 1
- 292 Receptor activator of nuclear factor- κ B ligand in T cells and dendritic cells communication. **2013**, 3, 3.1-3.3
- 291 Mammary gland-specific expression of biologically active human osteoprotegerin in transgenic mice. **2013**, 17, 1-8
- 290 mAbs targeting RANKL in bone metastasis treatment. **2013**, 42-53
- 289 Bone Biomarkers in Research and Clinical Practice. **2014**, 95-124
- 288 Bone-Implant Interface in Patients with Neoplastic Disease. **2014**, 327-333
- 287 Atypical Course of Rheumatoid Arthritis. **2014**, 65-74

286 Skeleton, Inflammatory Diseases of. **2014**,

285 Osteoclast Cell Lineage: Characteristics and Behavior of Osteoclast Precursors In Vivo. **2014**,

284 Bone-Targeted Therapy: Rationale and Current Status. **2014**, 139-153

283 Mechanism of inflammatory bone resorption. **2014**, 56, 5-11

282 Interaktion von Tumorzellen und Knochen bei osteolytischen/osteosklerotischen Metastasen, Circulus vitiosus der Knochenmetastasierung. **2014**, 13-21

281 Oxidative Stress in Musculoskeletal Disorders [Bone Disease. **2014**, 2951-2959

0

280 Bisphosphonates in Pediatric Burn Injury. **2014**, 101-115

1

279 Knochenmetastasen bei gynkologischen Malignomen. **2014**, 169-176

278 Osteoclast Cell Lineage: Characteristics and Behavior of Osteoclast Precursors In Vivo. **2014**, 181-192

277 Understanding and Manipulating Genes, Hormones and Bone Cells. **1999**, 295-299

276 Mineral metabolism prepares for the new millennium. **1999**, 8, 405-6

275 ROLE OF RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND (RANKL) AND OSTEOPROTEGERIN (OPG) IN PERIODONTAL BONE DESTRUCTION: A REVIEW. **2014**, 3, 4781-4785

274 Inhibitory Effects of Ursolic Acid from Prunella Vulgaris on Osteoclast Differentiation. **2014**, 27, 59-70

1

273 Effect of Macrophage Colony-Stimulating Factor Receptor c-Fms Antibody on Lipopolysaccharide-Induced Pathological Osteoclastogenesis and Bone Resorption. **2015**, 259-267

272 Bone Turnover and Spinal Cord Injury. **2015**, 1-34

271 Osteoimmunology. **2015**, 165-168

1

270 The Role of Th1 Cytokines on Mechanical Loading-Induced Osteoclastogenesis and Bone Resorption. **2015**, 269-279

269 Caldecrin: A pancreas-derived hypocalcemic factor, regulates osteoclast formation and function. **2015**, 6, 358-65

- 268 Hyperbaric Oxygen Stimulates the Proliferation and Differentiation of Raw264.7 Cells. **2015**, 05, 309-320 1
- 267 Mathematical Modelling of Basic Multicellular Units: The Functional Units of Bone Remodeling. **2015**, 45-74
- 266 Effect of Spinach Extract on RANKL-Mediated Osteoclast Differentiation. **2015**, 44, 532-539
- 265 Corticotomy and postmodern incarnations of surgically facilitated orthodontic therapy (SFOT). 210-227
- 264 Bone Homeostasis: Extracellular Calcium Levels and Their Control in Humans. 1-10
- 263 Antibodies for the Treatment of Bone Diseases: Preclinical Data. **2016**, 217-237 3
- 262 Bone Biomarkers in Intrauterine Growth Restriction. **2016**, 1-12
- 261 Bone Marrow Stem Cells and Bone Turnover in Diabetic Disease. **2016**, 147-179
- 260 Encyclopedia of Signaling Molecules. **2016**, 1-7
- 259 Basics of Bone Biology. **2016**, 1-30
- 258 Genetics of Paget's Disease of Bone. **2016**, 25-36
- 257 4. Bone responses to weight and exercise in obese animal models. **2016**, 81-98
- 256 Bone Homing and Metastasis. **2017**, 25-32
- 255 Molecular Pathogenesis and Diagnostic Imaging of Metastatic Jaw Tumors. **2017**, 9, S15-S22 1
- 254 Clinical Management of a Pediatric Patient Associated with Thalassemia Major: A Case Report. **2017**, 9, 55-58
- 253 Bone Biomarkers in Intrauterine Growth Restriction. **2017**, 783-794
- 252 Immunopathology of the Musculoskeletal System. **2017**, 615-648
- 251 Bone Turnover and Spinal Cord Injury. **2017**, 959-992

- 250 Application of Disease System Analysis to Osteoporosis: From Temporal to Spatio-Temporal Assessment of Disease Progression and Intervention. **2018**, 61-121 1
- 249 Cervical spine fractures in osteopetrosis: a case report and review of the literature. **2018**, 32, 68-76 4
- 248 Knochenzellbiologie. **2018**, 1-32
- 247 Encyclopedia of Signaling Molecules. **2018**, 3687-3693
- 246 Interleukin-33 and Osteoprotegerin Levels in Gingival Crevicular Fluid and Saliva in Chronic Periodontitis and Their Correlation to Diabetes Mellitus: A Cross-Sectional Study. **2018**, 2, 1-9
- 245 Vitamin D, Inflammation and Osteoporosis in Rheumatoid Arthritis. **2018**, 12, 300-312 2
- 244 BİOSFONAT KULLANIMINA BAĞLI BİR KEMİKLERİNDE GRÜEN OSTEONEKROZ VAKALARININ MEDİKAL VE CERRAHİ TEDAVİLERİ SONRASI UZUN DÖNEM TAKİPLERİ 89-97
- 243 Vitamin D: A Sun Shine on the periodontium. **2019**, 10, 227
- 242 Assessment of Osteoimmunological Changes Following Orthognathic Surgery. **2019**, 7, 632-636
- 241 Fisiología del tejido óseo. **2019**, 52, 1-25
- 240 Osteoprotegerin (OPG) Promotes Recruitment of Endothelial Progenitor Cells (EPCs) via CXCR4 Signaling Pathway to Improve Bone Defect Repair. **2019**, 25, 5572-5579 4
- 239 Fisiología del tejido óseo. **2019**, 21, 1-25
- 238 Immunological Basis of Inflammatory Arthritides. **2020**, 1-36
- 237 High-phytate/low-calcium diet is a risk factor for crystal nephropathies, renal phosphate wasting, and bone loss.
- 236 Radial extracorporeal shockwave therapy on calcaneal spurs: a randomized controlled trial. **2019**, 28, 316-21 0
- 235 Role of Inflammation and Inflammasomes in Bone Pathophysiology. **2020**, 103-111
- 234 Mechanisms of skeletal fragility in diabetes mellitus. **2020**, 39-59
- 233 Glucose transporter 4 mediates LPS-induced IL-6 production in osteoblasts under high glucose conditions. **2020**, 62, 423-426 1

- 232 Effects of Glucocorticoids on Diurnal Variations in Experimental Tooth Movement. **2020**, 29, 231-238
- 231 DC-STAMP and TACE Levels are Higher in Patients with Periodontitis. **2020**, 31, 122-126 2
- 230 The role of osteoprotegerin in the development, progression and management of abdominal aortic aneurysms. **2020**, 15, 457-463 0
- 229 A systematic dissection of human primary osteoblasts in vivo at single-cell resolution. 2
- 228 Familial Syndromes of Primary Hyperparathyroidism.
- 227 Acacetin inhibits RANKL-induced osteoclastogenesis and LPS-induced bone loss by modulating NFATc1 transcription. **2021**, 583, 146-153 1
- 226 The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density. **2021**, 81, 1831-1858 7
- 225 Ets-2 Propagates IL-6 Trans-Signaling Mediated Osteoclast-Like Changes in Human Rheumatoid Arthritis Synovial Fibroblast. **2021**, 12, 746503 1
- 224 Targeting MAPK/MKP Signaling as a Therapeutic Axis in Periodontal Disease. **2020**, 55-71 1
- 223 Bone Tumour Pathology. **2021**, 69-92
- 222 Characterization of large yellow croaker (*Larimichthys crocea*) osteoprotegerin and its role in the innate immune response against to *Vibrio alginolyticus*. **2021**, 258, 110680 0
- 221 Effect of DNA methylation modulators on the production of osteoprotegerin by rheumatoid fibroblast-like synoviocytes in vitro: their migration and invasion. **2019**, 18, 116-124
- 220 Cellular Contributors to Bone Homeostasis. **2020**, 333-371 1
- 219 Osteoclast Signal Transduction Pathways: The RANKL/RANK System. **2020**, 200-220
- 218 BEOSFONAT KULLANIMINA BAĞI ENİ KEMİKLERİNDE GİRİŞEN OSTEONEKROZ VAKALARININ MEDİKAL VE CERRAHİ TEDAVİLERİ SONRASI UZUN DÖNEM TAKİPLERİ
- 217 Origin and Differentiation of Osteoclasts. **2020**, 162-180
- 216 Evaluation and Medical Management of Vertebral Osteoporosis: Preventing the Next Fracture. **2020**, 31-47
- 215 Ipriflavone inhibits the differentiation of RAW 264.7 cells into osteoclasts via Foxo1. **2019**, 44, 400-402

214 Nature of Periodontal Diseases. **2020**, 9-19

213 Translational Pharmacology in The Development of RANKL Inhibitors. **2020**, 590-598

212 Historical Perspective of Osteoclast Research. **2020**, 149-151

211 Inflammation in Bone Loss. **2020**, 112-121

210 Cancer and Bone: Historical Perspective. **2020**, 161-165

209 Biologic and Pharmacologic Treatment of Legg-Calv²Perthes Disease. **2020**, 181-194

0

208 Dihydroartemisinin attenuates osteoclast formation and bone resorption via inhibiting the NF- κ B, MAPK and NFATc1 signaling pathways and alleviates osteoarthritis. **2022**, 49,

2

207 Abnormal Bone Metabolism May Be a Primary Causative Factor of Keel Bone Fractures in Laying Hens. **2021**, 11,

3

206 Cellular and tissue crosstalk in musculoskeletal development. **2021**, 123, 1-1

205 The Role of TGF- β in Bone Metastases. **2021**, 11,

4

204 Osteoclast Differentiation Factor is a Ligand for Osteoprotegerin / Osteoclastogenesis-Inhibitory Factor. **2002**, 243-247

1

203 The Role of Interleukin-11 in the Formation of Bone Metastases. **2001**, 67-78

202 Multiple Myeloma. **2006**, 1285-1296

201 Influence of the Bone Microenvironment on Breast Cancer Metastasis to Bone. **2005**, 149-164

1

200 Medikamentöse Therapie der Osteoporose. **2006**, 5-16

199 Bedeutung von RANK-Ligand und Osteoprotegerin für den Knochenstoffwechsel. **2006**, 479-509

198 Physiological Regulation of Bone Metabolism and Estrogen Agonism. 161-186

197 Death receptors and their ligands. **2000**, 5-28

196	RANKing c-Jun in osteoclast development. 2004 , 114, 463-5	28
195	Cytokines in Multiple Myeloma. 2007 , 181-197	
194	Etiology and Pathophysiology. 2008 , 15-23	
193	Laboratory Procedures [Culture of Cells and Tissues. 2009 , 559-593	
192	Osteoprotegerin as a potential therapy for osteoporosis. 2005 , 3, 121-125	1
191	Soluble RANKL exaggerates hindlimb suspension-induced osteopenia but not muscle protein balance.	
190	RANKL from Bone Marrow Adipose Lineage Cells Promotes Osteoclast Formation and Bone Loss.	
189	RANKL-Based Osteoclastogenic Assay from Murine Bone Marrow Cells. 2021 , 2230, 457-465	1
188	PDGF BB purified from osteoclasts acts as osteoblastogenesis inhibitory factor (OBIF). 2002 , 13, 62-71	8
187	Age and motor score predict osteoprotegerin level in chronic spinal cord injury. 2008 , 8, 50-7	14
186	Soluble molecules and bone metabolism in multiple myeloma: a review. 2008 , 5, 67-70	1
185	Therapeutic perspectives. 2008 , 5, 45-8	2
184	The role of osteoprotegerin (OPG) and estrogen receptor (ER) gene polymorphisms in rheumatoid arthritis. 2007 , 4, 156-60	5
183	An overview of bone cells and their regulating factors of differentiation. 2008 , 15, 4-12	11
182	Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. 2011 , 13, 131-6	36
181	Receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in gingival crevicular fluid. 2012 , 9, 752-7	5
180	Effects of diclofenac and celecoxib on osteoclastogenesis during alveolar bone healing, in vivo. 2014 , 11, 357-63	3
179	Hepatic osteodystrophy. 2014 , 11, 185-91	24

178	Evaluation of rs3102735 and rs2073617 Osteoprotegerin Gene Polymorphisms and the Risk of Childhood Acute lymphoblastic Leukemia in Zahedan Southeast Iran. 2014 , 8, 39-44	5
177	Correlation of increased plasma osteoprotegerin and cardiovascular risk factors in patients with adult growth hormone deficiency. 2015 , 8, 3184-92	5
176	The effects of dried root aqueous extract of <i>Salvia miltiorrhiza</i> and its major ingredient in acceleration of orthodontic tooth movement in rat. 2015 , 18, 1044-9	2
175	Adverse bone health among children and adolescents growing up with HIV. 2015 , 1, 159-67	2
174	Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection. 2014 , 16, 123-33	7
173	Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial. 2016 , 16, 24-32	69
172	Alterations in gene expression precede sarcopenia and osteopenia in botulinum toxin immobilized mice. 2016 , 16, 355-368	11
171	Bone Wasn't Built in a Day: Destruction and Formation of Bone in the Rheumatic Diseases. 2017 , 128, 24-43	7
170	The association between receptor activator of nuclear factor kappa- β ligand and clinical attachment level among waterpipe smoker. 2017 , 21, 376-379	
169	Tanshinone IIA attenuates osteoclastogenesis in ovariectomized mice by inactivating NF- κ B and Akt signaling pathways. 2018 , 10, 1457-1468	12
168	Vitamin B5 inhibit RANKL induced osteoclastogenesis and ovariectomy induced osteoporosis by scavenging ROS generation. 2019 , 11, 5008-5018	4
167	A protocol for humanized synovitis mice model. 2019 , 8, 47-52	1
166	[Role of autophagy in the pathogenesis of periodontitis]. 2019 , 37, 422-427	1
165	Effects of Selected Non-biological and Biological Disease-Modifying Anti-rheumatic Drugs, and mRNA Vaccines on Mononuclear Phagocyte System. 2021 ,	
164	Induced pluripotent stem cell-derived bone progenitors. 2022 , 133-158	
163	The SarcoEndoplasmic Reticulum Calcium ATPase (SERCA) pump: a potential target for intervention in aging and skeletal muscle pathologies. 2021 , 11, 25	3
162	Peripheral Blood Mononuclear Cells (PBMCs) to Dissect the Underlying Mechanisms of Bone Disease in Chronic Kidney Disease and Rare Renal Diseases. 2021 , 19, 553	0
161	Tgf-beta pathway inhibition as the therapeutic acceleration of diabetic bone regeneration. 2021 ,	1

- 160 Cellular and Molecular Biology in Bone Remodeling. **2022**, 3-15
- 159 Mesenchymal Hematopoietic Stem Cell Axis: Applications for Induction of Hematopoietic Chimerism and Therapies for Malignancies. **2021**, 35-57
- 158 Osteoimmunologia: uma breve introdução. **2012**, 30-34
- 157 Osteoonkologie: Von der Biologie zu neuen Therapien.
- 156 SAOLP-ISA: Structural Analysis of Osteoclast-Inhibitory Lectin Partial Using an In Silico Based Approach. **2021**,
- 155 Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF- κ B, Calcium, and NFATc1 Pathways.. **2021**, 12, 810322 4
- 154 Melatonin Attenuates RANKL-Induced Osteoclastogenesis via Inhibition of Atp6v0d2 and DC-STAMP through MAPK and NFATc1 Signaling Pathways.. **2022**, 27, 1
- 153 Antibody Treatment and Osteoporosis: Clinical Perspective. **2022**, 111-126
- 152 The Effects of Selenium on Bone Health: From Element to Therapeutics.. **2022**, 27, 2
- 151 Endosomal TLR3 signaling in stromal osteoblasts induces prostaglandin E-mediated inflammatory periodontal bone resorption.. **2022**, 101603 0
- 150 Insights Into Bone Marrow Niche Stability: An Adhesion and Metabolism Route.. **2021**, 9, 798604 1
- 149 Suppression of osteoclastogenesis signalling pathways and attenuation of ameloblastic osteolysis induced by local administration of CaP-bisphosphonate and CaP-doxycycline cements: Review of the literature and therapeutic hypothesis. **2022**, 5, 100241
- 148 Applications of Calcium-Based Nanomaterials in Osteoporosis Treatment.. **2022**,
- 147 Resolvin as a Treatment Modality in Experimental Periodontitis: A Systematic Review of Preclinical Studies.. **2022**, 14, e21095 0
- 146 Molecular Mechanisms Leading from Periodontal Disease to Cancer.. **2022**, 23, 2
- 145 Obesity Increases Time to Union in Surgically Treated Pediatric Fracture Patients.. **2022**, 6, 0
- 144 Role of the Interaction of Tumor Necrosis Factor- α and Tumor Necrosis Factor Receptors 1 and 2 in Bone-Related Cells.. **2022**, 23, 3
- 143 The role of flavonoids in inhibiting IL-6 and inflammatory arthritis.. **2022**, 2

142	PTH1R Actions on Bone Using the cAMP/Protein Kinase A Pathway.. 2021 , 12, 833221	1
141	Gap junctional intercellular communication attenuates osteoclastogenesis induced by activated osteoblasts.. 2022 , 597, 71-76	0
140	Study on the role of pyroptosis in bone resorption induced by occlusal trauma with or without periodontitis.. 2022 ,	0
139	Modulation of SIRT6 activity acts as an emerging therapeutic implication for pathological disorders in the skeletal system. 2022 ,	
138	MYC-mediated miR-320a affects receptor activator of nuclear factor κ ligand (RANKL)-induced osteoclast formation by regulating phosphatase and tensin homolog (PTEN).. 2021 , 12, 12677-12687	2
137	Medication-related osteonecrosis of the jaw: An update. 2022 ,	0
136	Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS).. 2022 , 37, e68	1
135	FAEE exerts a protective effect against osteoporosis by regulating the MAPK signalling pathway.. 2022 , 60, 467-478	0
134	Osteoblast-derived vesicles induce a switch from bone-formation to bone-resorption in vivo.. 2022 , 13, 1066	4
133	Phosphatidylserine liposomes containing curcumin inhibit bone loss in osteoporotic rats: A possible synergy through a common signaling pathway.. 2022 , e14120	
132	A Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases.. 2022 , 14,	
131	Effect of Cold Atmospheric Plasma (CAP) on Osteogenic Differentiation Potential of Human Osteoblasts.. 2022 , 23,	0
130	Colorimetric and fluorescent TRAP assays for visualising and quantifying fish osteoclast activity.. 2022 , 66,	0
129	Lipoproteins Cause Bone Resorption in a Mouse Model of Septic Arthritis.. 2022 , 13, 843799	0
128	Roles of the RANKL-RANK Axis in Immunity-Implications for Pathogenesis and Treatment of Bone Metastasis.. 2022 , 13, 824117	0
127	Pathogenesis and Treatment of Myeloma-Related Bone Disease.. 2022 , 23,	1
126	Sialylation of TLR2 initiates osteoclast fusion.. 2022 , 10, 24	0
125	Changes in adiposity over the life course and gene expression in postmenopausal women.. 2022 ,	

124	The ATF3-OPG Axis Contributes to Bone Formation by Regulating the Differentiation of Osteoclasts, Osteoblasts, and Adipocytes.. 2022 , 23,	
123	The Signaling Pathways Associated With Breast Cancer Bone Metastasis.. 2022 , 12, 855609	2
122	Comparison of Hydroxyapatite/Poly(lactide-co-glycolide) and Hydroxyapatite/Polyethyleneimine Composite Scaffolds in Bone Regeneration of Swine Mandibular Critical Size Defects: In Vivo Study.. 2022 , 27,	3
121	Potential mechanisms of osteoprotegerin-induced damage to osteoclast adhesion structures via P2X7R-mediated MAPK signaling.. 2022 , 49,	0
120	Systemic and local innate immune responses to surgical co-transplantation of mesenchymal stromal cells and biphasic calcium phosphate for bone regeneration.. 2021 ,	0
119	Chrysin Protects Against Titanium Particle-Induced Osteolysis by Attenuating Osteoclast Formation and Function by Inhibiting NF- κ B and MAPK Signaling.. 2022 , 13, 793087	2
118	Biomaterial-induced pathway modulation for bone regeneration.. 2022 , 283, 121431	3
117	The effects of microgravity on bone structure and function.. 2022 , 8, 9	3
116	RANKL biology.. 2022 , 159, 116353	2
115	Effects of the Lysine Methyltransferase Inhibitor AZ505 on Bone Metabolism.. 2021 , 28, 297-305	1
114	Regulation of TNF-Induced Osteoclast Differentiation.. 2021 , 11,	5
113	Colorimetric and fluorescent TRAP assays for visualising and quantifying fish osteoclast activity.	1
112	Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.	0
111	Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system.. 2021 , 2, 100470	0
110	Galectin-3 Contributes to the Inhibitory Effect of 1,25-(OH) $_2$ D on Osteoclastogenesis.. 2021 , 22,	
109	Yukmijihwang-Tang Suppresses Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Mediated Bone Loss.. 2021 , 26,	0
108	Autophagy Targeting nanoparticles in Rheumatoid arthritis and Osteoarthritis.	0
107	Angiotensin II Induces Aortic Rupture and Dissection in Osteoprotegerin-Deficient Mice.. 2022 , e025336	1

106 Genetic Association of rs1021188 and DNA Methylation Signatures of in the Risk of Conductive Hearing Loss.. **2022**, 9, 870244

105 IL-27 Modulates the Cytokine Secretion in the T Cell-Osteoclast Crosstalk During HIV Infection.. **2022**, 13, 818677

104 Image_1.pdf. **2020**,

103 Table_1.docx. **2020**,

102 Data_Sheet_1.docx. **2019**,

101 Image_1.JPEG. **2019**,

100 image_1.jpeg. **2018**,

99 image_2.jpeg. **2018**,

98 Data_Sheet_1.doc. **2020**,

97 Data_Sheet_2.docx. **2020**,

96 Induced pluripotent stem cells from homozygous Runx2-deficient mice show poor response to vitamin D during osteoblastic differentiation.. **2022**, 1

95 Calcitonin Gene-related Peptide Inhibits Osteoclast Differentiation by Inducing the Negative Regulators MafB and Bcl6 . **2022**, 31, 87-94

94 Osteoprotective effects of flavonoids: Evidence from and studies (Review).. **2022**, 25,

1

93 Bone stress injuries.. **2022**, 8, 26

2

92 The origins and roles of osteoclasts in bone development, homeostasis and repair.. **2022**, 149,

2

91 Notch2 Blockade Mitigates Methotrexate Chemotherapy-Induced Bone Loss and Marrow Adiposity.. **2022**, 11,

0

90 Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients.. **2022**, 12, 7781

89 The Osteoclast Traces the Route to Bone Tumors and Metastases. **2022**, 10,

0

- 88 Increased fracture risk in prostate cancer: causes and consequences. **2022**, 13, 6-10
- 87 RANKL elevation activates NIK/NF- κ B pathway, inducing obesity in ovariectomized mice. **2022**, 1
- 86 BHLHE40 promotes osteoclastogenesis and abnormal bone resorption via c-Fos/NFATc1. **2022**, 12, 1
- 85 Revisi3n sistem3tica de los efectos de microvibraci3n de baja magnitud alta frecuencia en osteocitos cultivados.. **2022**, 79, 165-176
- 84 Comparison of two non-union models with damaged periosteum in mice: Segmental defect and pin-clip fixation versus transverse fracture and K-wire stabilization. **2022**, 116475
- 83 Indigenous Nigeria medicinal herbal remedies: A potential source for therapeutic against rheumatoid arthritis. 153537022211029 1
- 82 Effect of a single-dose denosumab on semen quality in infertile men (the FITMI study): study protocol for a randomized controlled trial. **2022**, 23, 0
- 81 Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. **2022**, 7, 4
- 80 The impact of sex steroids on osteonecrosis of the jaw. **2022**, 1
- 79 Osteoprotegerin and MTHFR gene variations in rheumatoid arthritis: association with disease susceptibility and markers of subclinical atherosclerosis. **2022**, 12, 0
- 78 BoneFrom macrophage to osteoclast and osteolytic diseases. **2022**, 161-180
- 77 Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis. **2022**, 0
- 76 Bone Disease in Multiple Myeloma: Biologic and Clinical Implications. **2022**, 11, 2308 0
- 75 The role of secreted osteoclastogenic factor of activated T cells in bone remodeling. **2022**, 58, 227-232 1
- 74 Associations of Bone Mineral Density with RANKL and Osteoprotegerin in Arab Postmenopausal Women: A Cross-Sectional Study. **2022**, 58, 976
- 73 The Gestational Effects of Maternal Bone Marker Molecules on Fetal Growth, Metabolism and Long-Term Metabolic Health: A Systematic Review. **2022**, 23, 8328
- 72 The role of C5a-C5aR1 axis in bone pathophysiology: A mini-review. 10, 0
- 71 Inflammatory stimuli alter bone marrow composition and compromise bone health in the malnourished host. 13, 0

70	Phospholipase D2 controls bone homeostasis by modulating M-CSF-dependent osteoclastic cell migration and microtubule stability.	1
69	The origins and formation of bone-resorbing osteoclasts. 2022 , 164, 116538	0
68	Chi3L1 is a therapeutic target in bone metabolism and a potential clinical marker in patients with osteoporosis. 2022 , 184, 106423	0
67	Thioplakortone B attenuates RANKL-induced NF- κ B and MAPK signaling and dampens OVX-induced bone loss in mice. 2022 , 154, 113622	0
66	Cytokine-mediated immunomodulation of osteoclastogenesis. 2022 , 164, 116540	1
65	A bibliometrics visualization analysis and hotspots prediction for natural product on osteoporosis research from 2000 to 2021. 2022 , 2, 326-337	0
64	Osteoclasts/Osteoblasts. 2022 ,	0
63	Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.	0
62	Effects of <i>Moringa oleifera</i> L. and <i>Eucommia ulmoides</i> Oliver Mixed Formula on Ligation-Induced Experimental Periodontitis and Alveolar Bone Loss in Rats. 2022 , 51, 765-779	0
61	Molecular Biomarkers in Peri-Implant Health and Disease: A Cross-Sectional Pilot Study. 2022 , 23, 9802	2
60	Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis. 2022 , 13,	0
59	Osteoclast biology in the single-cell era. 2022 , 42,	2
58	Updated trabecular bone score accounting for the soft tissue thickness (TBSTT) demonstrated significantly improved bone microstructure with denosumab in the FREEDOM TBS post hoc analysis.	0
57	Biochemical characterization of a disease-causing human osteoprotegerin variant. 2022 , 12,	0
56	Water Extract of <i>Piper longum</i> Linn Ameliorates Ovariectomy-Induced Bone Loss by Inhibiting Osteoclast Differentiation. 2022 , 14, 3667	0
55	Neuronal Guidance Molecules in Bone Remodeling and Orthodontic Tooth Movement. 2022 , 23, 10077	0
54	Factors secreted by monosodium urate crystal-stimulated macrophages promote a proinflammatory state in osteoblasts: a potential indirect mechanism of bone erosion in gout. 2022 , 24,	1
53	Mitochondrial fatty acid β oxidation is important for normal osteoclast formation in growing female mice. 13,	0

- 52 Postmenopausal Osteoporosis: A Literature Review. **2022**, ○
- 51 Matrix-enabled mechanobiological modulation of osteoimmunology. **2022**, 5, 3194-3224 ○
- 50 Osteoclasts, Master Sculptors of Bone. **2023**, 18, 1
- 49 Regulation of LL-37 in Bone and Periodontium Regeneration. **2022**, 12, 1533 1
- 48 An inducible explant model for dissecting osteoclast-osteoblast coordination in health and disease. ○
- 47 Effect of Lymphocyte Subsets on Bone Density in Senile Osteoporosis: A Retrospective Study. **2022**, 2022, 1-11 ○
- 46 Neodymium Selenide Nanoparticles: Greener Synthesis and Structural Characterization. **2022**, 7, 150 ○
- 45 Osteoclastogenesis of human peripheral blood, bone marrow, and cord blood monocytes. ○
- 44 Where is bone science taking us?. **2022**, 101791 ○
- 43 Osteoimmunology: an interdisciplinary approach to studying the relationships between immune and bone cells. **2022**, 24, 911-930 ○
- 42 Cathepsin K in Pathological Conditions and New Therapeutic and Diagnostic Perspectives. **2022**, 23, 13762 ○
- 41 IL-1 β promotes osteoclastogenesis by increasing the expression of IGF2 and chemokines in non-osteoclastic cells. **2023**, 151, 1-8 ○
- 40 Osteoclast-derived extracellular miR-106a-5p promotes osteogenic differentiation and facilitates bone defect healing. **2023**, 102, 110549 ○
- 39 Fabrication of hesperidin hybrid lecithin-folic acid silver nanoparticles and its evaluation as anti-arthritis formulation in autoimmune arthritic rat model.. **2023**, 1276, 134722 ○
- 38 The effects of seeding density and osteoclastic supplement concentration on osteoclastic differentiation and resorption. **2023**, 18, 101651 ○
- 37 Role of Nitric Oxide in Type 2 Diabetes-Induced Osteoporosis. **2022**, 161-189 ○
- 36 Differential Recovery Patterns of the Maxilla and Mandible after Eliminating Nasal Obstruction in Growing Rats. **2022**, 11, 7359 ○
- 35 Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?. **2022**, 23, 15879 ○

34	Avicularin Alleviates Osteoporosis in Ovariectomized Mice by Inhibiting Osteoclastogenesis through NF- κ B Pathway Inhibition.	0
33	OPG/FDCR-1, a TNF Receptor Family Member, Is Expressed in Lymphoid Cells and Is Up-Regulated by Ligating CD40. 1998 , 161, 6113-6121	29
32	TRANCE, a TNF Family Member, Is Differentially Expressed on T Cell Subsets and Induces Cytokine Production in Dendritic Cells. 1999 , 162, 2562-2568	33
31	Osteoclast Differentiation Factor Acts as a Multifunctional Regulator in Murine Osteoclast Differentiation and Function. 1999 , 163, 434-442	52
30	Microphthalmic Mice Display a B Cell Deficiency Similar to that Seen for Mast and NK Cells. 1999 , 163, 6671-6678	1
29	IL-6 Plays a Critical Role in Stromal Fibroblast RANKL Induction and Consequent Osteoclastogenesis in Ameloblastoma Progression. 2023 , 103, 100023	0
28	Underdiagnosis in Background of Emerging Public Health Challenges Related to Peri-Implant Diseases: An Interventional Split-Mouth Study. 2023 , 20, 477	0
27	Bone circuitry and interorgan skeletal crosstalk. 12,	0
26	The Role of procollagen type 1 amino-terminal propertied (P1NP) Cytochrome P450 (CYPs) and Osteoprotegerin (OPG) as Potential Bone function markers in Prostate Cancer Bone Metastasis. 2023 , 31, 25-34	0
25	Prolactin regulates RANKL expression via signal transducer and activator of transcription 5a signaling in mammary epithelial cells of dairy cows.	0
24	Cathepsin K degrades osteoprotegerin to promote osteoclastogenesis in vitro.	0
23	Applications of Gene Therapy in Dentistry: A Review Article.	0
22	Nitric Oxide Scavengers Based on o-Phenylenediamine for the Treatment of Rheumatoid Arthritis.	1
21	Abnormal kynurenine level contributes to the pathological bone features of ankylosing spondylitis. 2023 , 118, 110132	0
20	The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeutics. 2023 , 118, 110081	0
19	Crosstalk within a brain-breast-bone axis regulates mineral and skeletal metabolism during lactation. 14,	0
18	Bacteria associated with apical periodontitis promotes in vitro the differentiation of macrophages to osteoclasts.	0
17	Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications. 2023 , 15, 1518	0

- 16 Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension. ○
- 15 Pulsed electromagnetic fields as a promising therapy for glucocorticoid-induced osteoporosis. 11, ○
- 14 THE THREE KEY PLAYERS IN OSTEOIMMUNOLOGY: RANK, RANKL AND OSTEOPROTEGERIN. **2023**, 54-57 ○
- 13 Osteoclastogenesis of human peripheral blood, bone marrow, and cord blood monocytes. **2023**, 13, ○
- 12 New Insights into the Role of Synovial Fibroblasts Leading to Joint Destruction in Rheumatoid Arthritis. **2023**, 24, 5173 ○
- 11 Effect of Bifidobacterium on osteoclasts: TNF- α /NF- κ B inflammatory signal pathway-mediated mechanism. 14, ○
- 10 Effects of anti-RANKL antibodies administered to pregnant mice on bone and tooth development in neonates. **2023**, ○
- 9 The STING inhibitor C-176 attenuates osteoclast-related osteolytic diseases by inhibiting osteoclast differentiation. **2023**, 37, ○
- 8 Clinical and Biochemical Effects of Smoking on Non-Surgical Periodontal Treatment in Grade III Stage C Periodontitis Patients. ○
- 7 The Role of Stem Cell on Orthodontic Tooth Movement Induced-Alveolar Bone Remodeling. **2023**, 123-128 ○
- 6 An inducible explant model of osteoclast-osteoprogenitor coordination in exacerbated osteoclastogenesis. **2023**, 26, 106470 ○
- 5 Lactobacillus plantarum LP45 inhibits the RANKL/OPG signaling pathway and prevents glucocorticoid-induced osteoporosis. 67, ○
- 4 Biomarkers of aging. ○
- 3 Molecular events in the jawvascular unit: A traditional review of the mechanisms involved in inflammatory jaw bone diseases. **2023**, 37, 1 ○
- 2 Histochemical assessment on osteoclasts in long bones of toll-like receptor 2 (TLR2) deficient mice. **2023**, ○
- 1 Discovery of RANKL and the current and future impact of its research. **2023**, 158, 247-252 ○